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The activation of naïve T cells results in their proliferation and differentiation into a
particular T-helper (Th) phenotype, namely Th1, Th2 or Th17 cells. This thesis
focuses on the role of pro-inflammatory Th1 and Th17 cells in the induction of
autoimmune disease of the central nervous system (CNS), using murine experimental
autoimmune encephalomyelitis (EAE) as the model.
Classically, EAE has been considered to be a Th1-mediated disease. However, since
the emergence of the Th17 cells, there has been a paradigm shift towards Th17 cells
being the key pathogenic subset in autoimmune disease. This thesis established
robust protocols for the differentiation of naïve T cells into myelin-reactive Th1 or
Th17 cells, producing ‘clean’ populations devoid of any contaminating cells. Passive
T cell-transfer experiments revealed that myelin-reactive Th1 cells could induce
EAE, whereas Th17 cells could not. This lack of disease correlated with the inability
of the Th17 cells to accumulate in the non-inflamed CNS. Myelin-reactive Th1 cells
did have this capability and only once inflammation was established, could Th17
cells be identified in the CNS, potentially exacerbating the disease. After these
differences were observed, the project investigated two main aims: 1) to identify
differences in homing molecule expression on Th1 and Th17 cells which could
explain the difference in their ability to home to the CNS, and to investigate the
functional significance of such differences, by molecular blockade; 2) to investigate
the requirements for three key cytokines in EAE pathogenesis in passive T cell
transfer models, investigating IFN- -17 and TNF- .
P-selectin glycoprotein ligand-1 appeared to be important for the initial entry of
inflammatory T cells into the CNS. Th1 cells deficient in IFN-
inducing EAE. A proportion of the mice developed “atypical” clinical signs, which
correlated with T cell infiltration predominantly of the brain, rather than the spinal
cord. This atypical EAE may be IL-17 dependent. In conclusion, this thesis indicates
the importance of not focusing all resources and therapeutic approaches on Th17-
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The immune system has evolved to protect the body against invading pathogens
through both the innate and adaptive systems, with the innate system initiating the
induction of the adaptive immune system. Naïve CD4+ T cells are activated in the
peripheral lymph nodes by recognition of their cognate peptide-MHC class II
complex displayed on the surface of antigen presenting cells (APCs), leading to their
proliferation and differentiation into various T helper (Th) cell phenotypes,
determined by the cytokine milieu in the immediate environment. This allows the T
effector cells to orchestrate a qualitatively appropriate immune response.
Importantly, the immune system must also be able to discriminate between self and
non-self to avoid autoimmune pathology. This is avoided through central and
peripheral tolerance mechanisms. Autoimmune disease arises when both of these
mechanisms fail, and a destructive immune response is mounted against self
antigens, resulting in the destruction of self tissue and organs. Multiple sclerosis
(MS) is an autoimmune disease of the central nervous system (CNS) (Hafler et al.,
2005). It is thought to be mediated by pro-inflammatory CD4+ T cells, namely Th1
and Th17 cells. In this thesis, the pathogenic ability of Th1 and Th17 cells is
investigated through the use of the murine model of MS, experimental autoimmune
encephalomyelitis (EAE). This model recapitulates the main features of multiple
sclerosis and allows the study of the roles of the various T effector cell lineages, to
assess their contribution to disease pathogenesis.
1.1.1 Basic T cell biology
All lymphocytes originate from the same common lymphoid progenitor cells,
haematopoietic stem cells, in the bone marrow. Whereas B cells develop within the
bone marrow, a proportion of the haematopoietic stem cells migrate from the bone
marrow to the thymus where they undergo several development steps to mature into
T cells. The absence of a thymus, due to a genetic defect or neonatal thymectomy
results in partial immunodeficiency due to a low peripheral T cell compartment
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(Miller, 1961), demonstrating the importance of the thymus in T cell development. In
humans, the thymus is fully developed at birth but is thought to undergo involution
from adolescence onwards (Aspinall and Andrew, 2000), resulting in decreased
output of newly generated T cells.
1.1.1.1 T cell development in the thymus
Two functionally distinct types of T cells are generated in the thymus: the T cells
in (Ciofani and Zuniga-Pflucker, 2010)). When entering the thymus, the
haematopoietic stem cells lack expression of the surface molecules characteristic of
mature T cells. There are several stages of thymocyte development, the earliest being
the ‘double negative’ (DN) stage in which the thymocytes lack the co-receptors CD4
or CD8 (as well as T cell specific CD3 and the T cell receptor (TCR)) (Figure 1.1).
The double negative cells are extremely heterogeneous and can be subdivided into
four different stages DN1, DN2, DN3a and DN3b defined on their expression of
CD44, CD25 and CD117 (Porritt et al., 2004). Between the DN1 and DN2 stages
gene rearrangement begins at the - - and -TCR gene loci and commitment
(Taghon et al., 2006). The
cells that have successfully
cells. TCR signalling and notch signalling are considered important for the decision
(Kreslavsky et al., 2010)).
As this thesis investigates T cells, a brief over-view of their thymic development
follows. Successful rearrangement of the VDJ gene segments of the -chain locus of
the TCR, results in commitment towards the T cell lineage. Those cells that do
not achieve successful -chain rearrangement undergo apoptosis. The -chain then
associates with a pT and this heterodimer (forming the pre-TCR) complexes with
the CD3 chains and is expressed on the surface of the thymocyte. This signals for the
-chain rearrangement to stop, the cells proliferate and the CD4 and CD8 molecules
are expressed forming CD4+CD8+ ‘double positive’ (DP) thymocytes. The -chain
gene rearrangement then begins and continues until a successful -chain is produced,
and this pairs with the -chain to form a mature TCR (Zuniga-Pflucker, 2004;
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Ciofani and Zuniga-Pflucker, 2010). T cells are ‘MHC restricted,’ as they only
recognise antigen when it is presented by MHC molecules on APCs. This MHC
restriction is thought to be coded by the germline-encoded complementary-
determining regions 1 and 2 (CDR1 and CDR2) of the TCR. These recognise the
conserved feature of the MHC helices, and the peptide specificity is dictated by the
highly variable CDR3s (Chothia, Boswell and Lesk, 1988; Davis and Bjorkman,
1988) (reviewed in (Mazza and Malissen, 2007). Numerous different cell types act as
APCs within the thymus, including cortical thymic epithelial cells, medullary thymic
epithelial cells and dendritic cells (DCs). These APCs and the thymic structure itself
have an important role in thymic selection which is explained below.
1.1.1.2 Positive Selection
The DP thymocytes undergo positive selection based on the affinity of their TCR
for MHC-peptide complexes on thymic epithelial cells. This is when DP thymocytes
that have no affinity for the self-peptide-MHC class I and class II complexes
(presented by the DCs) are deleted. This results in positive selection for those DP
thymocytes with functional TCRs with sufficient avidity for self-peptide-MHC-
complexes. These positively selected cells are then induced to differentiate into
mature T cells and lose expression of either CD4 or CD8, resulting in the formation
of CD4+ or CD8+ single-positive thymocytes. Those selected on MHC class I
molecules become CD8+ cells by downregulating CD4, and those selected on MHC
class II molecules become CD4+ cells by downregulation of CD8 (Zuniga-Pflucker,
2004).
1.1.1.3 Negative Selection
The thymocytes move from the cortex of the thymus towards the medulla region.
Here they undergo negative selection, also known as clonal deletion. This is the
elimination of both DP (CD4+CD8+) as well as single-positive (CD4+CD8- or CD4-
CD8+) thymocytes that respond strongly to self peptide. Many studies have shown
that strength of signal of the TCR for the peptide-MHC complex determines the fate
of thymocytes during the positive and negative selection process (Ashton-Rickardt et
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al., 1994; Sebzda et al., 1994; Germain, 2001; Daniels et al., 2006). The elimination
of strongly self-reactive T cells from the thymus is known as central tolerance and is
vital for the prevention of autoimmune disease.
1.1.1.4 Treg development in the thymus
CD4+ natural T regulatory cells (nTreg), which are vital for the maintenance of
peripheral tolerance and the suppression of inflammation, have been shown to
develop within the thymus as well. Forkhead Box P3 protein (FoxP3) was identified
as a marker of Treg (Hori, Nomura and Sakaguchi, 2003). nTreg are now known to
be produced late in thymic T cell development, and are differentiated from single-
positive CD4 T cells, to produce FoxP3+ Treg, which then migrate out in to the
periphery (Fontenot et al., 2005). In polyclonal mice, conventional T cells and nTreg
develop at a constant ratio, however in TCR transgenic systems that lack the RAG
genes i.e. the endogenously rearranged TCR chains, nTreg cells are absent (Lafaille
et al 1994; Picca et al 2006). An increase in development of nTreg was observed if
the cognate ligand for the respective TCR transgenic was expressed within the
thymus (Jordan et al, 2001; Kawahata et al, 2002). Processes distinct from either
positive or negative selection allow for the development of nTreg in the thymus. This
allows for Treg to exit the thymus into the periphery and to respond to specific self-
peptides with high affinity. The exact mechanisms involved in their own selection in
the thymus are still being determined however numerous factors including the
endogenous TCR gene rearrangement, the affinity for self-peptide, TGF- signalling
as well as the organisation of the thymic structure are important (Kawahata et al,
2002; Relland et al, 2009).
A two-step model of nTreg development in the thymus has recently been proposed.
Firstly, TCR signalling results in the upregulation of the IL-2R (CD25) and this
directly leads to the induction of FoxP3 expression (Lio and Hsieh, 2008).
Transforming growth factor (TGF)- is also involved in the development of nTreg.
Mice deficient in TGF- R I specifically within the T cells, had reduced numbers of
CD4+ CD25+ FoxP3+ thymocytes in young mice, however this reduction in number
was only temporary (Liu et al., 2008b). If both TGF and IL-2 signalling was lost,
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CD4+ CD25+ FoxP3+ thymocyte numbers were permanently reduced (Liu et al.,
2008b). Co-stimulation via CD28 has also been shown to upregulate FoxP3
expression in developing thymocytes independent of IL-2 (Tai et al., 2005). Once
developed, mature CD4+ and CD8+ single positive T cells and FoxP3+ nTreg are
























































Figure 1.1 Over-view of -T cell development within the thymus.
Haematopoietic stem cells enter the thymus and develop into double negative precursors through
Notch ligand signalling. Thymocyte differentiation is characterised by the expression of well defined
cell surface markers, for example those listed in the diagram, CD4, CD8, CD44 and CD25. Notch
signalling induces a complex programme of T cells maturation in the thymus resulting in the
development of single positive CD4+ or CD8+ T cells that migrate out into the peripheral pool of naïve
T cells. Positive and negative selection in the thymus ensures the maturation of functional T cells and
minimises the maturation of self-reactive T cells. CD4+ cells also develop into FoxP3+ Treg in the
thymus. Adapted from Zúñiga-Pflücker Nature Reviews Immunology (Zuniga-Pflucker, 2004).
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1.1.2 Development of immune response to infection
The innate immune system is vital for the early recognition of infection and the
triggering of the proinflammatory response to invading pathogens (Medzhitov and
Janeway, 2000). In contrast the adaptive immune system is responsible for the
elimination of specific pathogens later during infection and, importantly, for the
generation of immunological memory.
1.1.2.1 The innate immune system
Cells of the innate immune system include mast cells, eosinophils and basophils, and
the phagocytic cells macrophages, neutrophils and dendritic cells. These are all
derived from common myeloid progenitor cells within the bone marrow. Mast cells,
basophils and eosinophils are granular cells that function by release of
proinflammatory agents, for example histamine by mast cells and basophils, and
cationic proteins and cytokines by eosinophils (reviewed in (Abraham and St John,
2010; Stone, Prussin and Metcalfe, 2010). These cells have important roles in host
defence and allergy. Mast cells reside in tissues whereas basophils circulate in the
blood. Basophils have also been suggested to act as APCs and to be important for
modulating Th2 inflammation (Min et al., 2004; Oh et al., 2007; Schroeder, 2009)
although they have recently been shown not to be required for Th2 responses in
helminth infection and allergy (Hammad et al., 2010; Phythian-Adams et al., 2010).
Other important mediators of the innate immune system are the phagocytic cells,
macrophages, neutrophils and DCs. These are able to phagocytose and kill invading
pathogens. This is particularly true if opsonized by antibody which facilitates
antibody-Fc receptor binding on the phagocyte and complement (reviewed in
(Carroll, 2004)). Complement mediates both humoral and cellular interactions within
the immune response including phagocytosis and it can be activated via three
different routes, the classical and alternative pathways and the lectin pathway.
Both macrophages and DCs are also an important link between the innate and
adaptive immune systems, as they act as APCs to naïve T cells. The APCs are able to
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phagocytose the foreign invading antigens, process the antigen internally and present
resulting peptide fragments on their surface within the binding cleft of MHC
molecules. The activation of naïve T cells by antigen presentation signals the
activation of the adaptive immune response. The adaptive immune response is
required for key reasons: 1) it provides a specific response against a particular
antigen or pathogen; 2) it provides a long lasting response through immunological
memory, the generation of memory cells specific for a particular antigen.
1.1.2.2 The adaptive immune response
Naïve T cells emigrate from the thymus to establish the peripheral T cell pool in the
lymphoid organs and blood. T cells leave the blood circulation and enter the lymph
nodes via the high endothelial venules. Within the lymph node the T cells
accumulate in the T-cell zone where they encounter their cognate antigen during
antigen presentation by the APCs. The majority of the T cells are not activated, and
re-enter circulation via the medulla and the efferent lymph into the thoracic duct
(Westermann et al., 2001).
1.1.2.3 T cell activation
Bretscher and Cohn originally suggested that lymphocytes require two signals to
mount an effective immune response against an antigen (Bretscher and Cohn, 1970).
Over the years, this hypothesis has been refined, and it is now known that three
distinct signals are required for the full activation of the adaptive immune response,
or the activation of a naïve T cells: 1) activation through the TCR which recognises
the peptide-MHC complex on the surface of the APC; 2) non-specific signalling
through co-stimulatory molecules on the surface of the T cell and their respective
ligands on the surface of the APC; and 3) cytokines produced by either the APC or
the activated T cell itself induce cytokine receptor signalling within the T cell which
both amplifies the activation and aids differentiation of the T cell as summarised in
Figure 1.2. However, before these three signals can be elicited for T cell activation,




1.1.2.4 Signal 0: DC activation
Immature DCs recognise pathogen-associated molecular patterns (PAMPs)
(Janeway, 1989) of invading pathogens and this triggers the activation of the DC.
PAMPs are small molecular motifs present on entire classes of pathogens including
bacteria, viruses, fungi or parasites. PAMPs are recognised by pattern-recognition
receptors (PRRs) expressed by DCs. There are numerous different PRRs, for
example membrane bound or intracellular toll like receptors (TLRs) which are the
most widely characterised, and intracellular cytosolic PRRs, retinoid acid-inducible
gene I (RIG-I)-like receptors (RLRs) and nucleotide-binding oligomerisation domain
(NOD)-like receptors (NLRs) (reviewed in (Mogensen, 2009)). Of the cytosolic
PRRs, NLRs are implicated in recognising bacterial components (Inohara et al.,
2005) whereas RLRs are able to recognise viral dsRNA (Yoneyama et al., 2004).
LPS is the prototypical PAMP and signals through TLR4 (Kim et al., 2007). TLR9 is
able to recognise bacterial and viral DNA (Hemmi et al., 2000; Hochrein et al.,
2004).
The effect of PRR ligation is phagocytosis, upregulation of MHC, costimulatory
molecules and cytokine production. Following the antigen uptake by DCs as
mediated by PRR signalling, the antigen is processed internally and is presented on
the surface of the DC on the MHC molecules. The DCs migrate to the regional
lymph nodes to present their antigenic peptides to the naive T cells. Signal 0
therefore provides the important link between the innate and adaptive immune
systems.
1.1.2.5 Signal 1: Activation through the TCR
The TCR :TCR heterodimer forms the binding site for the cognate peptide-MHC
domains and cytoplasmic tails. The cytoplasmic tails of the CD3 chains contain
immunoreceptor tyrosine-based activation motifs (ITAMs) which assist in the signal
transduction after their phosphorylation. Associated with the TCR are the co-
receptors CD4 or CD8. Lymphocyte-specific protein tyrosine kinase (Lck), a
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member of the Src family of tyrosine kinases is associated with the cytoplasmic tail
of the CD4 or CD8 co-receptors (reviewed in (Nakayama and Yamashita, 2010)).
Following TCR ligation, the CD4 or CD8 co-receptors cluster with the TCR,
allowing activated Lck to phosphorylate the tyrosine residues on the ITAMs on the
-70 (a tyrosine kinase of the
spleen tyrosine kinase (Syk) family) binding to the ITAMs bringing it into the close
vicinity of Lck and allowing Lck to phosphorylate ZAP-70. Phosphorylated and
activated ZAP-70 initiates a series of complex intracellular signalling cascades
through the phosphorylation of LAT molecules. This leads to activation of various
signalling pathways including a) the Ras/ERK MAPK cascade, b) the
Ca2+
(Nakayama and Yamashita, 2010) which lead to activation of the T cell and gene
transcription.
1.1.2.6 Signal 2: Co-stimulation
If a T cell receives signalling through the TCR only, without any co-stimulation, this
results in the T cell entering an anergic state in which it is non-responsive to further
TCR stimulation, even in the presence of costimulation. Only through co-stimulatory
signalling can anergy be avoided and T cell activation achieved (reviewed in
(Schwartz, 2003). CD28, which is constitutively expressed on the surface of the T
cell, is the key co-stimulatory molecule providing initial robust signalling and is
important for T cell proliferation, cytokine production, cell survival and cellular
metabolism, and therefore, anergy prevention (Green et al., 1994; Boise et al., 1995).
This is highlighted as CD28-deficient mice have severely impaired CD4 T cell
proliferation (Green et al., 1994). CD28 binding to its ligands, CD80 (B7-1) and
CD86 (B7-2) on the surface of the APC, leads to a series of T cell signalling
pathways and to upregulation of many genes involved in T cell activation.
Antibodies against CD80 and CD86 can inhibit T cell activation in vitro, highlighting
the importance of CD28 co-stimulation for T cell activation (Salomon and Bluestone,
2001). Importantly, signalling through the TCR and CD28 results in IL-2 production,
whereas anergic cells produce little IL-2 (reviewed in (Powell et al., 1998)). The
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activated APCs therefore provide signal 1 through the MHC/peptide complex and the
signal 2 through co-stimulation. Blocking the CD28/B7 interaction in T cell clones
leads to T cell anergy (Tan et al., 1993).
Numerous other molecules on the surface of T cells have been shown to have co-
stimulatory properties including CD5, OX40 and inducible co-stimulator (ICOS).
There are also co-inhibitory molecules, which are upregulated after CD28
engagement, for example, cytotoxic T-lymphocyte antigen-4 (CTLA-4),
programmed death-1 (PD-1) and B and T lymphocyte attenuator-4 (BTLA-4)
(reviewed in (Salomon and Bluestone, 2001) and (Greenwald, Freeman and Sharpe,
2005)). Ligation of CTLA-4, which competes for the same ligands as CD28, results
in the inhibition of T cell activation (Walunas, Bakker and Bluestone, 1996; Salomon
et al., 2001).
CTLA-4-deficient mice develop lymphoproliferative disease, adding support to its
role in inhibiting T cell activation and proliferation (Tivol et al., 1995; Waterhouse et
al., 1995). More recently, Treg have been shown to require CTLA-4 for their
suppressive function (Tang et al., 2004). Although also a negative regulator of T cell
responses, PD-1 has a very distinct regulatory pathway from CTLA-4, due to the
different expression patterns of their ligands. PD-1 has two ligands, programmed
death ligand-1 (PD-L1) and PD-L2 (Freeman et al., 2000; Latchman et al., 2001).
PD-L1 is expressed on leukocytes and in non-lymphoid tissues whereas PD-L2 is
expressed on DCs and monocytes only (Freeman et al., 2000; Yamazaki et al., 2002).
Blockade of PD-1 has been shown to accelerate autoimmune disease in non obese
diabetic (NOD) mice and EAE (Ansari et al., 2003; Salama et al., 2003). CTLA-4-
deficient mice develop autoimmune disease or lymphoproliferative disease early in
life in comparison to PD-1-deficient mice, which develop autoimmunity after several
months (Waterhouse et al., 1995; Okazaki and Honjo, 2006). This supports the
hypothesis that CTLA-4 is required early in the initiation of a T cell response within
the lymph node. CTLA-4 and PD-1 have distinct roles in controlling autoreactive T
cells that have escaped central tolerance in the thymus.
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1.1.2.7 Signal 3: Cytokines
The third signal required for full activation and differentiation of a naïve T cell is
elicited through the cytokines produced by the APC and by the T cell itself. Without
the third signal from inflammatory cytokines, CD8+ T cells fail to develop into
optimal cytotoxic T cells (reviewed in (Mescher et al., 2006)). IL-12 and IFN- / are
important signal 3 mediators for CD8+ T cells leading to full activation of the cells,
after TCR/MHC class I and co-stimulation signalling resulting in effector function as
well as memory (Mescher et al., 2006). TNF- , and IL-1 have been found to be
important pro-inflammatory cytokines in the activation of CD4+ T cells (Pape et al.,
1997; Ben-Sasson et al., 2009) although their exact role and mechanism of action is
still to be elucidated.
The cytokine milieu when a CD4 T cell is activated is vital for the differentiation of
the naïve T CD4+ T cell into a particular Th phenotype. The cytokine signalling
results in down-stream activation of specific signal transducer and activator of
transcription (STAT) proteins which results in differentiation down a specific route.
CD4+ T cells can differentiate into at least four known subsets: Th1, Th2, Th17 and
adaptive (a)Treg cells (Mosmann et al., 1986; Bettelli, Korn and Kuchroo, 2007;
Curotto de Lafaille and Lafaille, 2009). Th1 cells require cytokine signalling through
interferon (IFN)- -12 to activate downstream STAT4 and STAT1 signalling
(Seder et al., 1993). Th2 cells require signalling through IL-4 to activate STAT5 and
STAT6 signalling (Le Gros et al., 1990). Th17 cells are differentiated in the presence
of IL-6 and TGF- (Veldhoen et al., 2006) via STAT3 signalling and iTregs in the
presence of TGF- and IL-2 (Chen et al., 2003; Yu and Malek, 2006) (reviewed in
(Zhu and Paul, 2010). The details of CD4+ T cell lineages and their differentiation
and function is given in Section 1.2. Signalling through signals 1 and 2 result in the
chromatin remodelling for gene activation, whereas signalling through signal 3 is

























Figure 1.2 Signals required for full T cell activation.
A, CD4+ T cells require three signals for successful activation: 1) signalling with the MHC cII/peptide
complex on the APC through the T cell receptor; 2) signalling through co-stimulatory molecules, for
example CD28 on the T cell surface with its ligands CD80 or CD86 on the APC surface; 3) signalling
through cytokines produced by the surrounding APCs or the T cell itself, e.g. TNF- and IL-1;
Signalling through signal one only, i.e. the TCR, in the absence of co-stimulation results in no
response and the induction of tolerance or anergy. Conversely, in the absence of signal one, ligation of
co-stimulatory receptors does not induce a T cell response. B, The role of co-stimulatory molecules
and co-inhibitory molecules in the regulation of T cell receptor signals. Although essential for a T cell
response, signalling through the TCR does not automatically determine activation or inhibition, and
depends on signals from co-stimulatory and co-inhibitory molecules to determine T cell activation, or
T cell inhibition. A balance between these two opposing signals determines the outcome. Adapted
from Chen, L, 2004, Nature Reviews Immunology (Chen, 2004).
The major advantage of the adaptive immune system is the generation of long-term
immunological memory to antigen. Antigen recognition is determined by TCRs and
BCRs which show a huge ability for diversity through recombination and (in the case
of the BCR) somatic hypermutation. This great diversity provides the opportunity for
the generation of self antigen-reactive receptors and hence the risk of an autoimmune
response. Central tolerance mechanisms have been discussed. Because these are not
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100% effective, autoreactive T cells do escape into the T cell repertoire in the
periphery and the peripheral tolerance mechanisms are in place to control these cells
(reviewed in (Anderton and Wraith, 2002). However, peripheral tolerance can also
be broken with the ultimate development of clinical autoimmune disease.
1.1.3 Autoimmune disease: Multiple Sclerosis
MS is a complex disease of the CNS that is thought to be initiated by autoimmune
inflammation. The prevalence of the disease varies in different areas in the world and
is found to be highest in northern Europe, southern Australia and North America
(Kurtzke, 1991). The reason for this is not understood and the etiology of MS is still
unknown. There is a strong genetic component, but several environmental factors
have been proposed (reviewed in (Noseworthy et al., 2000).
There are four pathological sub-types of demyelination in MS, as described by
Lassmann and Lucchinetti:
Pattern I) active demyelination with T cell and macrophage dominated inflammation.
Lesions are centred around the blood vessels.
Pattern II) active demyelination with T cell and macrophage dominated inflammation
as well as deposition of IgG and complement antigen. The lesions are also centred
around blood vessels.
Pattern III) inflammatory infiltrate made up of T cells, macrophages and microglia
with no Ig or signs of complement. These exhibit specific loss of myelin protein
myelin associated glycoprotein (MAG) and not of any other myelin proteins.
Pattern IV) T cell and macrophage dominated inflammation, with no Ig deposition or
complement. The demyelination here is associated with oligodendrocyte death
(Lucchinetti et al., 2000).
Patterns I and II clearly show signs of autoimmune encephalomyelitis and in
contrast, patterns III and IV exhibit oligodendrocyte dystrophy (Lucchinetti et al.,
2000) highlighting the clear heterogeneity in demyelination of MS lesions which is
reflected in the heterogeneity of disease from patient to patient. However, an MS
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patient can present all the patterns of demyelination and the pattern is not predictive
of MS clinical course.
1.1.3.1 Symptoms of MS
Disease often starts with sensory disturbances, optic neuritis, clumsiness and limb
weakness. As disease progresses this develops into cognitive impairment, vertigo,
progressive paralysis in all four limbs, spasticity, ataxia and apraxia. Diagnosis is
made on clinical manifestations as well as a defined set of laboratory criteria (Poser
et al., 1983) and more recently magnetic resonance imaging (MRI) (Miller et al.,
1998b) as well as the detection of B-cell-produced oligoclonal immunoglobulin in
the cerebrospinal fluid (CSF) (reviewed in Noseworthy et al 2000 (Noseworthy et al.,
2000).
1.1.3.2 Clinical courses of MS
A relapsing-remitting course (RRMS) develops in approximately 80% of MS
patients with a 2:1 incidence ratio in females:males (reviewed in Noseworthy et al,
2000; Compston and Coles 2008 (Noseworthy et al., 2000; Compston and Coles,
2008). RRMS is characterised by periods of symptoms of disease followed by
months to years of remission. This form of MS usually starts with a clinically
isolated syndrome (CIS; for example, optic neuritis or evidence of brain stem
dysfunction) and the majority of patients that experience this later develop MS.
Secondary progressive MS (SPMS) eventually develops in the majority of patients
with RRMS, and indicates a progressive neurologic decline without any periods of
remission. Primary progressive MS (PPMS) affects ~20% of MS patients (Fisniku et
al., 2008). It is characterised by a gradually progressive clinical course from onset,
with no periods of remission and has similar incidence between males and females
(Fisniku et al., 2008). The clinical courses of MS are summarised in Figure 1.3.
Importantly, there are forms of ‘borderline’ MS diseases including Marburg’s disease
(also known as fulminant MS), neuromyelitis optica (NMO; also known as Devic’s
disease), and Balo concentric sclerosis which can often be confused with MS.
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Marburg type MS has a very aggressive clinical course with large demyelinating
plaques in the hemispheric white matter of the brain. The disease evolves rapidly and
can result in death after only a few months (reviewed in (Capello and Mancardi,
2004). Balo concentric sclerosis is characterised by lesions in the brain in the shape
of concentric rings and appears to be more common in populations of Oriental origin
(Capello and Mancardi, 2004). NMO is more common in Asiatic people and usually
initiates with CIS i.e. optic neuritis. From this patients develop inflammation of the
spinal cord, myelitis. After these first two defining events, the disease can be
monophasic or relapsing (Bergamaschi and Ghezzi, 2004; Lennon et al., 2004).
Importantly the autoantigen for NMO has been identified as aquaporin 4 (Lennon et
al., 2005). These associated disorders are now clinically distinguishable from MS





Figure 1.3 Clinical courses of different sub-types of multiple sclerosis.
MS manifests itself in several different forms in different patients, ranging from relapsing remitting
disease (top), secondary progressive disease which normally develops from relapsing remitting MS
(middle) and primary progressive MS (bottom).
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1.1.3.3 The genetics of MS
MS has a strong genetic component. Studies in twins and siblings have shown that
there is a higher risk of developing MS in monozygotic twins (25-30% concordance),
dizygotic twins and non-twin siblings (2-5% concordance), as compared to unrelated
adoptees from non-affected parents (<0.2% concordance). This low risk in unrelated
adoptees reflects the risk in the general population (Willer et al., 2003; Compston
and Coles, 2008). In the 1970s the first association between MS and the alleles of the
MHC was identified (Compston, Batchelor and McDonald, 1976; Terasaki et al.,
1976). These have since been specified to human leukocyte antigen (HLA) serotypes
DR15 and DQ6 and the corresponding genotypes: DRB1*1501, DRB5*0101,
DQA1*0102 and DQB2*0602 (Olerup and Hillert, 1991). These are all associated
with the MHC and therefore have a role in T cell activation, supporting the thought
that MS is T cell mediated.
In a large genomewide association study, another set of single nucleotide
polymorphisms (SNPs) associated with MS was recently identified, outside of the
MHC region. These SNPs are within the IL-2R and IL-7R chains (Hafler et al.,
2007). Polymorphisms within the IL-2R (CD25) supports the idea that regulation of
the immune response is required during MS and correlating with this, Treg have been
shown to have impaired function in MS (Viglietta et al., 2004; Haas et al., 2005).
IL-7 signalling may be needed for the generation of autoreactive T cells in MS
patients (Bielekova et al., 1999).
Importantly, genetic studies have also brought to light the protective effects of some
alleles, namely HLA-C5 (Yeo et al., 2007), HLA-DRB1*11 (Ramagopalan et al.,
2007; Dean et al., 2008) and HLA-B*44 (Silva et al., 2009; Healy et al., 2010).
The association of the key risk alleles of MS to the immune system add weight to the
thought of the disease being autoimmune mediated. Also, the association of MS with




1.1.3.4 Environmental factors contributing to MS
There are a few environmental factors that are implicated to have an important role
in the pathogenesis of MS. The global distribution of MS can be generalised as
increasing with distance north or south of the equator. Also, the risk of developing
MS has been correlated to the place of residence during childhood. People have
decreased risk if they migrate from high-risk regions to low-risk regions during
childhood, or have an increased risk if they migrate from low-risk to high-risk
regions in childhood (before the age of 15), as compared to the population in their
place of origin (Dean and Kurtzke, 1971; Elian, Nightingale and Dean, 1990). The
contributing factors of vitamin D and viral infection in MS will now be discussed.
1.1.3.4.1 Vitamin D
The general observation of increased incidence of MS with increasing distance from
the equator has been attributed to vitamin D levels. People who, during their
childhood, spent large amounts of time outdoors in the sunlight have been found to
have a much lower risk of developing MS (van der Mei et al., 2003; Kampman,
Wilsgaard and Mellgren, 2007) and this was also observed between pairs of
monozygotic twins (Islam et al., 2007). Also, the intake of vitamin D through
supplements is thought to decrease the risk of developing MS (Munger et al., 2004).
Serum levels of vitamin D have been observed to be significantly lower in MS
patients as opposed to healthy controls (Soilu-Hanninen et al., 2005; Correale,
Ysrraelit and Gaitan, 2009), however this was not observed in all studies (Barnes et
al., 2007; Kragt et al., 2009).
The exact mechanisms by which vitamin D may be having a beneficial effect in MS
are still being elucidated. However it has been found that Vitamin D (or 1,25-
dihydroxyvitamin D(3) as the active form) inhibits the production of pro-
inflammatory cytokines by in vitro cultured human CD4+ CD25- effector T cells, and
in contrast promoted the development of CTLA4+ FoxP3+ Treg resulting in an anti-
inflammatory effect (Jeffery et al., 2009). Correlating with this, several studies have
looked at the effect of vitamin D3 on MS patients with results implicating a role in
inducing a regulatory phenotype. One study showed that proliferation of CD4+ T
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cells was inhibited by vitamin D3 and that the cells adopted a more regulatory
phenotype by inducing an increased development of IL-10-producing cells (Correale,
Ysrraelit and Gaitan, 2009). A second study observed increased serum levels of
TGF- 1 in patients supplemented with vitamin D3 for six months (Mahon et al.,
2003).
Numerous studies have indicated that exogenous vitamin D is protective in the
pathogenesis of EAE (Lemire and Archer, 1991; Spach et al., 2006; Pedersen et al.,
2007; Chang et al., 2010) although varied mechanisms of action were proposed.
These include inhibition via vitamin D mediated IL-10-production and suppression
(Spach et al., 2006), inhibition of chemokine-mediated monocytes trafficking
(Pedersen et al., 2007), or inhibition of pro-inflammatory Th17 differentiation
(Chang et al., 2010). Vitamin D also been shown to induce tolerogenic DCs which
can then promote FoxP3+ Treg and these mediate autoimmune responses (as
reviewed in (Adorini and Penna, 2009).
1.1.3.4.2 Viral infection
Epidemiological data and the inflammatory nature of the lesions in MS
patients have led to the consideration of MS being driven by infection.
Another explanation for the change in risk of MS after migration at an early
age could be early exposure to infection. Several viral infections have been
associated with pathogenesis of MS, including Epstein-Barr virus (EBV), and
measles and rubella (Compston and Coles, 2008). The majority of humans are
infected with EBV and it establishes a lifelong dormancy within the memory
B cell pool, with occasional reactivation and therefore continual viral
production. MS patients exhibit higher prevalence of anti-EBV antibodies,
indicating prior infection with EBV compared to healthy controls (Ascherio
and Munch, 2000; Pohl et al., 2006; Banwell et al., 2007). Interestingly,
increased levels of IgG against the EBV nuclear antigen (EBNA) in normal
people is associated with the increased risk of developing MS later in life as
compared to healthy controls (Sundstrom et al., 2004; Levin et al., 2005;
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DeLorenze et al., 2006). This was demonstrated in several short term and long
term studies with MS patients. However, despite these apparent correlations,
the mechanism by which EBV may contribute to MS pathology is still unclear.
A recent study investigating several different viral agents to determine if they
act as viral triggers to MS found that CIS patients exhibited elevated humoral
and cellular immune responses to EBNA-1, but not to other viral agents, i.e.
human cytomegalovirus (HCMV) or measles (Lunemann et al., 2010), and this
appeared to correlate with progression to MS. The study suggested
EBNA1-specific IgG titers could be used as a prognostic marker for disease
progression to MS in CIS patients.
1.1.3.5 Treatments of MS
There are various different forms of treatment available for MS, as outlined below.
1.1.3.5.1 Interferon- (IFN- -1b and IFN- -1a; Avonex®, Rebif®,
Betaseron®)
Interferon- has become one of the first-line agents used for the treatment of RRMS
having exhibited good efficacy in several phase III trials (IFNB-MS-Study, 1993;
IFNB-MS-Study, 1995; Durelli et al., 2002). Treatment with IFN- resulted in the
reduction in the rate of clinical relapse and in the development of new lesions as
determined by MRI. Despite its known efficacy, the exact mechanism by which
IFN- elicits its beneficial effects is still a matter of debate. It is thought to generally
shift the pro-inflammatory cytokine production, for example in a Th1 response,
towards a more anti-inflammatory/regulatory cytokine environment (Ozenci et al.,
2000a; Ozenci et al., 2000b; Zang et al., 2003). Only two thirds of MS patients
respond to IFN- treatment (Arnason, 1999; Chiu et al., 2009). This has recently
been attributed to the ability of IFN- to inhibit Th1 responses, by inducing increased
IL-10 production, but not Th17-mediated responses as shown in EAE (Axtell et al.,
2010). Correlating with this, RRMS patients that were non-responders to IFN-
treatment were found to have higher IL-17 levels (Axtell et al., 2010).
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1.1.3.5.2 Glatiramer acetate (Copaxone®)
This is a synthetic amino acid polymer composed of tyrosine, glutamate, alanine and
lysine and is used in the treatment of RRMS. It results in the reduction in the rate of
clinical relapse and a slight reduction in the development of new lesions (Johnson et
al., 1995; Mancardi et al., 1998; Comi, Filippi and Wolinsky, 2001). It is thought to
shift the T cell response from a pro-inflammatory Th1 response towards an anti-
inflammatory/regulatory Th2 response (Miller et al., 1998a; Duda et al., 2000). In
EAE, glatiramer acetate has recently been shown to downregulate Th17-associated
pro-inflammatory cytokines IL-6, IL-23, TNF- and IL-17 and this may have an
indication of the mechanism of action leading to its disease suppressive activity
observed in MS patients (Begum-Haque et al., 2008).
1.1.3.5.3 Mitoxantrone (Novantrone®)
Mitoxantrone is an immunosuppressive cytotoxic agent. It intercalates with DNA
causing single-stranded and double-stranded breaks to occur and also inhibits DNA
repair, thus able to suppress an inflammatory response from proliferating cells
namely B and T cells and macrophages (Fidler, DeJoy and Gibbons, 1986; Fidler et
al., 1986; Rosenberg, Carvlin and Krugh, 1986). It has been found to have anti-
inflammatory effects by decreasing the secretion of IFN- - and IL-2 (Fidler et
al., 1986). Mitoxantrone is effective for the treatment of RRMS and reduces the rate
of clinical relapse and delays the progression of disability.
1.1.3.5.4 Natalizumab (Tysabri®)
This was the first monoclonal antibody developed for the treatment of RRMS.
Natalizumab is a monoclonal antibody against the 4 chain of 4 1 integrin (very
late antigen-4) (Engelhardt and Kappos, 2008) for which successful trials were
performed (Tubridy et al., 1999; Miller et al., 2003). 4 1 is expressed on the surface
of all leukocytes and the monoclonal antibody acts to prevent the binding of
leukocytes to the ligand of 4 1, vascular cell adhesion molecule-1 (VCAM-1), at
the blood brain barrier, thereby preventing the entry of lymphocytes into the CNS
(Rice, Hartung and Calabresi, 2005; Johnson, 2007). Natalizumab was briefly
withdrawn from the market after two patients in a trial receiving both Natalizumab
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and IFN- -1 developed progressive multi-focal encephalopathy (PML) another
demyelinating disease (Kleinschmidt-DeMasters and Tyler, 2005; Langer-Gould et
al., 2005) but has since been re-introduced. PML occurs as a result of reactivation of
JC or BK virus which the majority of the population are infected with. Treatments
that suppress the immune system have been have been found to increase the
occurrence of PML (Matteucci et al., 2002; Jilek et al., 2010).
Other newer treatments for MS include Fingolimod (FTY 720; Gilenia®),
Cladribine, Alemtuzumab (Campath-1H), Minocycline, Rituximab and Daclizumab
(reviewed in (Vosoughi and Freedman, 2010). Fingolimod acts on sphingosine-1-
phosphate (S1P) receptors and prevents the egress of the lymphocytes out of the
secondary lymphoid organs (Massberg and von Andrian, 2006) thereby reducing the
number of circulating lymphocytes and has proved to be beneficial in MS (Kappos et
al., 2010). Cladribine (an analogue of purine nucleoside), Alemtuzumab (a
humanised monoclonal antibody targeting CD52), Rituximab (an anti-CD20
antibody) and Daclizumab (a humanised monoclonal antibody against CD25) have
all exhibited promise in trials for MS treatment (as reviewed in (Vosoughi and
Freedman, 2010).
1.2 CD4+ T cell subsets
During T cell activation, the fate of the CD4+ T cells is determined by signal 3. The
pro-inflammatory cytokine IL-1 has an important role in directly driving IFN-
IL-2 production by CD4+ T cells, driving a pro-inflammatory response (O'Sullivan et
al., 2006). Cytokine signalling drives the differentiation of naïve CD4+ T cells
towards their particular Th subset.
1.2.1 Cytokine signalling in CD4+ T cells
There are numerous different cytokines able to elicit an inflammatory response and
they are able to interact with each other to counter-regulate the immune response
under different circumstances. First the downstream signalling pathways will be
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described, followed by cytokine signalling by IL-12, IL-17 and IL-6, which are
important in Th1 and Th17 signalling.
1.2.1.1 The downstream events in cytokine signalling
Receptor mediated cytokine signalling results in a series of down-stream activation
events eventually leading to gene upregulation or downregulation. This process
allows the extracellular cytokine signal to be transmitted to the nucleus for gene
transcription. Cytokine signalling activates the intracellular janus kinase-signal
transducer and activation of transcription (JAK-STAT) signalling pathway (see
Figure 1.4). The JAKs are tyrosine kinases capable of phosphorylating the cytokine
receptor after ligand binding to the surface of the receptor. This leads to the
activation of specific STATs. The activation of STATs leads to the downstream
expression of the Th lineage specific master regulator transcription factors T-bet
(Th1), GATA3 (Th2), ROR (Zhu and Paul, 2010)
(Hebenstreit, Horejs-Hoeck and Duschl, 2005). Importantly the suppressor of
cytokine signalling (SOCS) family of proteins (SOCS1-7) which are produced after
JAK-STAT signalling, act to inhibit the JAK-STAT signalling pathway (Krebs and
Hilton, 2001) as summarised in Figure 1.4. The different SOCS proteins are able to
bind either the cytokine receptor or the JAK itself to inhibit STAT signalling. In this
way, JAK signalling induces transcription of both proinflammatory genes and SOCS
proteins which subsequently act to inhibit the JAK-signalling, highlighting a level of
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Figure 1.4 The JAK-STAT signalling pathway and its inhibition by the SOCS
proteins.
Left shows cytokine signalling through the JAK-STAT pathway which results in gene transcription.
Right shows the inhibition of the JAK-STAT pathway through SOCS proteins. 1) cytokine binds to
the cytokine receptor; 2) binding of the cytokine activates JAK which then phosphorylates the
intracellular domain of the cytokine receptor; 3) phosphorylation recruits the STAT proteins to the
cytokine receptor; 4) JAK then phosphorylates the STAT protein; 5) the phosphorylation allows the
STAT proteins to dimerise and migrate to the nucleus; 6) STAT dimers initiate the transcription of
specific transcription factors and inflammatory cytokines as well as the production of SOCS. The
SOCS proteins can then antagonise the JAK-STAT signalling pathway by binding to the
phosphorylation sites on the cytokine receptor, preventing the binding of STATs, and by binding to
JAKs directly preventing their phosphorylation of the cytokine receptor.
INTRODUCTION
25
1.2.1.2 The IL-12 cytokine family
IL-12, which promotes Th1 differentiation (Hsieh et al., 1993), is a member of the
IL-12 cytokine family which also includes IL-23, IL-27 and the recently identified
cytokine, IL-35. All four cytokines are heterodimers consisting of an chain (p19,
p28 or p35) and a chain (p40 or Ebi3). IL-12 is made up of subunits p40 and p35.
The p40 chain can heterodimerise with p19 to form IL-23 (Oppmann et al., 2000).
IL-27 is made up of chain p28 and chain Ebi3 (Pflanz et al., 2002) which was
identified in Epstein-Barr virus infected B cells some years ago (Devergne et al.,
1996). And finally, the newest member of the family, IL-35 is composed of the IL-12
chain p35 and the chain Ebi3 (Collison et al., 2007) as summarised in Figure 1.5.
IL-12, IL-23 and IL-27 are all mainly produced by APCs after APC activation (Ma et
al., 1996; Pflanz et al., 2002; Hibbert et al., 2003) whereas IL-35 has so far only been
suggested to be produced in bioactive form by FoxP3+ Tregs (Collison et al., 2007),
although this remains controversial. The receptors for these cytokines are composed
of various different receptor chains: IL-12R 1, IL-12R 2, IL-23R and gp130. The
receptor for IL-12 is a pairing of IL-12R 1 and IL-12R 2 (Parham et al., 2002). The
IL-23 receptor shares IL-12R 1 with IL-12 (Parham et al., 2002). IL-27 signals
through gp130 and WSX-1 (also known as IL-27R ) (Pflanz et al., 2004) and as yet,
the receptor for IL-35 is unknown as shown in Figure 1.5. IL-12 signalling, as
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Figure 1.5 IL-12 cytokine family highlighting the sharing of subunits in the
cytokines themselves, and the receptors.
The IL-12 family of cytokines is composed of IL-12, IL-23, IL-27 and IL-35. Each cytokine consists
of an chain and a chain, and different combination pairings of the chains results in the formation
of different cytokines. In the same way, IL-12, IL-23 and IL-35 share receptor subunits IL-12R 1 and
IL-12R 2 although the second component of the IL-35 receptor is still unknown. In contrast, IL-27
has its unique receptor composed of gp130 and WSX-1. Adapted from Palmer and Weaver, 2010
(Palmer and Weaver, 2010)
1.2.1.3 IL-6 signalling
IL-6 belongs to the family of gp130 cytokines, of which IL-27 is also a member. All
members have a four-helical protein structure and signal through a receptor complex
which includes at least one subunit of the signal transducing receptor glycoprotein
gp130 (Taga, 1997; Taga and Kishimoto, 1997; Pflanz et al., 2004).
IL-6 has been identified as being able to signal through two different pathways:
classical signalling via membrane bound IL-6R on the surface of the target cell, or
trans-signalling via a naturally occurring soluble IL-6R. In classical signalling, IL-6
binds to the membrane bound IL-6R; this binding leads to dimerisation of the IL-6R
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and activation of gp130 (Taga and Kishimoto, 1997; Rose-John, 2001). Gp130 is
expressed on all cells whereas IL-6R is not widely expressed, except on neutrophils
and macrophages and some lymphocytes, therefore classical signalling is restricted to
these cell types expressing IL-6R. During trans-signalling IL-6 binds to the naturally
occurring soluble IL-6R. This IL-6/soluble IL-6R complex then activates gp130
leading to downstream signal transduction (Peters, Muller and Rose-John, 1998;
Rose-John, 2001). In this way, cells that do not express IL-6R can still respond to
IL-6 signalling through the action of the soluble IL-6R thereby increasing the
spectrum of cell types on which IL-6 can have an effect.
1.2.1.4 The IL-17 cytokine family
IL-17 (or IL-17A) is part of the IL-17 family of cytokines. This is composed of
several homologues of IL-17A, namely, IL-17B, IL-17C, IL-17D, IL-17E and IL-17
F (reviewed in Gaffen, 2009 (Gaffen, 2009). IL-17A and IL-17F are the most well
characterised members of the family with apparent roles in inflammation and
autoimmunity (Yang et al., 2008b; Awasthi and Kuchroo, 2009) although this is
controversial (Haak et al., 2009) as will be discussed in later sections. The signals
elicited by IL-17F are much weaker in terms of downstream gene activation
compared to signalling through IL-17A. These two molecules can also dimerise to
form IL-17A-IL-17F heterodimers which signal at an intermediate level (McAllister
et al., 2005; Wright et al., 2007). The receptors of the IL-17 family, IL-17RA,
IL-17RB, IL-17RC and IL-17RD also share ligands and can dimerise to form
different receptors for each ligand. The exact nature of the receptor complex for each
ligand is still not fully defined. The heterodimer between IL-17A-IL-17F has been
found to signal through the IL-17RA/IL-17RC complex (Wright et al., 2008). IL-
17E, also known as IL-25, is considered to be a Th2 promoting cytokine. It binds IL-
17RB which pairs with IL-17RA (Claudio et al., 2009). It has been shown that mice
deficient in both of these receptor subunits cannot respond to IL-17E (Rickel et al.,
2008). The exact functions of IL-17B, IL-17C and IL-17D are still unclear. IL-17
signalling triggers the production of other pro-inflammatory cytokines, the release of
chemokines which attract other cells, especially neutrophils, to sites of inflammation
(reviewed in (Kolls and Linden, 2004)).
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1.2.2 CD4+ T cell differentiation
The main role of cytokine signalling is to trigger activation of downstream STAT
proteins which each in turn play an important role in the differentiation of CD4+ T
cells towards a particular phenotype. During T cell activation, the naïve CD4+ T cells
can differentiate in to Th1, Th2 or Th17 cells. Originally, Mosmann described two
distinct types of mouse CD4+ T cell clones, Th1 and Th2 cells (Mosmann et al.,
1986). These could be distinguished by their distinct cytokine production patterns as
well as their differential expression of cell surface molecules. A new Th subset,
distinct from Th1 and Th2 cells, has been recently defined, the Th17 lineage
(Harrington et al., 2005; Park et al., 2005). Even more recently, two new subsets
have been postulated, Th9 and Th22 cells (Dardalhon et al., 2008; Veldhoen et al.,
2008b; Duhen et al., 2009; Trifari et al., 2009) although they remain to be confirmed
as true Th subsets, as lineage specific transcription factors are yet to be identified. In
contrast to these Th subsets, CD4+ Treg cells play a crucial role in the regulation of
an immune response, as both natural Treg cells (those developed in the thymus) and
adapted Treg cells (aTreg; those differentiated from naïve CD4+ T cells in the
periphery). The role of each of these CD4+ subsets will now be summarised. For a
summary diagram of the main points see Figure 1.6 at the end of this section.
Each Th subset can be induced by TCR stimulation of naïve CD4+ T cells in vitro in
the presence of particular cytokine cocktails (with or without cytokine-neutralising
antibodies). The different Th subsets also express distinct sets of chemokine
receptors on their surface. This dictates their migration in vivo, and whether specific
T cells can enter particular tissues before or during inflammation. This will be
discussed in detail in section 1.4.
1.2.2.1 Th1 cells
Th1 cells make IFN-
TNF- . The production of these pro-inflammatory cytokines leads to the activation
of macrophages at the site of inflammation. As such Th1 cells are important for host
defence against intracellular pathogens, but they can also provoke unwanted
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autoimmune inflammation. The activation of macrophages by IFN-
defence against intracellular microbes.
In vitro Th1 differentiation was found to be promoted by the addition of IL-12 and
the neutralisation of IL-4 (Hsieh et al., 1993). The transcription factor T box
expressed in T cells (T-bet) was discovered to be the key transcription factor of the
Th1 lineage (Szabo et al., 2000). T-bet, a 530-amino acid protein with a 189-amino
acid T box DNA-binding domain, is required for the stable activation of the IFN-
gene and the induction of IFN- Importantly, ectopic expression of T-bet
resulted in the induction of IFN- -polarised cells, resulted
in their switching of their phenotype towards Th1-IFN- (Szabo et al.,
2000). It has also been shown that although T-bet induces the production of IFN-
IFN- -bet expression, highlighting an
important autocrine loop in which IFN-
that promotes its own production (Lighvani et al., 2001). IFN-
STAT1, and this in turn induces the expression of T-bet (Afkarian et al., 2002). The
mechanism by which T-bet upregulates IFN-
thought to be through the Ifng gene and through upregulating the IL-12R 2
expression, therefore increasing IFN-
responsiveness to IL-12 (Mullen et al., 2001; Mullen et al., 2002). This correlates
with the two step T-bet upregulation proposed recently (Schultz et al., 2009).
Through mathematical modelling it was suggested that IFN-
expression of T-bet during T cell activation whereas the IL-12R 2 was suppressed at
this stage. After TCR stimulation, T-bet upregulated IL-12R 2 and IL-12 was then
able to feedback to maintain the T-bet expression (Schultz et al., 2009).
STAT4 also seems to be required for Th1 differentiation. STAT4-deficient mice
display impaired Th1 responses together with an increase in Th2 responses,
indicating STAT4 may act to suppress Th2 responses under normal conditions
(Kaplan et al., 1996b; Thierfelder et al., 1996). Indeed, it has been found that
GATA3, the key regulator of the Th2 lineage, suppresses Th1 responses directly
through downregulation of STAT4, rather than acting upon T-bet, or the IL-12
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receptor (Usui et al., 2003). STAT4 has a key role in Th1 differentiation as it can act
directly to induce IFN- -12R 2 as well as T-bet
during the differentiation process (Usui et al., 2003; Usui et al., 2006).
IL-18 has also been implicated in differentiation towards a Th1 phenotype. It was
first described as IFN- -inducing factor (IGIF) in T cells and NK cells (Okamura et
al., 1995). IL-18 has been found to synergise with IL-12 for the induction of a Th1
IFN- -producing response (Micallef et al., 1996; Stoll et al., 1998) and is considered
to augment the Th1 response (Robinson et al., 1997). It is thought to increase TNF-
(not IFN- (Ito et al., 2003).
Th1 cells were originally thought to be the key players in autoimmune disease. The
pattern of cytokine production and chemokine expression on the autoreactive T cells
found in MS patients had a Th1-phenotype (Merrill, 1992; Sorensen et al., 1999) and
this was mimicked in murine EAE (Ando et al., 1989; Merrill et al., 1992), leading to
the thought that MS and EAE were Th1-mediated. In addition, when MS patients
were treated with IFN- (Panitch et al., 1987a;
Panitch et al., 1987b), indicating IFN-
evidence, the loss of T-bet or STAT4 led to the profound abrogation of EAE (Chitnis
et al., 2001; Bettelli et al., 2004). This evidence all pointed towards Th1 cells being
the key pathogenic Th subset in induction of autoimmune inflammation. This will be
discussed in more detail in a later section in light of more recent data.
In summary, the Th1 cells develop in the presence of IFN- -12 and IL-18 and
produce IFN- - and lymphotoxin. Th1
cells are T-bet+, and their differentiation is tightly controlled by STAT1 and STAT4.
1.2.2.2 Th2 cells
Th2 cells make IL-4, IL-5 and IL-13 as their signature cytokines and do not produce
IFN- - (Mosmann et al.,
1991; Minty et al., 1993). Th2 cells have a very different role to Th1 cells, being
required for the clearance of extracellular pathogens, for example helminth worm
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infections, as well as having a detrimental role in allergy. This is due to the CD4+
Th2 cell-dependent B cell antibody response after activation. The antibodies
produced by the B cells after antigen presentation to the Th2 cells (IgG1 and IgE),
and Th2 activation, provide the humoral response to eliminate extracellular
pathogens and during allergic reactions (reviewed in (Maizels et al., 2004; Lindell et
al., 2008). Th1-associated cytokines, IFN- -12 inhibit the differentiation of
naïve CD4+ T cells into Th2 cells. To achieve successful Th2 polarisation, naïve
CD4+ T cells are activated in the presence of IL-4, leading to the phosphorylation of
STAT6. This in turn leads to the induction of GATA3, the key transcription factor of
Th2 cells (Zheng and Flavell, 1997), and the subsequent activation of Th2-cytokines
IL-4, IL-5 and IL-13 (Zhang et al., 1997). GATA3 is also important for T cell
development and naïve T cells express it at a low level. On activation and
differentiation, Th2 cells upregulate GATA3 whereas cells differentiating toward the
Th1 lineage downregulate its expression (Zhang et al., 1997).
STAT6 is important for Th2 differentiation and IL-4 signalling (Kaplan et al., 1996a;
Takeda et al., 1996). The ectopic expression of STAT6 induces high levels of
GATA3 expression as well as production of Th2-specific cytokines during the in
vitro differentiation of Th1 cells (Kurata et al., 1999; Zhu et al., 2001) indicating its
important role in the differentiation of Th2 cells, being able induce Th2 phenotype
even in the presence of Th1-polarising conditions. STAT5, has also been found to be
required for Th2 differentiation (Zhu et al., 2003). To support this, it was found that
in the absence of either STAT5 isoform (STAT5a or STAT5b), Th2 differentiation is
severely impaired, both in vitro and in vivo (Kagami et al., 2000; Kagami et al.,
2001).
Th2 cells are not considered to be required in the induction of autoimmune disease.
Myelin-responsive Th2 cells were not able to induce EAE after adoptive transfer,
unless the Th2 cells were transferred into lymphopenic host mice (Baron et al., 1993;
Lafaille et al., 1997; Jager et al., 2009).
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In summary, Th2 cells produce IL-4, IL-5 and IL-13 as their signature cytokines.
GATA3 is the master regulator of Th2 cells, which works together with STAT6 and
STAT5 to ensure differentiation towards a Th2 phenotype and maintenance of the
Th2 cytokine profile.
1.2.2.3 Th17 cells
In 2003, a new CD4+ T cell subset, promoted by IL-23, was discovered (Aggarwal et
al., 2003; Murphy et al., 2003). This new Th subset was later defined as the Th17
lineage (Langrish et al., 2005; Bettelli, Korn and Kuchroo, 2007) phenotypically
distinct from the Th1 and Th2 lineages. In general, Th17 cells are required for
clearance of pathogens and fungi at epithelial/mucosal barriers, and can also have a
role to play in the induction of autoimmune inflammation (Littman and Rudensky,
2010).
Our understanding of the molecular requirements for Th17 differentiation is still
being refined.
Th17 differentiation was shown to be inhibited by IFN- -4, the key signature
cytokines of Th1 and Th2 cells respectively. Th17 cells were shown to produce
IL-17A and IL-17F, independently of STAT1, T-bet, STAT4 and STAT6 (reviewed
in Harrington et al, 2006 (Harrington, Mangan and Weaver, 2006). The transcription
factor retinoic acid-
an orphan nuclear receptor expressed on double-positive thymocytes (He et al., 1998)
and found to be important
required for the development of lymphoid tissue inducer (LTi) cells and LTi-like
cells which are required for development of lymphoid tissues (Sun et al., 2000; Eberl
et al., 2004)
differentiation of Th17 cells (Ivanov et al., 2006) -deficient mice lacked
IL-17-producing T cells, highlighting that in vivo as well as in vitro differentiation of
(Ivanov et al., 2006). Another
related nuclear receptor, ROR , has also been shown to be required for Th17
differentiation. The two transcription factors work together to promote Th17
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differentiation more than when either is expressed alone (Yang et al., 2008d). To
impaired the IL-17 production or Th17 generation, and also resulted in the
amelioration of disease in EAE (Yang et al., 2008d).
Initially it was thought that IL-23 was the key cytokine required for the
differentiation of IL-17-producing pro-inflammatory T cells (Aggarwal et al., 2003;
Langrish et al., 2005). However, it then emerged that IL-23 was not required for the
differentiation of naïve T cells, but rather for the maintenance of the Th17 phenotype
after their initial differentiation (Stritesky, Yeh and Kaplan, 2008). The IL-23R is not
expressed on naïve CD4+ T cells, but on differentiated Th17 cells, confirming that
IL-23 can only act to maintain the Th17 phenotype once the cells are terminally
differentiated. This IL-23 signalling is however essential for the development of a
full Th17 response (McGeachy et al., 2009). Mice deficient in either IL-23 itself or
the IL-23R exhibit an impaired ability to produce a significant Th17 response in vivo
(Langrish et al., 2005; Awasthi et al., 2009; McGeachy et al., 2009). IL-23 also has
the role of inducing the production of other effector cytokines by Th17 cells, for
example, IL-22 (Liang et al., 2006). It has been determined that IL-6 and TGF-
were the key cytokines required for the differentiation of naïve CD4+ T cells towards
a Th17 phenotype (Bettelli et al., 2006; Mangan et al., 2006; Veldhoen et al., 2006;
Korn et al., 2008).
IL-6 has been shown to be required for the in vitro and in vivo differentiation of
Th17 cells (McGeachy et al., 2007; Zhou et al., 2007; Korn et al., 2008). In addition
to this, IL-6-deficient mice are resistant to the induction of EAE highlighting a role
for IL-6 signalling in autoimmune pathogenesis, possibly through the induction of a
Th17 response, although roles in other pathways cannot be excluded (Okuda et al.,
1998; Samoilova et al., 1998; Okuda et al., 1999).
The differentiation of human Th17 cells has proved to be slightly different to murine
cells. In humans, IL-1 in combination with IL-6, TGF- and IL-21 have been shown
to be required for the differentiation towards a Th17 phenotype with the TGF-
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acting to inhibit Th1 cells (Manel, Unutmaz and Littman, 2008; Yang et al., 2008a;
Santarlasci et al., 2009).
Lack of STAT3 resulted in the lack of IL-17-producing Th17 cells being generated,
showing it is required for their differentiation, in both mouse and human cells (Harris
et al., 2007; Yang et al., 2007; Milner et al., 2008). STAT3 functions by binding to
the Il17 gene and also to the Il21 gene, (Chen et al., 2006b; Wei et al., 2007) and
induces the expression of both ROR -23R (Nurieva et al., 2007; Zhou et al.,
2007). IL-6 has the role of activating STAT3 and this is turn also acts to
downregulate FoxP3 expression, thereby suppressing the induction of FoxP3+ Treg,
and highlighting the important role IL-6 has in the balance between Th17 and Treg
differentiation (Yang et al., 2007). STAT5, a Th2-associated STAT protein, has an
inhibitory effect on Th17 cell differentiation (Laurence et al., 2007) which highlights
why IL-2 (which triggers STAT5 activation) can have a negative effect on the Th17
cell generation. However, once Th17 cells are terminally differentiated, it seems that
IL-2 signalling through STAT5 is required for their maintenance and expansion
(Amadi-Obi et al., 2007).
On discovery of IL-23 and the Th17 lineage there was a paradigm switch towards
Th17 cells being the key inducers of autoimmune disease. This will be discussed in
full in a section 1.3.5.2.
1.2.2.4 CD4+ T regulatory cells
A subpopulation of T cells has long been known to be a vital player in regulation and
maintenance of peripheral tolerance. Initially it was found that in mice the depletion
of the CD5+ population resulted in multi-organ inflammation (Sakaguchi et al.,
1985). The phenotype of these ‘regulatory cells’ was gradually refined over time and
defined as CD4+ CD25+ Treg (Sakaguchi et al., 1995). Similar experiments were
performed in the rat (as reviewed in (Powrie et al., 1991). The transfer of CD25-
depleted CD4+ cells into lymphopenic mice resulted in the induction of autoimmune
disease of several forms, i.e. thyroiditis, insulitis and polyarthritis (Sakaguchi et al.,
1995) due to lack of suppression of the inflammatory response. Reciprocally, co-
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transfer of CD4+ CD25+ T cells provided protection against autoimmune disease,
highlighting the regulatory potential of CD4+ CD25+ T cells (Sakaguchi et al., 1995)
in maintaining self tolerance. Treg develop in the thymus. This was determined after
it was observed that neonatal thymectomy 3 days after birth resulted in a block in the
presence of CD4+ CD25+ cells in the periphery (Sakaguchi et al., 1996).
Later, Foxp3 was identified to be the key transcription factor required by Treg for
their development and suppressive function (Fontenot, Gavin and Rudensky, 2003;
Hori, Nomura and Sakaguchi, 2003). To support this, scurfy mice deficient in
functional FoxP3, due to a mutation in the gene, have severe lymphoproliferative
disease (Brunkow et al., 2001). Similarly, the human autoimmune syndrome
immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX) is
caused by mutations in the human homolog of the Foxp3 gene (Bennett et al., 2001),
highlighting its importance in the control of immune homeostasis.
It was later determined that FoxP3 expression can also be induced in naïve FoxP3-
CD4+ T cells either in vivo (as defined in 1.2.2) or in vitro (induced Treg; iTreg) in
the presence of TGF- (Chen et al., 2003; Fu et al., 2004). As yet, it is not possible to
distinguish between nTreg and aTreg, as they both express FoxP3. The methylation
status of the foxp3 locus, however, has found to be a marker of FoxP3 expression
stability in Treg. nTreg, which remain stable and continue to express FoxP3, display
complete demethylation, whereas TGF- -induced Treg exhibit only partial
demethylation, despite high expression of FoxP3 (Floess et al., 2007). These iTreg
display plasticity in their phenotype and can lose FoxP3 expression as well as
suppressive function after re-stimulation in the absence of TGF- (Floess et al.,
2007).
Treg have been shown to elicit their regulatory suppression on multiple ‘layers,’
including: 1) within the lymph node during the steady state, by DC conditioning
leading to weak stimulation and no effector response during an inflammatory
response; 2) in the lymph node during an inflammatory response and exposure to self
antigen, Treg proliferate and are therefore able to counter the development of a T
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effector response; 3) some of these Treg leave the lymph node and migrate to the
target organ and initiate the resolution of the inflammation by suppression of the
inflammatory response (reviewed in (O'Connor and Anderton, 2008; Vignali,
Collison and Workman, 2008) .
Interestingly, it has been shown that to control Th1-mediated inflammation Treg
adopt the expression of T-bet, in response to IFN- (Koch et al., 2009). T-bet+
FoxP3+ Treg were better able to control the expansion of CD4+ T-bet+ Th1 effector
cells than T-bet- FoxP3+ Treg were. In the same way, T-bet- FoxP3+ Treg were better
able to control Th2 or Th17 mediated inflammation compared to T-bet+ Treg. This
suggested that in order to suppress a particular T helper response, Treg may partially
adopt the phenotype of the response they are attempting to control.
The expression of IFN regulatory factor 4 (Irf4) in Treg has been shown to be
important for their suppression of a Th2 response (Zheng et al., 2009). Similarly,
STAT3 expression in Treg has been found to be the key factor required to facilitate
Treg suppression of a Th17 response (Chaudhry et al., 2009). Therefore, Treg appear
able to suppress Th1, Th2 and Th17-mediated responses through the expression of
key transcription factors associated with each T effector subset and this highlights
how Treg are able to effectively control different immune responses.
The potential of Treg therapy in autoimmune disease is a subject of intense
investigation. Either the expansion of Treg in vivo or the transfer of in vitro expanded
nTreg or iTreg could provide a means to control autoreactive T cells in vivo.
However, the plasticity of Treg has been brought into question recently, with reports
that they can begin to produce proinflammatory cytokines i.e. IL-17 (Lochner et al.,
2008; Yang et al., 2008c).
1.2.2.5 The relationship between Th17 cells and Treg
Th17 cells and Treg share a close developmental relationship. Pro-inflammatory
Th17 cells require anti-inflammatory TGF- for their differentiation, as do aTreg in
the periphery. The presence of TGF- alone leads to the development of FoxP3+
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aTreg following TCR stimulation. In contrast, if TGF- is found together with pro-
inflammatory IL-6, Th17 cells are generated, thereby highlighting the importance of
IL-6 in suppressing the expression of FoxP3 and promoting the development of Th17
cells at the same time (Bettelli et al., 2006). It is interesting how TGF- is able to
differentiate two opposing phenotypes of T cells. It is thought that low
concentrations of TGF- favour Th17 differentiation in the presence of IL-6, whereas
high concentrations of TGF- favour differentiation towards aTreg phenotype,
suppressing the expression of IL-23R (Zhou et al., 2008). Functionally, Treg and
able to bind to each other and inhibit the others’ activity (Zhou et al., 2008).
-associated
cytokines, for example IL-6, IL-21 and IL-23 had the effect of removing the FoxP3-
a Th17 phenotype (Zhou et al., 2008). This highlights the importance of the
surrounding cytokine environment in determining the outcome of Treg or Th17
balance. Importantly, retinoic acid (all-trans retinoic acid, ATRA) inhibits Th17
differentiation and, instead, promotes FoxP3 expression and Treg differentiation
(Elias et al., 2008).
1.2.2.6 Th9 cells
Another possible Th subset, Th9, has recently been proposed. These are induced in
the presence of IL-4 and TGF- . The IL-4 suppresses TGF- -driven expression of
Foxp3 and results in a FoxP3- T effector cell that produces IL-9 and IL-10
(Dardalhon et al., 2008; Veldhoen et al., 2008b). These Th9 cells do not express
other lineage-specific transcription factors, for example, T-
FoxP3. However, a Th9 lineage-specific transcription factor is yet to be identified
and Th9 cells are therefore still to be confirmed as a true Th subset.
IL-9 and IL-10 have previously been associated with the Th2 lineage. However, Th9
cells produce very low levels of other Th2 cytokines, and produce high amounts of
IL-9 which has a pro-inflammatory role (Li and Rostami, 2010). Th9 cells have been
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shown to have a T effector phenotype, rather than a regulatory phenotype, despite
their production of IL-10 (Jager et al., 2009). Th9 cells were able to induce disease,
both in the EAE model (Jager et al., 2009) and in a model of colitis (Dardalhon et al.,
2008).
1.2.2.7 Th22 cells
Production of IL-22 was described in differentiated Th17 cells (Kreymborg et al.,
2007). However, Th22 cells have now been suggested to be a distinct subset able to
produce IL-22, but neither IL-17 nor IFN- (Duhen et al., 2009; Trifari et al., 2009).
Their differentiation is promoted in the presence of IL-6 and TNF- (Duhen et al.,
2009; Trifari et al., 2009). Human Th22 cells have been shown to express skin-
homing receptors CCR4 and CCR10 which implicate them skin homeostasis and
inflammatory pathology (Duhen et al., 2009; Eyerich et al., 2009).
1.2.2.8 Tr1 cells
Tr1 cells are another CD4+ regulatory T cell subset, producing IL-10 and IFN-
however Tr1 cells are FoxP3- compared to the FoxP3+ Tregs (Vieira et al., 2004).
Tr1 cells are induced in the presence of IL-10 and IL-27 (Groux et al., 1997; Awasthi
et al., 2007; Fitzgerald et al., 2007) and may have an important role to play in
regulating autoimmune disease, especially with respect to regulating Th17 responses
















































Figure 1.6 Differentiation of the key CD4+ T cell subsets, and their relationship
with each other.
Th differentiation from naïve CD4+ T cells in the presence of polarising cytokines. Highlights the
cytokines required for differentiation and maintenance of Th1, Th2 and Th17 lineages, and the aTreg
and iTreg, and the relationship and interplay between the different subsets.
INTRODUCTION
40
1.3 EAE: The primordial CD4+ T cell-driven autoimmune
disease model
1.3.1 History
The origin of EAE dates back to when spinal cord inflammation was induced in
rabbits by injection with human spinal cord homogenate (Koritschoner and
Schweinburg 1925). Since then, this has been reproduced in primates (Rivers et al
1933) and rodents, and EAE has now developed into a robust model of MS. EAE
recapitulates most of the main features of inflammation observed in MS, and the
study of EAE has been extremely useful in terms of understanding basic T cell
biology, tolerance, inflammation and autoimmune disease. Importantly, in terms of
what EAE has taught us about MS, two current therapies for MS were originally
developed after observations that they were efficacious in EAE: glatiramer acetate
and natalizumab (anti- 4 1-integrin) (Yednock et al., 1992; Ben-Nun et al., 1996;
Teitelbaum et al., 1996). Other current treatments of MS, IFN- and Mitoxantrone,
were initially developed independently of EAE. Due to the heterogeneity of both MS
and EAE it is unfortunately not possible to predict whether a therapeutic showing
promise in EAE will be as successful in treating disease when translated to MS.
1.3.1.1 EAE as a CD4+ T cell-driven disease
T cells were implicated in EAE when it was observed that disease could be initiated
by the transfer of lymph node cells from donor rats sensitised to spinal cord, into
non-immunised recipient rats (Paterson, 1960), indicating that the disease was cell-
mediated and not antibody mediated. Neonatal thymectomy resulted in the
prevention of EAE development (Arnason et al., 1962) implicating the importance of
T cells in disease induction. Subsequently, CD4+ T cells specifically were implicated
in disease pathogenesis after the observation that EAE was inhibited by the depletion
of CD4+ T cells prior to transfer to recipient mice, whereas the depletion of CD8+ T
cells had no effect on disease induction (Pettinelli and McFarlin, 1981). The transfer
of disease with CNS autoantigen specific CD4+ T cells gave the ultimate evidence
for the importance of CD4+ T cells in mediating disease in rats (Ben-Nun, Wekerle
and Cohen, 1981). Similarly this was also determined in mice (Zamvil et al., 1985).
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1.3.1.2 CNS autoantigens of EAE and TCR transgenic models
Since the initial induction of EAE with the use of brain and spinal cord homogenate,
several CNS autoantigens have been defined and the main ones are outlined in Table
1.1, along with the corresponding mouse strain with which they can be used. The
autoantigens myelin basic protein (MBP) (Zamvil et al., 1985; Zamvil et al., 1986),
proteolipid protein (PLP) (Tuohy et al., 1989; Greer et al., 1992) and myelin
oligodendrocyte glycoprotein (MOG) (Mendel, Kerlero de Rosbo and Ben-Nun,
1995) have been shown to induce EAE upon immunisation in susceptible mice
strains.




















s) 5B6 (Waldner et al., 2000)
Table 1.1 CNS autoantigens of EAE
The autoantigen, relevant peptide and corresponding mouse strain and TCR transgenic in key EAE
models. This table highlights MOG, MBP and PLP autoantigens. MOG and MBP are the antigens
used within this thesis.
Early EAE experiments were performed on susceptible strains of mice using MBP
immunisation, or transfer of MBP-reactive cells into naive recipients e.g. B10.PL or
PL/J mice. C57BL/6 mice were found to be largely resistant to the induction of EAE.
However, after the discovery of the autoantigen MOG, it was found that MOG could
induce the development of chronic EAE in C57BL/6 mice on immunisation (Mendel,
Kerlero de Rosbo and Ben-Nun, 1995) using either recombinant MOG, or a peptide
of MOG (pMOG35-55). This development was a big step forward as it then allowed
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for the assessment of EAE in the many gene knock-out mice on the C57BL/6
background. MOG is also implicated in the pathogenesis of MS with human T and B
cells being responsive to MOG (Sun et al., 1991; Kerlero de Rosbo et al., 1993).
There are different models of EAE: monophasic EAE, chronic relapsing remitting
EAE and spontaneous EAE, each recapitulating different aspects of MS. The
autoantigen used to induce disease has a part in determining the disease phenotype
and pattern of lesion distribution in the CNS (Berger et al., 1997). Also the
development of the TCR transgenic mice, for example the MOG-reactive 2D2 mice
(Bettelli et al., 2003) and the MBP-reactive Tg4 mice (Liu et al., 1995) has been a
great advantage as it allows the investigation of the development of naïve TCR-
transgenic T cells into inflammatory T effector cells both in vitro and in vivo. The
Tg4 mice express a TCR which recognises the immuno-dominant Ac1-9 peptide of
MBP (4Lys) when presented in the context of I-Au. The Tg4 mice have been crossed
with CD45.1 mice to produce Tg4 CD45.1 mice, which allow Tg4 cells to be tracked
in vivo when transferred.
EAE can be induced as both ‘active’ EAE and ‘passive transfer’ EAE. Active EAE is
the immunisation of host mice with the autoantigen as defined above, mixed together
with complete Freund’s adjuvant (CFA). Naïve CD4+ T cells are activated in vivo
and migrate towards the CNS to elicit an inflammatory response. In contrast passive
EAE is the transfer of pre-activated autoantigen reactive encephalitogenic T cells
into susceptible host mice. The transferred cells can be either in vivo primed non-
transgenic donor cells, or in vitro primed TCR transgenic donor cells. Within the
chronic form of EAE extensive demyelination in the CNS is evident. During passive
transfer EAE however, the demyelination is not extensive. Instead, the activated
encephalitogenic T cell interacts with the MHC-II/peptide complex presented by the
resident APCs in the CNS (for example microglia or astrocytes), and this results in
the development of an inflammatory response within the micro-environment. This is
mediated by the production of pro-inflammatory cytokines, increased permeability of
the blood brain barrier as well as the recruitment of other inflammatory T cells or




In this thesis the passive transfer model of EAE is mainly used, using both pMOG-
reactive in vivo primed cells and the in vitro primed MBP-reactive TCR transgenic
Tg4 cells. These donor cells, as mentioned above, are traceable in vivo, due to the
presence of congenic markers (CD45 or CD90). Passive transfer models have the
advantages of 1) allowing the generation of both in vivo primed and in vitro primed
encephalitogenic T cells; 2) determining the encephalitogenic potential of different
Th subsets in vivo; 3) being able to track the donor T cells to determine their
migration potential as well as their phenotypic stability in vivo.
The use of the TCR transgenic model allows for the investigation of the role of
different T cell subsets in a system in which all the T cells concerned are specific for
a particular antigen and is therefore a ‘cleaner’ system. The polyclonal model is also
important to use as it investigates the same question in a system in which all the T
cells are not specific for a particular antigen which would be more realistic as
compared to the TCR transgenic model. The use of C57BL/6 mice for the polyclonal
model (as opposed to B10.PL) allowed for the use of gene-knock-out host mice
which were on the C57BL/6 background, and is also the general approach used in the
Anderton Lab as well as in other EAE research groups.
1.3.1.3 B cells in EAE
B cells have the ability act in various different ways in EAE. They can produce
pathogenic autoantibodies; B cells can act as APC and enhance the activation of the
autoreactive T cells; or they can also act in a regulatory fashion. This has been
demonstrated by autoantibodies which can increase the severity of disease
(Litzenburger, 1998). In contrast, IL-10 production by B cells has been shown to be
regulatory in EAE (Fillatreau et al., 2002). B cells have also been shown to have a
regulatory role, controlling self-reactive T cells, by other mechanisms. Firstly, they
have recently been shown to have a role to play in the induction of negative selection
of self-reactive T cells in the thymus (Frommer and Waisman, 2010). Secondly,
antigen presentation by B cells has been shown to result in induction of tolerance to
EAE by the upregulation of coinhibitory molecules including CTLA-1 and PD-1
(Frommer et al., 2008).
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1.3.2 Nature of pathogenic CD4+ T cells in EAE
1.3.2.1 EAE and MS as Th1 mediated diseases
EAE was originally considered to be a Th1-mediated autoimmune disease due to the
Th1-phenotype of the encephalitogenic T cells (Ando et al., 1989). This correlated
with MS in that the inflammatory T cells detected in the peripheral blood and CSF of
MS patients had a predominantly Th1 phenotype (Balashov et al., 1999; Strunk et al.,
2000; Teleshova et al., 2002). Treatment of MS patients with IFN-
exacerbation of disease (Panitch et al., 1987a; Panitch et al., 1987b), suggesting that
IFN- -12-driven Th1
differentiation and IL-12 signalling led to the abrogation of EAE (Bright et al.,
1998a). The expression of IL-12p40 mRNA was observed to be upregulated
specifically in the brain and spinal cord of EAE mice and came down to baseline
levels on resolution of disease (Bright et al., 1998b). The treatment of mice with an
anti-IL-12 antibody (Bright et al., 1998b) led to the inhibition of disease, once again
pointing towards the importance of IL-12 and a Th1 response in the induction of
EAE.
However, there were always those conflicting data that IFN- -deficient mice as well
as IFN- -deficient mice were still susceptible to EAE, and actually exhibited more
severe disease than their wild-type counterparts (Ferber et al., 1996; Willenborg et
al., 1996). In the same way, mice treated with antibodies against IFN-
severe disease (Billiau et al., 1988; Lublin et al., 1993). So, the apparent role of a
Th1 response did not correlate with the exacerbated disease observed in the absence
of IFN-
1.3.2.2 The move from Th1 to Th17 mediated EAE and MS
IL-23 is a heterodimeric cytokine composed of the IL-23 unique subunit p19, and the
p40 subunit which is shared with IL-12 (Oppmann et al., 2000). The discovery of
IL-23 and its structure highlighted that previous studies on IL-12 using the anti-IL-
12p40 antibody, had in fact been blocking both IL-12 and IL-23. From this initial
discovery of IL-23, research then focused on trying to determine the role of IL-23 in
INTRODUCTION
45
autoimmune pathogenesis. IL-23 was found to be more important than IL-12 in the
pathogenesis of EAE (Cua et al., 2003). This was determined by generating specific
IL-12-deficient (p35-/-) and IL-23 deficient (p19-/-) mice for the comparison with the
previously used double-deficient (p40-/-) mice. IL-12 deficient mice were still
susceptible to MOG-induced EAE, whereas disease was abrogated in IL-23 deficient
mice (either IL-23 alone, or double-deficient mice) (Cua et al., 2003). This suggested
that IL-23 had a more important role to play in autoimmune disease induction in the
CNS. The same result was observed in collagen induced arthritis (CIA), a murine
model of human rheumatoid arthritis (RA) (Murphy et al., 2003) suggesting IL-23
was important for autoimmune disease induction on a wider scale.
It was then reported that IL-23 could drive an IL-17-producing T cell population and
that those IL-17-producing cells appeared to have a pro-inflammatory phenotype,
inducing EAE (Aggarwal et al., 2003; Langrish et al., 2005). IL-23 appeared to
promote a cell population that produced IL-17A, IL-17F, IL-6 and TNF- and, on
adoptive transfer, these cells were able to target the CNS and induce EAE (Langrish
et al., 2005). This observation led to the description of Th17 cells as a novel Th
subset as described in section 1.2.2.3. To add weight to the importance of IL-23 in
autoimmune pathogenesis, treatment of mice with an anti-IL-23 antibody led to the
amelioration of EAE (Chen et al., 2006a).
To investigate the role of IL-17 and the newly discovered Th17 lineage EAE was
induced in IL-17A-deficient mice. Disease was found to be reduced, but not
completely abrogated (Komiyama et al., 2006). IL-17 was then hailed as the key
proinflammatory cytokine in the pathogenesis of EAE. However, as disease was not
completely ameliorated in its absence, this was a large assumption.
As mentioned in section 1.2.2.3, IL-23 was later shown to be dispensable for the
differentiation of naïve CD4+ T cells towards a Th17 phenotype, but was required for
the maintenance and survival of Th17 cells (Stritesky, Yeh and Kaplan, 2008).
Importantly, polarisation of ‘Th17’ cells using IL-23 alone led to the generation of a
mixed population of IFN- -17-producers (O'Connor et al., 2008). Therefore,
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in previous publications that used IL-23-driven ‘Th17’ populations to induce disease
it was unclear as to which population, IFN- + or IL-17+, had actually induced
inflammation (Harrington et al., 2005; Park et al., 2005). IL-6 and TGF- were
identified to be the key cytokines required to generate Th17 cells, and IL-23 required
to maintain and stabilise their IL-17-producing phenotype (Veldhoen et al., 2006;
McGeachy et al., 2007). In the absence of IL-1 signalling, another cytokine shown
to be important for Th17 differentiation, EAE was significantly reduced in severity
due to fewer Th17 cells after immunisation of IL-1R-deficient mice (Sutton et al.,
2006).
Despite the evidence pointing towards Th17 cells being a key pathogenic subset in
autoimmune disease, recent data have shown that IL-17 itself is not required for the
induction of EAE. The over-expression of IL-17A, specifically on T cells, or its
complete loss, has no effect on EAE induction (Haak et al., 2009). In the same way,
the loss of IL-17F, which may compensate for IL-17A, had no effect on EAE
induction, and antibody blockade of IL-17A in IL-17FKO mice did not induce
resistance to EAE.
In MS, IL-17-producing cells have been shown to promote the disruption of the BBB
through interactions with IL-17R which is expressed on the endothelial cells making
up the BBB in MS lesions (Kebir et al., 2007). In addition, pro-inflammatory IL-6,
one of the main promoters of Th17 differentiation, is upregulated in active lesions in
MS patients, as compared to inactive lesions (Baranzini et al., 2000; Mycko et al.,
2004) suggesting possible upregulation of a Th17 response in these areas. A clinical
trial using a monoclonal antibody against the p40 subunit of IL-12 and IL-23
(thereby neutralising both IL-12 and IL-23 signalling) named Ustekinumab was used
to treat patients with relapsing-remitting MS (Segal et al., 2008). This however had
no beneficial effects on MS patients as compared to the placebo controls. The effect
of neutralising IL-17 specifically in MS is yet to be determined.
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1.3.2.3 T cell transcription factors in EAE
T-bet, the master transcription factor of Th1 cells has an important role in EAE
induction. T-bet-deficient mice have consistently been reported to be resistant to
EAE (Bettelli et al., 2004; Nath et al., 2006). Silencing T-bet signalling through the
use of small interfering RNAs (siRNA) had an adverse effect on Th1-mediated
processes (Lovett-Racke et al., 2004). Silencing T-bet reduced IFN-
well as STAT1 expression levels. Importantly, transfer of T-bet siRNA-transfected
myelin responsive T cells led to the reduction in EAE incidence and severity (Lovett-
Racke et al., 2004).
Extending this, T-bet expression was recently found to be required within
encephalitogenic T cells in a passive transfer model (Yang et al., 2009).
IFN- -producing cells could be divided into those that were T-bet+ - and a
smaller population that were T-bet+ + (Abromson-Leeman, Bronson and Dorf,
2009). The T-bet+ - cells produced IFN- -17. However, the T-bet+
+ cells were able to produce both IFN- -17, highlighting the plasticity
of these cells. The double positive cells were able to switch between IFN- -17
production. Interestingly both populations, irrespective of ROR
able to induce EAE to the same extent indicating a role for T-
EAE induction (Abromson-Leeman, Bronson and Dorf, 2009). In contrast, the
-deficient T cells resulted in reduced severity
of disease (Ivanov et al., 2006).
Another recent publication has highlighted how the expression of T-bet is required
for encephalitogenicity, rather than the end products of Th1 or Th17 pathways, i.e.
IFN- -17. Encephalitogenic cells from spontaneous EAE and actively induced
EAE were investigated for the expression of various markers (Yang et al., 2009).
T-bet was found to be consistently expressed on the encephalitogenic T cells,
whether they were producing IFN- -17, highlighting that the T-bet expression
was the key factor for disease pathogenesis (Yang et al., 2009).
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STAT1, another key transcription factor required for the generation of the Th1
lineage, has been shown to be dispensable for the induction of EAE as
STAT1-deficient mice are fully susceptible to EAE induction (Bettelli et al., 2004)
whereas STAT4 deficient mice are protected (Thierfelder et al., 1996).
1.3.2.4 T regulatory cells in EAE
It has long been known that Treg have a role in the inhibition of inflammation in
EAE (Kohm et al., 2002; Zhang et al., 2004). Transferred polyclonal Treg have been
shown to inhibit the development of disease by affecting the priming of the
autoreactive T cells within the lymph node (Kohm et al., 2002). However, the
accumulation of IL-10-producing FoxP3+ Treg within the CNS itself has also been
observed during EAE (McGeachy, Stephens and Anderton, 2005). This accumulation
correlated with disease resolution and the Treg, when recovered from the CNS were
able to suppress T effector cells in vitro as well as transfer protection to recipient
mice.
Interestingly, the increase in the number of FoxP3+ Treg within the CNS during
recovery from EAE is due to their activation and proliferation within the target organ
(O'Connor, Malpass and Anderton, 2007) as opposed to increased infiltration of Ag-
reactive Treg into the CNS previously primed in the periphery. Importantly, these
CNS-derived Treg were able to suppress an IFN- -17
response, from the CNS derived effector cells (O'Connor, Malpass and Anderton,
2007). This result led on to the central hypothesis for this thesis project, which will
be explained in section 1.5.
The frequency of CD4+ CD25hi Treg in MS patients in the peripheral blood was
found to be similar to that in healthy individuals (Viglietta et al., 2004) indicating
that there was no lack of Treg in MS patients. Interestingly, the function of these
Treg in MS patients was found to be impaired. CD4+ CD25hi Treg isolated from
healthy controls were able to suppress the proliferation of CD4+ CD25- responder T
cells; however the Treg isolated from MS patients were unable to suppress
proliferation (Viglietta et al., 2004). Therefore, Treg isolated from the blood of MS
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patients, appear to be present in comparable levels to those in the healthy controls
however they lack efficient regulatory function. This could account for the lack of
control of the autoreactive T cells in the periphery, resulting in disease onset.
To investigate the potential role of Treg as a cellular therapy for EAE, and eventually
MS, it is important to firstly determine whether adoptively transferred Treg are able
to have a suppressive effect on on-going disease rather than only when transferred
before the induction of disease. It is also important to determine whether antigen-
specificity of the Treg is important. It may be essential to use antigen-specific Treg
in patients to ensure an effect on auto-aggressive T cells specifically and to prevent a
global immunosuppressive effect. Promising results have been found. Myelin-
specific CD4+ CD25+ Treg from TCR transgenic mice were able to suppress disease
on transfer into mice with chronic EAE (Stephens, Malpass and Anderton, 2009).
Interestingly this was not observed with polyclonal Treg indicating that the antigen-
specificity is important.
1.3.3 Classical versus atypical EAE
Classically, EAE is characterised by inflammation of the spinal cord in particular,
with no overt involvement of the brain-stem or cerebellum (Cross, O'Mara and
Raine, 1993; Archambault et al., 2006). In contrast, a different form of EAE has been
described, termed atypical, or non-classical, EAE. This is characterised by
inflammation within the cerebellum and brain-stem, and not the spinal cord and is
particularly evident when the pathogenic T cells lack IFN- (Wensky et al., 2005).
The clinical signs of atypical EAE are therefore distinctly different from those of
classical disease. Classical EAE is characterised by increasing paralysis from the tail
forwards, whereas atypical EAE presents with disturbances in balance and
co-ordination. As mentioned earlier, no one model of EAE is able to recapitulate all
the features of MS. Investigating atypical EAE could lead to insights into the
mechanisms of the balance and co-ordination problems in MS sufferers.
A recent publication has shown that the transfer of polyclonal IFN- -deficient T cells
into WT hosts resulted in the initiation of atypical EAE with the encephalitogenic T
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cells infiltrating into the brainstem preferentially (Kroenke, Chensue and Segal,
2010). Interestingly, this induction of atypical EAE was dependent on IL-17
signalling because when IFN- -deficient cells were transferred into
IL-17R -deficient mice, the clinical disease reverted to classical EAE, indicating that
IL-17 signalling was required for the development of atypical EAE (Kroenke,
Chensue and Segal, 2010). This also indicated, in an indirect manner that in the
absence of both IFN- -17 signalling, classical EAE is still induced suggesting
that neither cytokine is required for EAE induction. In contrast, the induction of
classical EAE was found to be dependent on GM-CSF production by CD4+ T cells in
the CNS (Kroenke, Chensue and Segal, 2010). Moreover, it has previously been
shown that GM-CSFKO mice are resistant to disease induction (McQualter et al.,
2001; Ponomarev et al., 2007).
Correlating with the role of IL-17 in the induction of atypical EAE, the constitutive
production of IL-6 specifically within the cerebellum of mice resulted in the
development of atypical EAE after MOG-immunisation (Quintana et al., 2009). The
production of IL-6 within the cerebellum could lead to the generation of
IL-17-producing Th17 response, which would result in the induction of atypical EAE




1.4 Trafficking of encephalitogenic T cells in to the CNS
The CNS was originally considered to be an immune privileged site. The blood brain
barrier (BBB) acts as a physical barrier preventing the entry of lymphocytes into the
CNS. In 1986 Wekerle and colleagues hypothesised that under normal physiological
conditions activated lymphocytes are capable of entering the CNS to undertake
immune-surveillance (Wekerle et al., 1986; Hickey, Hsu and Kimura, 1991).
However, during inflammatory conditions, for example during MS and EAE, as well
as during viral or bacterial infection, a large number of inflammatory cells gain
access into the CNS across the BBB.
The CNS derives nutrients from two main sources –the blood vasculature that
traverses the meninges and the parenchyma, and from the CSF. The blood brain
barrier is formed by the vascular endothelium with the CNS parenchyma. The CSF is
mainly made by a richly vascularized invagination of specialized secretory
ependymal cells in the lateral, third and fourth cerebral ventricles, known as the
choroid plexus. The CSF itself is contained within the sub-arachnoid space (SAS)
which is created between the inner pia mater, an arachnoid membrane and the outer
dura mater. The SAS allows circulation of the CSF around the brain and spinal cord.
The epithelium of the choroid plexus constitutes the blood-CSF-barrier and the BBB
is formed by the vascular endothelium with the CNS parenchyma (Engelhardt and
Ransohoff, 2005; Abbott, Ronnback and Hansson, 2006). Tight junctions between
the epithelial cells of the choroid plexus and between the vascular endothelial cells
found within the CNS parenchyma forming physical barriers to entry into the CNS.
These tight junctions restrict the flow of macromolecules from the blood into the
CSF increasing the reliance on trans-cellular transport. Importantly, the tight
junctions also prevent cellular egress. The capillary endothelial cells of the BBB are
surrounded by a basal lamina, pericytes and astrocytic end-feet with microglia. Any
physiological and pathological changes in the activity of the glial cell populations
can weaken the BBB integrity and therefore its permeability. Pro-inflammatory
cytokines for example IL-1 , IL-6 and TNF- can be produced by these microglia
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and contribute to increasing the permeability of the BBB (Prendergast and Anderton,
2009).
When a naïve T cell is activated, as mentioned in earlier sections, it differentiates
into an effector T cell according to the local cytokine environment. During this
process naïve T cells downregulate molecules required for entry into lymph nodes,
for example, CD62L and CCR7 (von Andrian and Mempel, 2003; Klinger et al.,
2009), and upregulate molecules involved in lymphocyte migration to non-lymphoid
tissues, for example tissue-homing integrins, chemokine receptors and particular
selectins. Each Th subset is believed to have a distinct pattern of expression of
homing molecules. This differential expression of homing molecules would indicate
differential abilities to enter inflamed tissues or differential abilities to cross the BBB
or blood-CSF-barrier into the CNS. Human Th1 cells are known to express CCR5
and CXCR3 (Bonecchi et al., 1998; Sallusto et al., 1998) whereas Th2 cells express
CCR3 and CCR4 (Sallusto, Mackay and Lanzavecchia, 1997; Sallusto et al., 1998).
Th17 cells express CCR6 mainly and to a lesser extent CCR2 (Sato, Aranami and
Yamamura, 2007; Liu and Rohowsky-Kochan, 2008; Singh et al., 2008). This
correlates with chemokine receptor expression in mouse Th1, Th2 and Th17
polarised cells.
1.4.1 Routes of entry into the CNS
It is important to understand how lymphocytes are able to enter the CNS during an
inflammatory response. There are thought to be three distinct entry routes into the
CNS from the blood. These are 1) from the blood, via the choroid plexus into the
CSF, or 2) from the blood, across the BBB or blood-spinal cord barrier into the
parenchymal perivascular space, or 3) from the blood to the sub-arachnoid space
(Ransohoff, Kivisakk and Kidd, 2003). It may be that entry via the CSF is required
for immuno-surveillance of the CNS under normal physiological conditions, whereas
entry to the parenchymal spaces of the brain can occur during localised inflammatory
responses. Migration via the choroid plexus involves extravasation from the
fenestrated capillary bed into the perivascular spaces. This is followed by crossing
tight junctions of the ependymal epithelial layer. Under normal conditions, adhesion
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molecules intercellular adhesion molecules (ICAM)-1, vascular cell adhesion
molecule (VCAM)-1 and mucosal addressin cell adhesion (MAdCAM)-1 have been
found to be expressed on the apical surface of the choroid plexus epithelial cells and
not on the fenestrated capillaries of the choroid plexus (Wolburg et al., 1999;
Kivisakk et al., 2003) and their expression was found to be increased during EAE.
The molecular mechanisms defining the entry of lymphocytes into the CNS either
under normal conditions or under inflammatory conditions are still not well
understood. The mechanisms involved in the entry of the initial pioneer lymphocytes
into the CNS are very likely to be different from those involved in the entry once
inflammation is established. Cell adhesion molecules, including selectins, integrins
and chemokine receptors and their ligands are all involved in this process. Leukocyte
trans-endothelial migration can be divided into four main steps, described below (as
reviewed in (Prendergast and Anderton, 2009):
1. Low-affinity contact between the endothelium and the lymphocytes. This is
mediated by selectins on the endothelial surface binding to the glycosylated ligands
on the lymphocyte surface (Engelhardt, 2008). This low-affinity contact results in
tethering of the lymphocyte to the endothelium, and facilitates their rolling along the
endothelial cell surface.
2. Whilst rolling, the lymphocyte encounters chemokines secreted by endothelial
cells. The activation of the corresponding chemokine receptors on the lymphocyte
leads to the induction of G protein-linked intracellular signals. This results in the
activation of the integrins on the surface of the lymphocyte. This activation alters the
conformation of the integrin from the low affinity to the high affinity state.
3. The high affinity integrins are then able to interact with their appropriate ligands
on the surface of the endothelium. This interaction provides firm adhesion or arrest
of the lymphocyte on the endothelium surface.
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4. The final step of lymphocyte trans-endothelial migration is the extravasation of the
lymphocyte across the endothelial layer and into the perivascular space. This requires
negotiating the tight junctions of the BBB or the blood-spinal cord barrier in order to
enter the brain parenchyma or the spinal cord respectively (Engelhardt and Wolburg,
2004).
1.4.2 Selectins
Selectins are membrane glycoproteins with distal lectin-like domains. L-, P- and E-
selectin constitute the family of Ca2+-dependent lectins, which, as the names
suggests, bind to and dissociate from, their ligands in a Ca2+-dependent manner (Ley
and Kansas, 2004). L-selectin (CD62L) is expressed on most circulating
lymphocytes and is required for the entry of lymphocytes into the peripheral lymph
nodes via high endothelial venules (Kanda et al., 2004; Miyasaka and Tanaka, 2004).
L-selectin binds to glycosylation-dependent cell adhesion molecules-1 (GlyCAM-1)
which is constitutively expressed on endothelial cells of the peripheral lymph nodes.
CD62L also binds to MAdCAM-1. There is conflicting evidence as to whether
CD62L is required for EAE. CD62L-deficient mice are protected from disease in
myelin basic protein (MBP) specific systems (Archelos et al., 1998; Grewal et al.,
2001). However, in the C57BL/6 or SJL mice, there was no role for CD62L in EAE,
these mice being fully susceptible (Uboldi et al., 2008).
PSGL-1 is a 240 kDa homodimer that, if glycosylated, is capable of binding E-, P-
and L-selectin (McEver, 1995; Moore, 1998). Therefore, despite PSGL-1 being
expressed on all T lymphocytes not all of the different T cell subsets are capable of
binding the selectins, depending on whether they are able to glycosylate the PSGL-1.
The two enzymes that are required for the glycosylation and therefore expression of
functional PSGL-1 on T lymphocytes are core 2 -1.6-N-acetyl
glycosaminyltransferase (C2GnT-I) and -(1,3)-fucosyltransferase-VII (FucT-VII)
(Smithson et al., 2001; Sperandio et al., 2001; Piccio et al., 2005; Deshpande, King
and Segal, 2006). The glycosylation of PSGL-1 by these enzymes allows its binding
to P-selectin in particular. Mice lacking either of these enzymes have impaired
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binding of PSGL-1 to P-selectin, which leads to reduced rolling of lymphocytes on
venules in vivo (Smithson et al., 2001; Sperandio et al., 2001).
The expression of functional PSGL-1 on Th1 cells and the binding to P-selectin is
required for the migration of Th1 cells into the inflamed skin in vivo (Austrup et al.,
1997; Borges et al., 1997). In contrast despite Th2 cells also expressing PSGL-1 on
their surface it was not necessary for the migration of Th2 cells into the inflamed
skin, highlighting a particular requirement of functional PSGL-1 on Th1 cells
specifically, for their entry into the inflamed skin (Borges et al., 1997).
The requirement of P-selectin and PSGL-1 for entry into the CNS remains
controversial. PSGL-1-deficient C57BL/6 mice, or C57BL/6 mice treated with a
blocking antibody against PSGL-1, do not have a significant difference in disease
induction or severity compared to wild-type controls (Engelhardt et al., 2005;
Osmers, Bullard and Barnum, 2005). Another study however does suggest a role for
the P-selectin/PSGL-1 interaction for the entry of T cells into the CNS. IL-12p70 has
been found to increase the expression of C2GnT-I (Deshpande, King and Segal,
2006), leading to the increase in expression of functional PSGL-1. The pre-treatment
of IL-12-stimulated myelin-reactive CD4+ T cells with a blocking antibody against
PSGL-1 prior to adoptive transfer led to significantly reduced onset, incidence and
severity of EAE (Deshpande, King and Segal, 2006). Therefore, depending on the
model, PSGL-1 may indeed have a role to play in the entry of encephalitogenic T
cells into the CNS across the BBB or the B-CSF-B as summarised in Figure 1.6 at
the end of this section.
1.4.3 Chemokines and chemokine receptors
Chemokines are small (8-10 kDa) proteins that fall into four main families of
chemokines categorised on their structure and relative location of their cysteine
residues. The largest family is the CC chemokines in which the first two cysteine
residues are adjacent to each other. The three remaining families include the CXC
chemokines, the CX3C chemokines and the XC family of chemokines, which have
differing numbers of amino acids between the cysteine residues.
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Chemokines function by binding their corresponding seven-transmembrane-domain
G-protein-couple receptors (Charo and Ransohoff, 2006) which leads to a signalling
cascade. There are two main mechanisms by which chemokine binding can influence
the migration of leukocytes across the BBB. Firstly, as mentioned earlier,
chemokines immobilised on the surface of the endothelium binding to their
respective receptor on the surface of the lymphocyte results in the activation of
surface integrins on the lymphocyte, leading to the firm adhesion of the leukocyte.
CCL19 (macrophage inflammatory protein (MIP)-3 ), CCL20 (MIP-3 ) and CCL2
(monocyte chemotactic protein (MCP)-1) have been shown to induce adhesion via
activation of LFA-1 binding to ICAM-1 (Campbell et al., 1998; Gerszten et al.,
1999).
The second mechanism by which chemokines can influence migration is by
mediating the locomotion of the leukocytes along the endothelium to their nearest
endothelial tight-junction. As the leukocyte migrates through the tight junction it is
thought to extend chemokine receptor-rich processes and these seek chemokines in
the abluminal space (Schreiber et al., 2007). This chemokine dependent mechanism
facilitates their movement through the tight junction and into the perivascular space.
Due to the different roles of chemokines and their receptors, dissecting their
specificity and function at each stage is challenging.
Due to the original hypothesis that MS and EAE were Th1-mediated diseases,
numerous studies investigated the requirements for CCR5 and CXCR3 in entry into
the CNS, both of these chemokine receptors being Th1-associated. The ligands of
CXCR3 and CCR5 the chemokines IP-10 (CXCL10), MIP-1 (CCL3) and RANTES
(regulated upon activation, normal T cell expressed and secreted (CCL5)) were
found to be upregulated in the CSF of MS patients during episodes and also within
MS lesions (Balashov et al., 1999; Sorensen et al., 1999). In addition to this CCR5+
and CXCR3+ T cells were increased in the blood and CFS of MS patients (Sorensen
et al., 1999; Teleshova et al., 2002).
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As mentioned above, CCR5+ T cells are found to be upregulated in MS patients.
However the requirement of CCR5 for EAE induction is still controversial. C57BL/6
CCR5-deficient mice, or MIP-1 -deficient (one of the ligands of CCR5) mice are
susceptible to MOG-induced EAE (Tran, Kuziel and Owens, 2000). These mice
showed no differences in the kinetics or severity of disease compared to the wild-
type mice, or in the infiltration of lymphocytes into the CNS. In contrast, it has been
shown that in the model experimental autoimmune uveitis (EAU) CCR5 is required
for the entry of Th1 cells into the target organ, the eye (Crane et al., 2006).
CCR6 and its ligand are now considered to be Th17-associated migration molecules.
Both CCR6 and its ligand have been found to be upregulated in the spinal cord
during EAE (Fife et al., 2001). Recently, since the emergence of the Th17 lineage,
more studies have been done on the requirements of CCR6 for CNS inflammation,
often with conflicting results. Two studies showed total protection from EAE in the
absence of CCR6 (Liston et al., 2009; Reboldi et al., 2009) whilst a third study
reported only delayed onset (Yamazaki et al., 2008). The mechanisms underlying the
observed effects also conflicted with two reports of impaired migration of the Th17
cells into the CNS (Yamazaki et al., 2008; Reboldi et al., 2009) and another
implicated altered T cell priming in the lymph nodes (Liston et al., 2009).
Interestingly one report implicated the CCR6/CCL20 interaction specifically within
the choroid plexus as a key check-point in Th17 cell entry into the CNS. Small
numbers of CCR6+ cells were found to restore susceptibility to EAE in
CCR6-deficient mice. Intense expression of CCL20 was observed specifically at the
choroid plexus. Greater numbers of T cells could be found in the choroid plexus of
CCR6-deficient mice than in wild-type mice primed for EAE (Reboldi et al., 2009),
suggesting that an intact CCR6/CCL20 interaction is essential, not for extravasation,
but to allow the accumulating pathogenic T cells to cross the tight junctions of the
ependymal layer that constitute the blood-CSF-barrier as shown in the summary
diagram, Figure 1.6 at the end of this section.
Treg have also been shown to express CCR6 (Kleinewietfeld et al., 2005; Lim et al.,
2008; Yamazaki et al., 2008). If CCR6 expression is indeed required for the
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infiltration of T cells into the CNS, this suggests that both effector Th17 cells and
regulatory T cells and perhaps even effector Th1 cells if they are found to express
CCR6, are able to infiltrate the CNS at the same time and route. When targeting
particular cell types for therapeutics and the prevention of inflammation in the CNS,
this would pose a problem, especially if blocking a CCR6+ inflammatory T cell from
infiltrating the CNS would also prevent CCR6+ Tregs from infiltrating.
1.4.4 Integrins
Integrins mediate the firm adhesion of leukocytes to the surface of the endothelium.
Structurally, integrins are heterodimeric proteins containing and chains. There
are 18 different subunits and 8 subunits in vertebrates, and together these form 24
known pairs. Approximately 10 members of the integrin family of the 2, 7, and
1 subfamilies are expressed by immune cells including monocytes, macrophages, T
lymphocytes, dendritic cells and neutrophils. The 2 and 7 subfamilies are
expressed on leukocytes whereas the 1 subfamily of integrins is expressed on a
wide variety of cells (Reviewed in (Luo, Carman and Springer, 2007)).
Integrin signalling involves two forms of signalling: ‘inside-out’ and ‘outside-in’.
‘Inside-out’ signalling results in a conformational change of the integrin which leads
to increased affinity for ligand binding as well as clustering of integrins in the
membrane. In contrast, ‘outside-in’ signalling refers to the signalling events
occurring after the clustering of integrins. Circulating lymphocytes maintain their
integrins in a non-adhesive conformation which does not support ligand binding. On
integrin activation, this conformation changes to an extended integrin conformation
due to unfolding of the ectodomain of the receptor. This extended conformation
facilitates clustering of integrins on the cell membrane and high affinity binding of
the ligand to the receptor. The family of integrins include LFA-1 ( L 2) which binds
ligands ICAMs 1-5; 4 1 which binds VCAM-1 as well as 4 7 (reviewed in
(Abram and Lowell, 2009)). Defective integrin expression results in human




It has been shown that ICAM-1 is expressed on the endothelium surrounding the
CNS lesions both in patients with MS and in mice with EAE suggesting a role in
entry of the inflammatory T cells into the CNS (Raine et al., 1990; Sobel, Mitchell
and Fondren, 1990; O'Neill et al., 1991). Numerous studies have implied a role for
the LFA-1/ICAM-1 interaction in lymphocyte adhesion and migration across the
blood brain barrier into the CNS (Archelos et al., 1993; Steffen, Butcher and
Engelhardt, 1994; Laschinger, Vajkoczy and Engelhardt, 2002; Lyck et al., 2003;
Schenkel, Mamdouh and Muller, 2004). Data suggests that the LFA-1/ICAM-1
interaction is required for the movement of the adhered cell across the endothelium
to the nearest tight junction, as opposed to being required for the adhesion of the
lymphocyte to the activated endothelium. This is consistent with in vitro studies that
have shown that cells lacking ICAM-1 are still capable of supporting adhesion of T
cells to the activated endothelium however are unable to support transmigration
across the endothelium (Lyck et al., 2003).
Complementary to this, the 4 1/VCAM-1 interaction has been shown to be required
for the firm adherence of lymphocytes to the endothelial surface and not for the
transmigration across the endothelium (Laschinger and Engelhardt, 2000). Although
VCAM-1 binds both 4 1 and 4 7, only 4 1 is required for the migration of T
cells across the blood brain barrier during EAE (Engelhardt et al., 1998).
MAdCAM-1, the ligand for 4 7 integrin, and ICAM-1 and VCAM-1 are all
upregulated on the apical surface of the choroids plexus epithelial cells during EAE
(Steffen et al., 1996; Engelhardt, Wolburg-Buchholz and Wolburg, 2001). However
the blockade of MAdCAM-1, the ligand for 4 7, has been shown to prevent the
development of EAE (Kanwar et al., 2000). VCAM-1, ICAM-1 and MAdCAM-1
have each been shown to have a role in T cell migration across the blood brain
barrier. Combination treatments with anti-MAdCAM-1, VCAM-1 and ICAM-1 were
trialled and faster remission from disease was observed, however the same effect was
not found with advanced EAE (Kanwar et al., 2000). Activated leukocyte cell
adhesion molecule (ALCAM; CD166) another integrin, is upregulated on the
endothelium of the blood brain barrier in both EAE and MS and its blockade results
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in reduced severity of disease due to the inability of CD4+ lymphocytes and
monocytes to enter the CNS during EAE (Cayrol et al., 2008).
In summary, the obvious requirement of integrins in the migration of lymphocytes
into the CNS makes them an attractive target for therapeutics to prevent the entry of
inflammatory T cells into the CNS, some of which have already been successfully
exploited (as discussed in the MS therapeutics section).
Once T cells have penetrated the endothelial surface in to the perivascular space,
they still need to infiltrate the brain parenchyma via the basement membrane which
consists of extracellular matrix proteins (for example laminins, collagen type IV,
nidogens and heparin sulphate proteoglycans) (Hallmann et al., 2005). Chemokines
and matrix metalloproteinases (MMPs) are required for this process (as reviewed in
(Prendergast and Anderton, 2009).
Targeting the infiltration of inflammatory T cells into the CNS to prevent
inflammation is an attractive therapeutic target, especially due to the vast number of
molecules involved in the process. The potential for this route of therapeutics has
already been proven by the success of Natalizumab in treatment of MS (Miller et al.,
2003). The challenge is finding a target that is non-redundant, yet specific enough to
target particular subsets of lymphocytes that infiltrate the CNS to cause autoimmune
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Figure 1.7 Summary of requirements for entry of T cells into the CNS via the
BBB and the blood-CSF-barrier to induce CNS autoimmune disease.
1) Myelin responsive T cells are activated in the lymph node in the presence of their cognate antigen.
The naïve T cells downregulate lymph node homing molecules and express integrins and chemokine
receptors indicative of their Th phenotype. These activated T cells then exit the lymph node and enter
the circulation; 2) T cells reach the choroid plexus and cross the fenestrated capillaries. This is
mediated by expression of CCL20 and CCR6; 3) The T cells migrate via the CSF through the sub-
arachnoid space and into the brain parenchyma or spinal cord parenchyma; 4) T cells are re-activated
and produce inflammatory cytokines. The inflammatory conditions lead to the activation of the local
endothelium and expression of adhesion molecules and the release of chemokines by immune cells
and the stromal/endothelial cells; 5) Circulating T cells with the appropriate homing molecules
localise on the CNS endothelium and extravasate into the perivascular space. MMPs facilitate the
process of migrating across the perivascular space and into the brain parenchyma. Figure taken from




The central hypothesis for this thesis was based on the following observations:
Treg are required for the resolution of actively-induced EAE.
Passive transfer of Th1 cells provides resolving/monophasic EAE with Treg
accumulation evident in the CNS.
CNS derived Treg can suppress Th1 effector function (IFN- in
vitro, but not Th17 function (IL-17 production).
These observations led to the following hypothesis:
‘Myelin-responsive Th17 cells produce chronic EAE due to their resistance to Treg
mediated suppression, whereas their Th1 counterparts provide only acute EAE.’
1.6 Aims
The aims of this PhD project are three-fold:
To establish rigorous Th1 and Th17 polarisation and culture conditions to
generate ‘clean’ populations of both IFN- -producing Th1 and
IL-17-producing Th17 cells devoid of any contaminating cells.
To compare EAE driven by myelin reactive Th1 and Th17 cells using the
passive transfer system.
To investigate the molecular mechanisms underlying any differences seen in
pathogenic activity of Th1 versus Th17 cells.
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2 Materials and Methods
2.1 Mice
C57BL/6 (H-2b background; CD45.2/CD90.2; CD45.1/CD90.2, or CD45.2/CD90.1),
B10.PL (H-2u background), Tg4 (Liu et al., 1995) (CD45.1 or CD90.1) and H-2b
IFN- (Dalton et al., 1993) mice were bred under specific pathogen-free
conditions at the University of Edinburgh (Edinburgh, U.K.). Experiments received
University of Edinburgh ethical approval and were performed under U.K. legislation.
Tg4 CD45.1 IFN- sity of Edinburgh
(Edinburgh, U.K.). This was done by crossing the IFN-
mice and back-crossing for ten generations. Before ten generations was reached cells
from Tg4 CD45.1 IFN- All
mice were age and sex matched for experiments and were used between the ages of
6-10 weeks.
2.2 Peptides
Myelin oligodendrocyte glycoprotein peptide 35-55 (pMOG35-55
MEVGWYRSPFSRVVHLYRNGK) and myelin basic protein acetylated peptide
(MBP Ac1-9; Ac-ASQKRPSQR) were synthesised by the Advanced Biotechnology
Centre, Imperial College London (London, U. K.).
2.3 General Reagents
2.3.1 Wash Buffer
RPMI 1640 medium containing 25 mM Hepes (Gibco, Invitrogen, Life
Technologies, Paisley, UK) supplemented with 2 mM L-Glutamine (Gibco),





RPMI 1640 medium containing 25 mM Hepes (Gibco), supplemented with 10 %
heat-inactivated fetal calf serum (FCS; Sigma), 2 mM L-Glutamine (Gibco),
100 U/ml Penicillin (Gibco), 100 g/ml Streptomycin (Gibco) and 50 M
2- -Mercaptoethanol (Gibco).
2.3.3 MACS Buffer
Hanks Balanced Salt Solution (Gibco) supplemented with 2 % heat-inactivated FCS
(Sigma).
2.3.4 FACS Buffer
PBS supplemented with 2 % heat-inactivated FCS (Sigma) and 0.1 % sodium azide
(Sigma).
2.4 T cell isolation, purification and sorting
2.4.1 Single cell suspensions from spleen and lymph nodes
Spleen and lymph nodes were harvested from mice and mashed through gauze
(Sefar) to obtain a single cell suspension. Red blood cells (RBC) were lysed by
treatment with 2 ml Red Blood Cell Lysis Buffer (Sigma) for 2 minutes at room
temperature and then washed with RPMI and the number of live cells determined by
trypan blue (Sigma) exclusion. Samples were then used for flow cytometry analysis,
or for cell sorting as outlined below.
2.4.2 CD4+ Sorting by Magnetic cell sorting
After RBC lysis and counting, cells were resuspended in MACS buffer and counted.
Cells were then resuspended in 45 l MACS Buffer per 107 cells and 5 l CD4
(L3T4) Microbeads (Miltenyi) added per 107 cells. Cells were incubated at 4 °C for
20 minutes with frequent mixing, and then washed in MACS buffer and resuspended
in 3 ml MACS Buffer. The CD4+ cells were then positively selected using an MS or
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LS column (Miltenyi) using the manufacturers protocol: After preparing the column
by rinsing through with 3 ml MACS Buffer, the sample was applied to the column,
followed by 3x3ml MACS Buffer washes to remove the unlabelled cells. The CD4+
T cells were then flushed out by removing the column from the magnet and putting it
into an appropriate collection tube and firmly flushing through 5 ml MACS Buffer
using the plunger. The positive fraction of cells were then counted to determine the
yield and washed in MACS Buffer.
2.4.3 Naïve T cell sorting by FACS
Naïve Tg4 CD45.1+ or Tg4 CD90.1+ T cells were sorted from splenocytes and lymph
node cells to culture and polarise in the presence of irradiated splenocytes. After
CD4 sorting by magnetic columns (above) the cells were stained with
anti-CD4-APC, anti-CD62L-FITC and anti-CD25-PE in MACS Buffer at 4 °C for 20
minutes. Cells were then washed in MACS Buffer, and resuspended in ~3 ml MACS
Buffer (at ~1x107 cells/ml). The naïve cells were then sorted on the FACS Aria for
the CD4+ CD62Lhi CD25- population.
2.4.4 Isolation of CNS-infiltrating mononuclear cells
Mice were sacrificed by CO2 asphyxiation and perfused through the eye or through
the left ventricle of the heart with 10 ml cold PBS. The brain was removed by
dissection and the spinal cord by intrathecal hydrostatic pressure. Tissues were cut up
into small pieces using scissors and disrupted using a 1 ml syringe, and subsequently
digested with 300 l of 2.5 mg/ml collagenase (Lorne Laboratories) and 100 l of 10
mg/ml deoxyribonuclease (Sigma) at 37 °C for 40 minutes. Cells were then washed
once with RPMI. The mononuclear cells were recovered from the interface of a
30:70 discontinuous Percoll (GE Healthcare) gradient after centrifugation for 20
minutes at 850 x g without brake, and washed in RPMI.
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2.5 In vivo manipulations
2.5.1 Immunisations
Mice were immunised with 100 g pMOG35-55, or 100 g MBP (Ac1-9), emulsified
in Complete Freund’s Adjuvant (CFA) containing 50 g heat-killed Mycobacterium
tuberculosis H37Ra (Sigma) at a final volume of 100 l; 50 l injected
sub-cutaneously (s.c.) into each hind leg.
2.5.2 Induction of Passive EAE
Pre-activated myelin specific cells (either in vivo primed and in vitro polarised
polyclonal Th1/Th17 cells, or, transgenic Tg4 Th1/Th17 cells) were harvested and
washed in serum free PBS (Gibco) and counted. 4x106 blasts were transferred per
host (unless stated otherwise) by intravenous (i.v.) injection in a volume of 200 l in
PBS (Gibco). Host mice also received 200 ng Pertussis Toxin (P.tx; Health
Protection Agency, Dorset, UK) in 500 l PBS by intra-peritoneal (i.p.) injection.
Clinical signs of EAE were assessed daily from day 6 post-transfer using the
system/s described below in sections 2.5.4 and 2.5.5.
2.5.3 Induction of Active EAE
Mice were immunised s.c. with 100 g pMOG35-55, or 100 g MBP (Ac1-9),
emulsified in Complete Freund’s Adjuvant (CFA) containing 50 g heat-killed
Mycobacterium tuberculosis H37Ra, at a final volume of 100 l with 50 l in each
hind-leg . Mice also received 200 ng P.tx i.p. in 500 l PBS on day 0 and day 2 post-
immunisation. Clinical signs of EAE were assessed daily from day 6 post-
immunisation using the system described below in sections 2.5.4 and 2.5.5.
2.5.4 Scoring of Classical EAE
0, no clinical signs, healthy; 1, flaccid tail; 2, impaired righting reflex and/or walk; 3,
partial hind limb paralysis; 4, total hind limb paralysis; 5, hind limb paralysis with
any partial front limb paralysis; 6, moribund or dead.
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2.5.5 Scoring of atypical EAE
0; no clinical signs; 1, head tilted slightly/hunched appearance; 2, head turning more
pronounced/ ataxia/ scruffy coat; 3, body tilted and inability to walk in a straight line;
4, laying on side or involuntary and continuous rotation; 5, moribund. (Adapted from
(Stromnes et al., 2008)).
2.5.6 In vivo Administration of Tak-779
Tak779 was kindly supplied as a free gift from the NIH AIDS Research and
Reference Reagent program (catalogue number 4983). Tak-779 (N,Ndimethyl-N-[4-
[[[2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-
yl]carbonyl]amino]benzyl]tetrahydro-2Hpyran-4-aminium chloride, Mr 531.13) was
resuspended in PBS to 5 mg/ml, aliquoted and stored at -20 °C. For administration,
Tak779 was further diluted to 250 g/ml and each host mouse received 200 l (i.e.
50 g Tak779) i.v. every other day as stated in the experiment scheme.
2.5.7 Administration of anti-CD62L (Mel-14)
Mel-14 was obtained from Bioxcel. The stock was diluted to 500 g/ml in PBS and
each mouse received 200 l (i.e. 100 g Mel-14) i.v. every other day as stated in the
experiment scheme.
2.5.8 Administration of anti-CD162/PSGL-1 (4RA10)
Anti-CD162/PSGL-1 (4RA10) and its isotype control, IgG1, were obtained from BD
Pharmingen. For the in vitro pre-treatment of cells with anti-PSGL-1, in vitro
polarised Tg4 Th1 cells were harvested and treated with 10 g/ml anti-CD162, or
10 g/ml IgG1 isotype control, for 1 hour on ice whilst at a density of 5-10x106
cells/ml. Cells were then washed in PBS to remove any unbound antibody and
resuspended in PBS for transfer into host mice. For the in vivo treatment with anti-
PSGL-1, the stock antibody (1 mg/ml) was further diluted to 125 g/ml in PBS, and
200 l administered per mouse i.v. to give a dose of 25 g per mouse.
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2.6 Cell culture and T cell polarisations
2.6.1 TCR Transgenic system
Tg4 CD45.1, Tg4 CD90.1 or Tg4 CD45.1 IFN-
taken. Tissues were disrupted to form a single cell suspension and treated with RBC
lysis buffer (Sigma), MACS sorted for the CD4+ fraction and subsequently sorted by
FACS for the naïve CD4+ T cells i.e. CD4+ CD62Lhi CD25- as described in sections
2.4.1-2.4.3. Naïve T cells were cultured in a 1:5 ratio with irradiated splenocytes
from B10.PL or B10PLxC57BL/6 mice as antigen presenting cells (APCs) for 72
hours with 10 g/ml MBP (Ac1-9). When whole splenocytes were used for
polarisations, Tg4 CD45.1 or Tg4 CD90.1 splenocytes and lymph node cells were
treated as above and then cultured at a concentration of 4x106 cells/ml for 72 hours
with 10 g/ml MBP (Ac1-9) and relevant polarising cytokines as outlined below in
section 2.6.1.3.
2.6.2 Polyclonal system
C57BL/6, CD45.1 or CD90.1 mice were immunised s.c. with 100 g pMOG35-55 with
CFA. Ten days later the draining lymph nodes were excised and the cells recovered
and cultured at a concentration of 4x106 cells/ml, with 10 g/ml pMOG35-55 and
relevant polarising cytokines as outlined below in section 2.6.1.3.
2.6.3 In vitro polarisation towards Th1, Th17 and Th2
phenotype
To achieve a Th1 polarisation, cells were cultured with 25 ng/ml rIL-12 (R&D
Systems), 25 ng/ml rIL-18 (MBL) and 0.5 ng/ml rIL-2 (R&D Systems) for 72 hours.
The rIL-2 concentration was increased to 2.5 ng/ml for the final 24 hours of culture.
For a Th17 polarisation, cells were cultured with 20 ng/ml rIL-6, 20 ng/ml rIL-23
and 3 ng/ml rTGF- (all R&D Systems) for 72 hours. For a Th2 polarisation, cells
were cultured with 4 ng/ml rIL-4 (Peprotech), 5 g/ml anti-IL-12 (Bioxcell), 5 g/ml
anti-IFN- -2 for 5 days.
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2.6.4 Re-stimulation of T cells for analysis of peptide specific
cytokine production
For cells being re-stimulated in the presence/absence of peptide for subsequent
intracellular cytokine staining, cells were cultured at 8x106 cell/ml in the
presence/absence of 20 g/ml peptide (pMOG35-55 or MBP (Ac1-9)) over-night. The
following day, Brefeldin A (eBioscience) was added at a 1:1000 final dilution for 4-6
hours prior to intracellular cytokine staining.
2.7 Fluorescence Assisted Cell Sorting Analysis
2.7.1 Antibodies
Antibodies used were all from eBioscience unless stated otherwise. See Table 2.1 for
a list of all the antibodies, conjugates, clones and dilutions used.
2.7.2 Surface staining
Cells were stained in 25 l FACS buffer using the antibodies outlined in Table 2.1
(from eBioscience unless stated) for 15 minutes at 4 °C. Afterwards cells were
washed in FACS buffer and resuspended in either 200 l FACS buffer and collected
immediately, or in 200 l 1% paraformaldehyde (PFA; Sigma) and stored at 4 °C and
collected as soon as possible.
2.7.3 Intracellular cytokine staining
Cells were incubated with Brefeldin A (1:1000 dilution of stock; eBioscience) for the
final 4-6 hours of culture. For maximal stimulation and cytokine production, cells
were also re-stimulated for these 4-6 hours with 50 ng/ml phorbol myristate acetate
(PMA) and 1 g/ml Ionomycin (Sigma). Cells were washed in FACS buffer and
resuspended in 50 l permeabilisation buffer (FACS Buffer containing 0.1%
saponin; Sigma) containing the appropriate anti-cytokine antibody or relevant isotype
control and were stained for 30–40 minutes at room temperature in the dark. Cells
were then washed in FACS Buffer and stained for the cell surface markers of interest
in 25 l FACS Buffer for 15 minutes at 4 °C in the dark and subsequently washed in




Cells were stained for cell surface markers of interest as explained in section 2.7.2
first and then washed in FACS Buffer. Subsequent staining for FoxP3, T-bet or
manufacturer’s protocol. Cells were incubated in 400 l Fixation/Permeabilisation
Buffer (eBioscience) for at least 1 hour, or overnight, and subsequently washed in
FACS Buffer to permeabilise the cells. Cells were then stained in 50 l 1x
Permeabilisation Buffer (eBioscience) containing the anti-FoxP3/T-
antibody or appropriate isotype controls for 30 minutes at 4 °C in the dark. After this
cells were washed in FACS Buffer and resuspended in 200 l FACS Buffer or
200 l 1% PFA and collected as soon as possible.
2.7.5 Intracellular cytokine staining in conjunction with
FoxP3/T-
When performing intracellular cytokine staining together with intracellular staining
for transcription factors, cells were first stained for surface markers of interest as
above in section 2.7.2. Then cells were washed in FACS buffer and resuspended in
400 l Fixation/Permeabilisation Buffer (eBioscience) for at least 1 hour, or
overnight. Cells were then washed in FACS Buffer and stained with the appropriate
anti-cytokine and anti-transcription factor antibodies in 50 l 1x Permeabilisation
Buffer (eBioscience) for 30 minutes at 4 °C in the dark. Cells were then washed in
FACS Buffer and resuspended in 200 l FACS buffer or 1% PFA prior to collection.
2.8 Flow cytometry data analysis
For all intracellular staining flow cytometry analysis, gates were determined from the
isotype control for each sample. Representative gating strategies are highlighted in
the relevant appendices. All flow cytometry data was collected on the LSR II flow
cytometer, LSR Fortessa or Canto (all BD Biosciences) and data analysed using




2.9 IL-17 Secretion Assay –Cell Enrichment and
Detection Kit Miltenyi Biotec
Assay specific reagents:
Buffer: phosphate buffered saline pH 7.2 (Sigma) containing 0.5% bovine serum
albumin (BSA) (Sigma) and 2mM EDTA (Sigma). Filter sterilised and allowed to
cool to 4 °C.
Culture Medium: RPMI 1640 containing 5% FCS.
Method
1) In vitro re-stimulation: Three day in vitro polarised cells were re-stimulated with
10 g/ml MBP (Ac1-9) for 3 hours at 37 °C. Negative controls were un-stimulated
cells. Cells were then collected by rinsing out of the plate with cold buffer to ensure
collection of all cells. Viable cells were counted using trypan blue exclusion and
2x107 live cells were used per 50 ml tube.
2) Labelling cells with IL-17 Catch Reagent: Cells were first labelled with IL-17
catch reagent. Cells were washed with 10 ml cold buffer, centrifuged at 300xg for 5
minutes at 2-8 °C and the supernatant removed. The cell pellet was resuspended in
80 l of cold medium per 107 total cells and 20 l IL-17 Catch Reagent added per
107 total cells, mixed and incubated for 5 minutes on ice.
3) IL-17 secretion period: As greater than 1% IL-17-secreting cells was a
possibility, and to avoid non-specific staining, a large volume of pre-warmed (37 °C)
medium was added to each tube (i.e. 30 ml) for the IL-17 secretion period. Cells
were incubated in the closed tubes for 45 minutes at 37 °C with regular turnings of
the tubes to prevent settling of the cells. The tube turning prevented cell to cell
contact in the tube, to avoid cross contamination with cytokines.
4) Labelling of cells with IL-17 Detection Antibody (PE): The tube was then
placed on ice, topped up with cold buffer and centrifuged at 300xg for 5 minutes at
2-8 °C and the supernatant removed completely. The cell pellet was then
resuspended in 80 l cold buffer per 107 total cells and 20 l of IL-17 Detection
Antibody (PE) added per 107 total cells. At this stage, cells were also stained with
surface staining antibodies (i.e. 10 l anti-CD4-APC). The cells were mixed well and
incubated for 10 minutes on ice. Cells were then washed by adding 10 ml cold buffer
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per 107 total cells and centrifuged at 300xg for 10 minutes at 2-8 °C and the
supernatant removed completely.
5) Magnetic labelling: The cell pellet was then resuspended in 80 l of cold buffer
per 107 total cells and 20 l of Anti-PE MicroBeads added per 107 total cells. The
cells were mixed well and incubated for 15 minutes in the fridge (2-8 °C). After
incubation, the cells were washed by adding 10 ml cold buffer per 107 total cells and
centrifuged at 300xg for 10 minutes at 2-8 °C and the supernatant removed. The cell
pellet was then resuspended in 500 l of cold buffer (and a small aliquot removed at
this stage for flow cytometric analysis of the pre-sort sample).
6) Magnetic separation: An MS column was placed in the magnetic field of a
MACS separator and rinsed with 500 l of buffer and the flow through discarded.
The cell suspension was applied to the column and the unlabeled cells collected in a
fresh tube. Three separate 500 l washes were applied to the column and the effluent
collected as the unlabelled fraction of cells. The column was then removed from the
separator and placed in a collection tube, 1 ml of buffer applied to the column and
the magnetically labelled cells flushed out by firmly pushing the plunger into the
column. As the negative unlabelled cells were the cells of interest in this case, these
cells were reapplied to a fresh column, and three more 500 l washes performed and
the unlabelled fraction collected. This second column sort was performed to increase
the purity of the cell population obtained.
Analysis: a small fraction of the negative and positive fractions were taken for flow
cytometric analysis of the cells post sort.
2.10 Cytokine quantification by ELISA
For the analysis of IFN- -17 cytokine production an enzyme-linked
immunosorbent assay (ELISA) was used. MaxiSorp microtiter plates (Nunc
International) were coated with 50 l/well of the relevant cytokine-capture antibody
diluted in 1x bicarbonate buffer (10x stock: 6.36 g Na2CO3 (BDH) + 11.72 g
NaHCO3 (BDH) in 400 ml dH2O, pH 9.6) i.e. 2 g/ml anti-IFN- (clone R4-6A2);
0.5 g/ml anti-IL-17 (clone TC11-18H10) (all BD Pharmingen), and incubated at 4
°C overnight. The following day, plates were washed twice with PBS 0.1 % Tween
(PBS-Tween; Sigma) and then blocked for 1 hour at 37 °C with 200 l/well PBS/1 %
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BSA (PBS/BSA; Sigma). Plates were then washed twice with PBS-Tween. A ten
point standard curve of doubling dilutions across the plate of the relevant cytokine
was then set up (100 l/well in duplicate) with the following top final concentrations:
anti-IFN- -IL-17 10 ng/ml (anti-IFN-
Pharmingen; anti-IL-17 standard from R&D). 4 blank wells with 100 l/well
PBS/BSA were also set up. Duplicate samples of relevant cell supernatant (100
l/well) were added and the plates incubated for 2 hours at room temperature. Plates
were then washed four times with PBS-Tween. The detection antibody was then
added (100 l/well) at the following final concentrations: anti-IFN- (clone
XMG.12) 0.5 g/ml and anti-IL-17 (clone TC11-8H4.1) 0.25 g/ml diluted in
PBS/BSA (all from BD Pharmingen). Plates were incubated at room temperature for
30 minutes and subsequently washed six times with PBS-Tween. The ELISA was
then developed by adding 100 l/well 3,3’,5,5’-Tetramethylbenzidine (TMB)
solution (TMB solution: 100 l 10 mg/ml TMB in DMSO (both Sigma), 9.9 ml
phosphate-citrate buffer (25.7 ml 0.2 M Na2HPO4 (BDH) + 24.3 ml 0.1 ml citrate
(anhydrous) (Fluka) made up to 100 ml, pH 5)), 3 l H2O2 (Sigma)). Reactions were
then stopped by the addition of 100 l 2 M H2SO4 (BDH) and the plate read at 450
nm using a Multiskan plate reader (Labsystems,UK). Data was then analysed using
Prism software.
2.11 Molecular Biology Protocols
2.11.1 RNA Extraction by Chloroform/Isopropanol Method
For the analysis of mRNA expression levels in cells derived from immunised mice,
cells were washed in cold PBS, centrifuged at 12,000xg for 5 minutes. The PBS was
then carefully removed and the cell pellet resuspended thoroughly in 1 ml Qiazol
Lysis Reagent (Qiagen) and stored at -80 °C. To extract the RNA from these samples
the chloroform/isopropanol method of RNA extraction was used. Qiazol samples
were thawed slowly on ice. Once fully thawed the tubes containing the homogenate
were incubated at room temperature (15-25 °C) for 5 minutes to promote the
dissociation of nucleoprotein complexes. 0.2 ml of chloroform (molecular grade;
Sigma) was added per 1 ml Qiazol Lysis Reagent added originally, and the tubes
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capped and shaken vigorously for 15 seconds. The tubes were then incubated at room
temperature for 2-3 minutes and then centrifuged for 15 minutes at 12,000xg at 4 °C.
This allowed the separation of the sample into three phases: the upper colourless
aqueous phase containing the RNA, a white interphase, and a lower red organic
phase. After centrifugation the upper aqueous phase was transferred carefully into a
new tube without carrying through any contamination from the other phases. 0.5 ml
isopropanol (molecular grade, Sigma) was added per 1 ml Qiazol Lysis Reagent
added originally and the samples mixed thoroughly by vortexing and the tubes then
placed at room temperature for 10 minutes and subsequently centrifuged at 12,000xg
for 10 minutes at 4 °C. The RNA pellet was visible at this stage and the supernatant
was carefully removed by pipetting. Then 1 ml of 75% ethanol (molecular grade,
Sigma) was added per 1 ml Qiazol originally added, and the samples centrifuged at
7,500xg for 5 minutes at 4 °C. The supernatant was then removed completely and the
RNA pellet briefly air dried. Once dry the pellet was redissolved in 100 l of RNase-
free water for subsequent RNA clean-up.
2.11.2 RNA Cleanup using Qiagen RNeasy Mini Kit
RNA samples extracted using the Qiazol/chloroform/isopropanol method were also
cleaned-up using the Qiagen RNeasy Mini kit as per the manufacturer’s protocol, to
remove any contaminating phenol that could have been carried through in the
extraction outlined in section 2.10.1. All centrifugation steps were performed at room
temperature. 350 l Buffer RLT was added to the 100 l RNA samples and mixed
well. 250 l of 100% ethanol (molecular grade, Sigma) was added to the diluted
RNA and mixed well by pipetting. The samples were then transferred to RNeasy
Mini spin columns placed in 2 ml collection tubes. The lids were closed and the
columns centrifuged for 15 seconds at 12,000xg to allow the RNA to bind to the
membrane. Then the flow through was discarded and the same collection tube
replaced for re-use. 500 l Buffer RPE was added to the RNeasy spin columns, the
lid closed and the columns centrifuged for 15 seconds at 12,000xg to wash the
membrane. Another 500 l of Buffer RPE was added to the spin columns and the
columns centrifuged for 2 minutes at 12,000xg to ensure the membrane was dry. The
RNeasy spin columns were then placed into fresh 2 ml collection tubes and
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centrifuged for 1 minute at 12,000xg to avoid any possible carryover of Buffer RPE.
Next the RNeasy spin columns were placed in new 1.5 ml collection tubes, and 40 l
RNase-free water added directly to the spin column membrane. The columns were
then centrifuged for 1 minute at 12,000xg to elute the RNA. RNA was then
transferred to fresh RNase-free tubes, the concentration measured using the
Nanodrop (ThermoScientific), and then stored at -80 °C.
2.11.3 RNA extraction using the Qiagen RNeasy Mini Kit
Th1 and Th17 in vitro polarised cells used to investigate the mRNA expression levels
of various genes by RT-qPCR were simply washed in cold PBS (~5x106 cells),
centrifuged at 12,000xg for 5 minutes, the supernatant removed and the cell pellets
stored at -80 °C for subsequent RNA analysis. The RNA from these samples was
extracted using the RNeasy Mini Kit (Qiagen) directly as outlined here. All
centrifugation steps here were performed at room temperature. The cell pellet was
first thawed on ice briefly and the pellet loosened by flicking the tube. 600 l of
Buffer RLT was added to the cell pellets and mixed thoroughly by pipetting up and
down 20 times. Next one volume (i.e. 600 l) of 70% ethanol (Sigma) was added to
the lysate and mixed well by pipetting. 700 l of the samples were then transferred to
the RNeasy spin columns placed in a 2 ml collection tube. The tubes were
centrifuged for 15 seconds at 12,000xg and the flow-through discarded. This process
was repeated, with the rest of the sample volume applied to the same columns, and
centrifuged. Next 700 l of Buffer RW1 was added to the RNeasy spin columns and
the columns centrifuged for 15 seconds at 12,000xg and the flow-through discarded.
500 l of Buffer RPE was then added to the RNeasy spin columns, the columns
centrifuged for 15 seconds at 12,000xg and the flow-through discarded. Another
500 l of Buffer RPE was added to the RNeasy spin columns and the tubes
centrifuged for 2 minutes at 12,000xg to allow the membrane to dry. After this the
RNeasy spin columns were transferred to fresh 2 ml collection tubes and centrifuged
for 1 minute at 12,000xg to prevent any possible carryover of Buffer RPE. The
RNeasy spin columns were then placed in 1.5 ml collection tubes and 40 l RNase-
free water added directly to the column membrane. The tubes were centrifuged for 1
minute at 12,000xg to elute the RNA. RNA was then transferred to fresh RNase free
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tubes, concentration measured using the Nanodrop (ThermoScientific) and stored at
-80 °C.
2.11.4 Reverse Transcription of RNA to cDNA for Real-Time
qPCR
To perform reverse transcription of RNA to cDNA, the QuantiTect Reverse
Transcription Kit (Qiagen) was used as per the manufacturer’s protocol. To do this,
template RNA was first thawed on ice, and the kit components, the gDNA wipeout
buffer, Quantiscript Reverse Trascriptase, Quantiscript RT Buffer, RT Primer Mix
and Rnase-free water thawed at room temperature (15-25 °C) and each solution
mixed by flicking the tubes. First the samples were treated with a genomic DNA
Wipeout buffer which eliminated any possible contaminating genomic DNA in the
RNA samples. The genomic DNA elimination reactions were prepared on ice
according to Table 2.2. Once the reactions were prepared, the samples were
incubated for 2 minutes at 42 °C and placed immediately on ice afterwards. Next the
reverse-transcription master mix was prepared on ice as a master mix according to
Table 2.3 and stored on ice. 6 l of the master mix was added to each template RNA
(i.e. the whole genomic DNA elimination reaction) and each tube mixed and stored
on ice. The samples were then incubated for 30 minutes at 42 °C for the reverse
transcription reaction to occur, followed by 3 minutes at 95 °C to inactivate the
Quantiscript Reverse Transcriptase. The cDNA samples were then stored at -20 °C
for subsequent real-time PCR analysis.
2.11.5 Quantitative real-time PCR using SYBR Green
For the real-time PCR reaction, the QuantiTect SYBR Green PCR Kit was used
(Qiagen) using SYBR Green I as per the manufacturer’s protocol. Firstly the 2x
QuantiTect SYBR Green PCR Master Mix was thawed on ice, as well as template
cDNA, primers and RNase-free water, and each solution mixed thoroughly. The
reaction mix was prepared for each primer set according to Table 2.4. A final
concentration of 0.3 M was used for all primers. A total reaction volume of 20 l
was utilised per reaction, using 2 l template cDNA. The cDNA was first pipetted
into the plate, and 18 l of the master mix containing the SYBR Green PCR master
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mix, primers and water was added to this. The volume of cDNA added should not
exceed 10% of the final PCR volume. Any bubbles were removed from each
reaction, and the plate was sealed with adhesive film and briefly centrifuged for a
few seconds to ensure the contents of each well was at the bottom. The real-time
cycler was programmed according to Table 2.5 and the plate containing the samples
placed in the machine and the program started.
The StepOne Real-Time PCR System (Applied Biosystems) and the ABI PRISM
7000 (Applied Biosystems) were used. When using the ABI PRISM reaction
volumes of 50 l were used. Melting curve analysis was performed for each reaction
to verify the specificity of the PCR primers and products. All the primers used for
SYBR Green real-time PCR are listed in Table 2.6. When choosing primers, it was
ensured that targets were 100-150 bp pairs in length to maximise the efficiency of the
real-time PCR using SYBR Green I.
2.11.6 RT-qPCR data analysis
method) which measures the relative changes in gene expression (Livak and
Schmittgen, 2001). All samples were normalised to the housekeeping gene
hypoxanthine-guanine phosphoribosyltransferase (HPRT). The cycle threshold (CT)
value for each sample denoted the cycle number at which the exponential
amplification reached the threshold level (the threshold level was the chosen point at
which all genes were in the exponential amplification phase).
T sample = CT
target gene – CT T value for each sample was obtained
T T sample – T calibrator). Finally, the normalised target gene
expression level in each sample was calculated as 2 - . The 2- value for the




All statistics was performed using Prism software. When two parameters were being
compared, the non-parametric Mann Whitney test was used with the following
significance levels (‘*’ denoting p<0.05, ** denoting p<0.01, and *** denoting
p<0.001). When three or more groups were being compared the non-parametric
ANOVA, the Kruskal-Wallis (KW) test, was used to determine if there was any
significance between the groups, and the Dunn’s multiple comparison post test to
compare the different groups. When a KW test is used and shows a significant
difference between the groups, the p value for this is indicated in the figure legend,
and the significance level (if any) of the Dunn’s post test indicated in the figure. Due
to the low numbers in the groups analysed these non-parametric tests were used, as
opposed to their parametric versions. This allowed for more stringent significance
testing when the normal distribution of data could not be assumed due to low sample
numbers.
To determine significance in EAE scores/disease courses, a Fisher’s exact test was
used. This compared the disease severity between two groups (e.g. number of mice
with score 3 and below, versus number of mice with score 4 and above) to determine
if a proportion of mice with severe EAE was significantly different. The severity cut
off point was determined for each separate experiment (due to the variability across
different experiments) based on the observed severity for that experiment. The Mann
Whitney test, as discussed above, was also used to determine whether there was a
significant difference in the time of disease induction between two different groups.
Data shown is representative of the number of experiments indicated. However,
different experiments could not be pooled together to increase dataset sizes due to the
variability in EAE in terms of disease severity and/or start date.
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Antibody Conjugate Clone Dilution Concentration
CD4 -AF700 (Invitrogen) RM4-5 1:200 0.5 mg/ml
CD44 -FITC IM7 1:200 0.5 mg/ml
CD62L -FITC; -PE Mel-14 1:200 0.5 mg/ml
CD25 -APC 7D4 1:200 0.5 mg/ml
CD11b -APC; -eF450 M1/70 1:200 0.2 mg/ml
4-integrin -FITC (BD Pharmingen) R1-2 1:200 0.5 mg/ml
CCR2 -PE (SantaCruz) E68 1:200 0.5 mg/ml
CCR3 -FITC (R&DSystems) 83101 10 l per test 25 g/ml
CCR4 -PE (SantaCruz) CKR-4 (H-48) 1:200 200 g/ml
CCR5 -PE HM-CCR5-(7A4) 1 l per test 0.2 mg/ml
CCR6 -APC (R&DSystems) 140706 10 l per test 10 g/ml
CXCR3 -APC (R&DSystems) 220803 10 l per test 10 g/ml
PSGL-1 -PE (BD) 2PH1 1:200 0.2 mg/ml
IFN- -FITC XMG1.2 1:100 0.5 mg/ml
TNF- -PE MP6-XT22 1:100 0.2 mg/ml
IL-17 -APC eBio17B7 1:100 0.2 mg/ml
FoxP3 -APC; -PE; eF450 FJK-16s 1:100 0.2 mg/ml
T-bet -Percp-Cy5.5; -FITC
(SantaCruz Biotechnology)
eBio4B10; 4B10 1:100 0.2 mg/ml
-PE AFKJS-9 1:150 0.2 mg/ml
CD45.1 -FITC; -PerCP-Cy5.5 A20 1:200 0.2 mg/ml
CD90.1 -PE; -APC OX-7; HIS-51 1:200 0.2 mg/ml
IgG1 iso control -PE; -FITC; -APC; -
PerCP-Cy55
eBRG1 1:100 0.2 mg/ml




-PE eBio299Arm 1 l per test 0.2 mg/ml
Table 2.1 Flow cytometry antibodies used for flow cytometry analysis.
Component Volume per reaction
gDNA Wipeout Buffer 2 l
Template RNA Variable (up to a 1 g)
RNase-free water Variable
Total volume 14 l
Table 2.2 Reaction components of genomic DNA elimination reaction per tube.
Component Volume per reaction
Quantiscript Reverse Transcriptase 1 l
Quantiscript RT Buffer 4 l
RT Primer Mix 1 l
Template RNA: genomic DNA elimination
reaction
14 l
Total volume 20 l
Table 2.3 Reverse-transcription reaction components per reaction
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Component Volume per reaction
2x QuantiTect SYBR Green PCR Master Mix 10 l
Forward Primer Variable
Reverse Primer Variable
Template cDNA (10-100 ng) Variable
RNase-free water Variable
Total volume 20 l
Table 2.4 Reaction set up for SYBR Green quantitative PCR
Step Time Temperature
PCR initial activation step: 15 minutes 95 °C
Cycling conditions:
Denaturation 15 seconds 94 °C
Annealing 30 seconds 55 °C
Extension 30 seconds 72 °C
Table 2.5 Real-time cycler conditions.






























C2GnT-I C2GnT-I_F TCA TAA CCT GGT TCA TCA TCG C
C2GnT-I_R CGA TCC AGC ACT GTT TCG T
HPRT HPRT_F GAC CGG TCC CGT CAT GC
HPRT_R TCA TAA CCT GGT TCA TCA TCG C
Table 2.6 Real-Time PCR Primers for SYBR Green I
All primers were obtained from MWG Biotec.
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3 Th1 cells are capable of entering the non-
inflamed CNS and induce EAE, whereas Th17
cells cannot.
3.1 Introduction
Classically, EAE was considered a Th1-mediated autoimmune disease with several
lines of evidence leading to this conclusion. Myelin-reactive T cell clones able to
induce disease appeared to have an IFN- -producing Th1 phenotype (Ando et al.,
1989; Kuchroo et al., 1993). T cell differentiation towards a Th1 phenotype is driven
by IL-12 production from DCs (Seder et al., 1993; Macatonia et al., 1995) and the in
vivo administration of anti-IL-12 antibody significantly reduced the severity of EAE
(Leonard, Waldburger and Goldman, 1995; Segal, Dwyer and Shevach, 1998). In
addition to this, IL-12-deficient mice exhibited resistance to EAE induction (Segal,
Dwyer and Shevach, 1998), indicating the importance of this Th1-inducing cytokine
in the initiation of autoimmune disease. This apparent role of the IL-12-Th1 lineage
in EAE correlated with evidence that there was an increase in CD4+ Th1 cells in the
serum and CSF of MS patients (Balashov et al., 1999; Teleshova et al., 2002).
IFN-
expression of adhesion molecules on endothelial cells, thereby facilitating the entry
of encephalitogenic T cells across the BBB during EAE (Dore-Duffy et al., 1996).
However, despite the apparent importance of the IL-12/Th1 lineage in EAE
induction, IFN-
with anti-IFN- (Billiau et al., 1988;
Lublin et al., 1993) and mice deficient in IFN- -
susceptible to disease (Ferber et al., 1996; Willenborg et al., 1996).
The discovery of the novel cytokine IL-23 shed light on this discrepancy,
highlighting that IL-12 and IL-23 share a subunit, p40 (Oppmann et al., 2000).
Previous experiments that had blocked IL-12 signalling had also unknowingly been
blocking IL-23. Importantly, IL-23 was also found to be key to the induction of
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autoimmune disease (Cua et al., 2003). It was then possible to distinguish between
IL-12 and IL-23, and IL-12-deficient (p35-/-) mice were found to be susceptible to
disease whereas IL-23-deficient (p19-/-) mice, or double-deficient (p40-/-) mice, were
protected (Cua et al., 2003). From this the IL-23-induced Th17 lineage were then
described and shown to have a important role in EAE induction (Langrish et al.,
2005; Park et al., 2005) with IL-17-deficient mice exhibiting reduced severity of
disease (Komiyama et al., 2006).
Since the emergence of the Th17 lineage there has been an important shift towards
understanding the role of Th17 cells in disease pathogenesis with aims to developing
therapeutics specifically targeting Th17 cells. At the start of this project, there was no
robust method for the generation of pure populations of IFN- + Th1 cells or IL-17+
Th17 cells devoid of any contaminating cells. Secondly, the role of IL-23 in Th17
differentiation was controversial with it being generally considered to be essential for
differentiation of naïve T cells towards a Th17 phenotype (Langrish et al., 2005). It
was later determined that IL-23 was required more for the stabilisation of the
already-differentiated Th17 cells (Stritesky, Yeh and Kaplan, 2008; McGeachy et al.,
2009).
The ability Treg to suppress IFN- -17 production in vitro
(O'Connor, Malpass and Anderton, 2007) led to the central hypothesis that
Th17-induced EAE resulted in more severe chronic EAE, due to the lack of
Treg-mediated suppression. To investigate this it was important to establish disease
induced by either Th1 or Th17 cells and to elucidate the contributions that each made
to disease pathology. This results chapter attempts to do this.
It is not fully understood what cytokines are first upregulated in response to antigen
during an immune response in the lymph node. Naïve CD4+ T cells are activated
when presented with antigen by the APCs within the draining lymph node.
Depending on the immediate cytokine milieu in their environment, CD4+ T cells
differentiate into effector Th1, Th2 or Th17 cells, or into inducible Treg. As
mentioned earlier, DC derived IL-12 is the main driver towards a Th1 phenotype
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(Seder et al., 1993; Macatonia et al., 1995). The presence of IL-6 and IL-23 skews
towards differentiation to a Th17 phenotype (Zhou et al., 2007; Stritesky, Yeh and
Kaplan, 2008), whereas TGF- is required for the differentiation into FoxP3+ Treg
(Zhou et al., 2008). The final aim of this chapter attempts to investigate what
cytokines are upregulated in the lymph node after immunisation with peptide and
CFA, and to determine whether there is a skewing towards a Th1 or a Th17
phenotype during this time.
3.1.1 Aims
The aims of this chapter were: a) to establish rigorous protocols for the in vitro
generation of myelin-reactive Th1 and Th17 cells, b) to establish EAE driven by
either Th1 or Th17 cells; c) to investigate the differences in disease pathogenesis of
Th1- or Th17-driven EAE, if any were observed; d) to determine if there was a
skewing towards a Th1 or Th17 phenotype after the in vivo activation of naïve T
cells when using EAE-inducing protocols, by analysis of both innate and T cell
derived cytokines.
3.1.2 Approach
Once protocols to produce pure populations of IFN- + Th1 cells and IL-17+ Th17
cells were established, the pathogenic capability of Th1 and Th17 cells were
investigated through the passive transfer model, using the polyclonal pMOG
C57BL/6 model and the TCR transgenic Tg4 model. This allowed the investigation
of the ability of populations of Th1 and Th17 cells to induce disease in vivo. The
polyclonal passive transfer model involved the subcutaneous immunisation of
C57BL/6 mice with pMOG and CFA. The draining lymph nodes were collected ten
days later, and these primed T cells re-activated in vitro in the presence of pMOG
and polarised towards a Th1 or Th17 phenotype. For the Tg4 passive transfer model,
naïve MBP-reactive CD4+ Tg4 cells were polarised in vitro towards a Th1 or Th17
phenotype in the presence of MBP (Ac1-9). The transferred donor cells were
traceable due to the presence of congenic markers (CD45.1 or CD90.1). For analysis
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spleen and CNS samples were taken at indicated time-points, and the cytokine
production in response to antigen stimulation determined by flow analysis.
Two approaches were used to determine if there was a skewing towards a Th1 or
Th17 phenotype after immunisation in vivo. Firstly, C57BL/6 mice were immunised
with pMOG/CFA or with CFA alone. The lymph nodes (draining and non-draining)
were sampled at various time-points to investigate the mRNA expression of a
selection of innate cytokines and T cell derived cytokines, as well as the lineage
specific transcription factors. The level of expression was compared to that in non-
immunised naïve controls. Secondly, naïve Tg4 cells were transferred into host mice
and these immunised with MBP (Ac1-9) the following day to induce EAE. Samples
were then taken at day 6 post-immunisation to investigate the phenotype of the naïve
T cells and determine their in vivo polarisation status by flow cytometry analysis.
3.2 Results
3.2.1 Optimisation of Th1 and Th17 polarising protocols of
pMOG-reactive cells
The optimal protocol for polarising pure Th1 or Th17 cells in vitro was investigated
in order to then go on and establish both Th1 and Th17 induced EAE. To do this,
pMOG-reactive cells were polarised in vitro under various conditions (Figure 3.1 A).
Not all the cells in the population produce the cytokines investigated, therefore there
was always a proportion of ‘cytokine negative’ cells, producing neither IFN-
IL-17. Polarising towards a Th1 phenotype using IL-12, or IL-18, alone (with the
addition of IL-2) produced a level of IFN- + cells above that of medium alone,
however below the level of IFN- + cells produced after stimulation in the presence of
pMOG with no exogenous cytokines. In addition to this, IL-17+ contaminants were
evident, either as IL-17+ or IL-17+ IFN- + (‘double-positive’) cells after polarisation
with IL-12 or IL-18 alone. However, polarising with IL-12 and IL-18 together gave
rise to the highest level of IFN- + cells, above that produced in the presence of
pMOG alone, and using this combination also decreased the numbers of IL-17+
CHAPTER 3 RESULTS
86
contaminating cells. Therefore, a combination of IL-12 and IL-18 was used for all
future experiments to polarise towards a Th1 phenotype, (with the addition of IL-2 to
promote survival). This protocol consistently generated a population with high
proportions of IFN- + cells and low or negligible numbers of IL-17+ cells.
For polarisation towards a Th17 phenotype, using IL-6 alone produced a very mixed
population, with equal proportions of IL-17+ cells and IFN- + cells and a few double
producers, as did polarising with TGF- alone, although this generated lower levels
of cytokine producing cells. In contrast, using IL-23 alone gave rise to high numbers
of IL-17+ cells, but there was still a clear proportion of IFN- + cells in the form of
both single and double-positive cells. Combinations of the three cytokines were
trialled. Using IL-23 and IL-6 together produced the highest level of IL-17+ cells, but
again this population had IFN- + contaminating cells within it. A combination of all
three polarising cytokines (IL-6, TGF- and IL-23) gave the highest proportions of
IL-17+ cells and reduced levels of IFN- + contaminants. Therefore, for all future
Th17 polarisations IL-6, IL-23 and TGF- were used to polarise towards a Th17
phenotype.
Th1 cells polarised using IL-12 and IL-18 were T-bet+ (Figure 3.1 -
(Figure 3.1 C). Reciprocal to this, Th17 cells polarised with IL-6, IL-23 and TGF-
were T-bet- (Figure 3.1 + (Figure 3.1 C). The mRNA levels of T-bet
in vitro polarised cells were also determined by RT-qPCR as
compared to control Th0 cells. Th1 cells had high T-bet levels (Figure 3.1 D) and
Figure 3.1 E). In contrast, Th17 cells, polarised
using either IL-6+TGF- +IL-23 (Th17), or using IL-6 and TGF- only, had highly
-times upregulated compared to the




3.2.2 Optimisation of Th1 and Th17 in vitro polarised Tg4 cells
As shown in Fig. 3.1, a combination of IL-12, IL-18 and IL-2 could efficiently
polarise towards a Th1 phenotype, whereas a combination of IL-23, IL-6 and TGF-
generated a Th17 phenotype. To deduce if the same was found in the TCR transgenic
system, naïve Tg4 cells were FACS sorted and cultured in the presence of polarising
cytokines (Figure 3.2 A). The same conditions identified using the pMOG system,
gave the optimal results using the Tg4 system. There was a large variability in the
level of cytokine producing cells between different experiments. As shown in Figure
3.2 A, the percentage of cytokine producing cells was lower in the MBP (Ac1-9)
system compared to the pMOG system (Figure 3.2 A). However, this was not always
the case. The reason for this variability is not clear, but the challenges of intracellular
cytokine staining are likely to be a contributing factor. The Tg4 Th17 cell
polarisation in the presence of IL-23 alone generated more IFN- + cells compared to
IL-17+ cells, although the level of cytokine production here was very low. In this
case polarising Th17 cells using IL-23 and IL-6 gave rise to the highest proportion of
IL-17+ cells, but this was not consistent across different polarisation experiments. A
combination of IL-6, IL-23 and TGF- gave the most consistent results of high levels
of IL-17+ cells and very few IFN- + contaminants (Figure 3.2 A).
T- RT-qPCR on Tg4 cells polarised
under the various conditions outlined (Figure 3.2 B). T-bet was upregulated on cells
polarised with IL-12 or IL-18 alone and when both were used in combination (Figure
3.2 B, left) as compared to the Th17 control. Interestingly, the Th0 cells also had
upregulated T-bet expression levels. Cells cultured under Th0 conditions always had
IFN- + cells in the population, so the upregulated T-bet expression was not
various
Th17-associated cytokine conditions (Figure 3.2 C) compared to the Th1 control
cells and it was also upregulated on the Th0 cells. Interestingly, cells ‘polarised’
using IL-23 alone, had upregulated levels of both T- Figure 3.2 B and
C) as compared to their respective controls highlighting the heterogeneity of this cell
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population. In addition, IL-
in Th0 cells.
In both systems the cytokine production correlated with the expression of the
appropriate transcription factor, i.e. T-bet+ cells produced IFN- + cells
produced IL-17 (data not shown). Comparing the two approaches, despite the
pMOG-reactive cells being initially primed in vivo, the polarisation they received in
vitro was still able to push the previously in vivo skewed cells towards the
appropriate phenotype, in the same way as polarising naïve T cells. In fact, the in
vivo primed cells appeared to exhibit a more stable phenotype as discussed later in
this chapter, compared to those cells that were stimulated with their cognate antigen
for the first time in vitro.
3.2.3 pMOG-reactive Th1 cells induce EAE, whereas their Th17
counterparts do not
To test the central hypothesis that Treg could not suppress Th17-induced EAE
efficiently, Th17-induced EAE first had to be established. To do this, traceable
(distinguishable from each other by flow cytometry based on CD45 and CD90
isotype expression) pMOG-reactive Th1 and Th17 cells were generated (as shown in
Figure 3.3 A) and transferred in to C57BL/6 host mice, either alone or in
combination. It was found that pMOG-reactive Th1 cells were able to induce disease
when transferred alone, or in combination with Th17 cells (Figure 3.3 B).
Surprisingly however, pMOG-reactive Th17 cells could not induce disease when
transferred alone (Figure 3.3 B).
3.2.4 Disease induction correlates with the entry of donor T
cells into the CNS
Donor CD45.1+ Th1 cells could clearly be seen in the spleen and CNS of Th1-only
transferred mice, as well as the Th1 + Th17 co-transferred mice (Figure 3.4 A and
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B). Quantitatively, either population was clearly found in the spleen, when
transferred alone or together (Figure 3.4 C). A significant number of donor CD90.1+
Th17 cells were located in the CNS when co-transferred with the Th1 cells (Figure
3.4 D). When transferred alone, however, the Th17 cells appeared unable to enter the
CNS, or at least unable to establish a population in the CNS (Figure 3.4 D).
3.2.5 Both pMOG-reactive Th1 and Th17 transferred
populations did not switch phenotype in vivo
After an over-night in vitro restimulation in the presence of pMOG, intracellular
cytokine staining of the transferred Th1 populations revealed high percentages of
IFN- + donor cells in the CNS when the cells were transferred alone or together with
Th17 cells (Figure 3.5 A and B, left and middle panels). No IL-17+ cells were
evident in the Th1 donor populations. Th17 cells, when able to gain access to the
CNS, also appeared stable and continued to produce IL-17, but not IFN-
response to pMOG stimulation (Figure 3.5 A and B, right panel). This is represented
quantitatively in comparison to the spleen showing IFN-
donor cells ((25-30% IFN- + in the spleen and 15-20% IFN- + in the CNS) (Figure
3.6 A and C), with no significant numbers of IL-17+ cells in the CNS or the spleen
(Figure 3.6 B and D) in the Th1 donor cells. Th17 donor cells in the spleen or CNS
did not switch towards a Th1 phenotype but continued to produce IL-17 and not
IFN- (10-15% IL-17+ cells in the spleen and ~8% IL-17+ cells in the CNS) (Figure
3.6 B and D). Importantly, there were negligible numbers of IFN- + contaminants in
the Th17 donor populations (Figure 3.6 A and C).
3.2.6 TCR transgenic Tg4 Th1 cells induce EAE, whereas Th17
cells do not
The above observations in the pMOG passive transfer model indicated surprisingly
that the Th1 cells, rather than Th17 cells, were the prime initiators of EAE. To
determine whether this was also the case using myelin responsive T cells receiving
primary activation in vitro, Tg4 TCR transgenic mice were used (Figure 3.7 A and
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B). Consistent with results from the pMOG passive transfer model, Tg4 Th1 cells
induced disease whereas the Th17 cells did not (Figure 3.7 C). The Th1 cells induced
monophasic classical EAE with the onset of disease around day 9 post-transfer
(Figure 3.7 C). Samples were taken from the spleen and CNS at day 16 post-transfer.
There were significantly higher total viable cell numbers (Figure 3.7 D, top) and
CD4+ cells (Figure 3.7 E, top) in the spleen in the Th17 transfer compared to the Th1
transfer, however the absolute number of donor cells in the spleen was comparable
between the two groups (Figure 3.7 F top). An inability of the Th17 cells to enter the
CNS mimicked that seen in the pMOG passive transfer model. There were lower
total cell numbers in the CNS of the Th17 transfer (Figure 3.7 D, bottom), and
significantly fewer CD4+ T cells (Figure 3.7 E, bottom) and donor T cells in the CNS
of the Th17 transfer compared to the Th1 transfer (Figure 3.7 F, bottom).
3.2.7 Tg4 Th1 cells migrate to the CNS as early as day 3 post-
transfer
In order to determine how early Th1 cells can be found in the CNS in the Tg4
passive transfer model, EAE was induced using Tg4 Th1 cells and samples taken at
days 3, 6 and 9 post-transfer (Figure 3.8 A, B and C). As early as day 3 post-transfer,
the Th1 donor cells were approximately 10% of the CD4+ population within the CNS
(Figure 3.8 D, left). This percentage increased to 30% at day 6 and to over 60% by
day 9 post-transfer (Figure 3.8 D, left). This increasing proportion of Th1 donor cells
in the CNS correlated to increasing absolute numbers of donor Th1 cells in the CNS
over time (Figure 3.8 D, right). There were roughly 200 Th1 donor cells present in
the CNS at day 3 post-transfer with a 100-fold increase by day 6 (to 20,000 cells),
and reaching a further 10-fold increase by day 9 to approximately 200,000 Th1 donor
cells in the CNS (Figure 3.8 D, right). This total number of donor Th1 cells at day 9
post-transfer was still ~60-70% of the CD4+ population in the CNS at this time-point,




3.2.8 Tg4 Th1 cells appeared phenotypically stable in vivo
After an over-night in vitro re-stimulation in the presence of MBP (Ac1-9), the
cytokine production by the donor Th1 cells was determined for the CNS and spleen
sampled at day 9 post-transfer. Donor Th1 cells could be clearly detected in the
spleen (Figure 3.9 A) and the CNS (Figure 3.9 B). Cytokine staining revealed high
percentages of IFN- + cells in the donor cells in both the spleen and the CNS (Figure
3.9 C and D). No IL-17+ cells were apparent in either tissue (Figure 3.9 C and D)
indicating the stability of the donor Th1 cells in vivo.
3.2.9 Deducing a dose of Tg4 Th1 cells for induction of sub-
optimal EAE
Results using the pMOG model (Section 3.2.4) indicated that, once the BBB had
been made more ‘permeable’ by Th1-induced inflammation, Th17 cells could gain
access to the CNS. If so, could the Th17 cells influence disease progression or
severity? To develop this, a sub-optimal number of Th1 cells were to be co-
transferred with Th17 cells to allow the co-transferred Th17 cells access to the CNS.
Therefore a dose of pathogenic Tg4 Th1 cells that would give rise to low level, or
sub-optimal, disease had to be determined. Th1 cells were polarised and a range of
Th1 cells (from 0.2x106 up to 4x106 blasts) were transferred (Figure 3.10 A and B).
The highest number of Th1 blasts transferred (4x106) correlated with the highest
severity of disease (Figure 3.10 C) and disease severity and incidence decreased with
decreasing numbers of Th1 blasts transferred (Figure 3.10 C). A dose of 1x106 Th1




3.2.10 Transfer of a sub-optimal number of Th1 cells together
with Th17 cells resulted in the increase in EAE severity
Based on the above results, a sub-optimal dose (1x106) of Th1 cells was co-
transferred with a high number (4x106) of Th17 cells to determine if, once the Th17
cells gained access to the CNS they were able to influence EAE severity (Figure 3.11
A). The relevant control doses of Th1 and Th17 cells were also included i.e. high
(4x106) dose of Th1 cells, a low (1x106) dose of Th1 cells and a high (4x106) dose of
Th17 cells. The pre-transfer phenotype of the cells was determined by intracellular
cytokine staining after PMA re-stimulation for IFN- -17 and TNF- , and by
ELISA for IFN- -17 (Figure 3.11 B and C). The FoxP3 expression levels on
the Th1 and Th17 cells were determined and found to be comparable (Figure 3.11
D).
The Th1hi transfer, as expected, gave a significantly increased severity of disease
compared to the Th1lo transfer (Figure 3.12 A). The Th17hi transfer resulted in no
induction of disease. However, when the Th17hi cells were co-transferred with a sub-
optimal number of Th1 cells, the disease severity observed was comparable to that
induced by the high number of Th1 cells alone (Figure 3.12 A) indicating the Th17
cells were able to contribute to pathology once this was initiated by Th1 cells.
3.2.11 A significant number of Th17 cells were able to enter the
CNS when co-transferred with a low number of Th1 cells
The location of the donor Th1 and Th17 cells was determined from samples taken on
day 20 post-transfer. In the spleen the total number of viable cells was comparable
across the four groups (Figure 3.12 B), as was the percentage and absolute number of
CD4+ cells (Figure 3.12 C). A significantly lower percentage and absolute number of
donor Th1 cells were found when a lower number were transferred compared to the
Th1 high transfer (Figure 3.12 D). Comparable percentages and absolute numbers of
Th17 cells were found in the spleen (Figure 3.12 E).
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Within the CNS, the total number of viable cells was significantly lower in the
Th17hi transfer, compared to the Th1hi transfer (Figure 3.13 A). The percentage and
absolute number of CD4+ cells was also significantly lower in the Th17hi transfer
group (Figure 3.13 B). There were significantly fewer donor Th1 cells in the Th1lo
transfer group compared to the Th1hi group (Figure 3.13 C). Importantly, fewer
donor Th17 cells were found in the CNS of the Th17hi transfer group compared to in
the Th1lo + Th17hi co-transfer group (Figure 3.13 D, right) as these cells were unable
to gain access to the CNS.
In summary, there was no significant difference in the number of Th17 cells between
the two Th17 groups (Figure 3.13 E) in the spleen. However, there were a significant
number of Th17 cells in the CNS in the co-transferred group, compared to when the
Th17 cells were transferred alone (Figure 3.13 F). This suggested the increase in the
number of Th17 cells in the CNS on co-transfer was specific to the target organ. The
small but significant population of Th17 cells in the CNS of the co-transferred group
appeared able to increase the severity of disease observed, however the mechanism
for this increase in disease severity is as yet unknown.
3.2.12 Cytokine production in the CNS during active EAE
The data shown above suggested a superior role of IFN- -producing Th1 cells in the
induction of disease by passive transfer. During active EAE naïve T cells are
activated and differentiated in vivo and subsequently migrate to the CNS to induce
disease. To determine the dominant pro-inflammatory response (Th1 or Th17) in
active EAE, mice were immunised to develop pMOG-induced active EAE (Figure
3.14 A). In the CNS at the peak of disease, the CD4+ population had a mixed
phenotype of IFN- +, IL-17+ and TNF- + cells in response to pMOG re-stimulation
(Figure 3.14 B) indicating that both Th1 and Th17 cells were at least present within
the CNS at this time.
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3.2.13 Both a Th1 and Th17 inflammatory response is induced
after immunisation with pMOG/CFA
To determine what response is dominant after immunisation with CFA and/or
pMOG/CFA, C57BL/6 mice were immunised and the level of mRNA expression
above that of non-immunised controls was determined for various Th1- and Th17-
associated cytokines (Figure 3.15 A). IL-12 (Figure 3.15 B), IL-18 (Figure 3.15 C),
IFN- Figure 3.16 A) and T-bet (Figure 3.16 B) showed upregulated mRNA
expression above the non-immunised controls indicative of a Th1 response. The level
of mRNA expression of IL-17 (Figure 3.16 C), TGF- (Figure 3.15
(Figure 3.16 D) were also upregulated above the non-immunised control samples
indicative of a Th17 response. IL-6 mRNA was found at very low levels of
expression in the immunised mice, never above the control samples (Figure 3.15 E).
Interestingly FoxP3 mRNA was slightly upregulated above the controls (Figure 3.16
F). IFN- -17
expression came up later (around day 5 and 7 post-immunisation) (Figure 3.16 A and
C), suggesting that a Th1 response was induced first, followed closely by a Th17
response.
3.2.14 In vivo activation of naïve Tg4 T cells in response to MBP
(Ac1-9) immunisation
The above results suggested that both a Th1 and a Th17 response occurred after
immunisation with pMOG and CFA. To determine if this was the same in the Tg4
TCR transgenic model, naïve Tg4 cells were transferred into host mice and these
were subsequently immunised with MBP (Ac1-9)/CFA to induce disease (Figure
3.17 A and B). Samples were taken on day 6 post-immunisation to determine the
phenotype of the donor cells after in vivo activation. The CD4+ population and
CD45.1+ donor cell population could clearly be found in the CNS, spleen and
draining (inguinal) lymph nodes (Figure 3.17 C-F). Intracellular cytokine staining of
the donor T cells revealed a mixed population of IFN- +, IL-17+ and TNF- + cells in
all tissues sampled (Figure 3.18 A) indicating differentiation of the naïve T cells
towards both a Th1 and a Th17 phenotype. The proportion of FoxP3+ cells was low
CHAPTER 3 RESULTS
95
on the donor T cells in the CNS and spleen compared to the host population (Figure
3.18 B) suggesting the transferred Tg4 cells had not differentiated towards a
regulatory phenotype. Lastly, T-bet upregulation could not be detected on the donor
cells in any tissue, whereas the ROR
cells above the isotype control, but was comparable across the tissues sampled
(Figure 3.18 C). These results were indicative of polarisation of the naïve T cells
towards both Th1 and Th17 phenotypes.
3.3 Discussion
It is well established that IL-12 is required for Th1 cell development (Gately et al.,
1998) leading to the upregulation of IFN- -bet, the key
transcription factor of the Th1 lineage (Szabo et al., 2000; Lighvani et al., 2001).
IL-12 induces the expression of IL-12R 2 which allows the cells to become
responsive to IL-12 signalling (Langrish et al., 2005). Here, polarisation with IL-12
led to an increase in IFN- + cells. However, the addition of IL-18 to the cytokine mix
increased the level of IFN-
frequency of IL-17+ contaminants in the Th1 population. IL-18 (previously known as
IFN- -inducing factor) has the ability to induce IFN- - and GM-CSF
production by T cells as well as the upregulation of IL-2R (Kohno and Kurimoto,
1998; Okamura et al., 1998). Therefore, for this project, the polarisation of naïve T
cells, or pMOG-reactive cells towards a Th1 phenotype was routinely performed
using a combination of IL-12 and IL-18. This consistently produced a T-bet+
population (as determined at both the protein level by flow cytometry analysis, and
the mRNA level by RT-qPCR) with a high proportion of IFN- + cells and,
importantly, very few IL-17+ contaminants. The use of IL-18 in the Th1 polarising
cocktail increased the number of IFN- + and TNF- + cells and also resulted in a more
severe form of EAE being induced on transfer (Ito et al., 2003) (also see Chapter 5).
The cytokines required for the development of Th17 cells have been a topic of much
debate since the description of this Th subset. Initially, it was thought that IL-23 was
the key cytokine required for differentiation towards a Th17 phenotype (Cua et al.,
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2003; Langrish et al., 2005) due to the high numbers of IL-17+ cells induced after
expansion with IL-23 alone. As shown here, expansion with IL-23 produced a
population with high numbers of IL-17+ cells (~30%), but also with a high number of
IFN- + cells (~20%, both IFN- + single positive cells and IFN- + IL-17+ double
positive cells). Therefore, disease conferred after the transfer of IL-23 conditioned
‘Th17’ cells, as has been done in numerous studies (Langrish et al., 2005; McGeachy
et al., 2007) would not give conclusive results as to which cell type, IL-17+ Th17 or
IFN- + Th1, had contributed to the disease induction, due to the mixed population
used on input.
IL-23 is not required for the initial differentiation of Th17 cells from naïve T cells.
However, it is important for the maintenance of their stability and for their terminal
differentiation (Stritesky, Yeh and Kaplan, 2008; McGeachy et al., 2009). The key
cytokines for the differentiation of naïve T cells towards a Th17 phenotype have
been determined to be IL-6 and TGF- (Serada et al., 2008). IL-6 has been shown to
be directly needed for the differentiation into Th17 cells (Bettelli et al., 2006) and the
(Ivanov et al., 2006). TGF- has been shown to
indirectly mediate Th17 differentiation by blocking the expression of STAT4 and
GATA-3, thereby preventing Th1 or Th2 differentiation (Das et al., 2009) and
promoting Th17 differentiation. For this project, a combination of IL-6, IL-23 and
TGF- were used for the in vitro polarisation of Th17 cells as this generated the
‘cleanest’ cell populations with minimal IFN- + contaminating cells in our models.
It has been suggested that polarising Th17 cells with only IL-6 and TGF- (i.e. in the
absence of IL-23) results in the increase in IL-17, but also in the anti-inflammatory
cytokine, IL-10 (McGeachy et al., 2007). Although these cells polarised in this way
upregulate IL-17, they cannot induce inflammatory disease due to their production of
IL-10 (McGeachy et al., 2007). Other protocols for the differentiation of Th17 cells
involve an initial stimulation in the presence of IL-6 and TGF- , followed by a rest
period in the presence of IL-23, and finally a re-stimulation with anti-CD3/anti-
CD28 (Jager et al., 2009) producing a Th17 cell population with high numbers of
IL-17+ cells. However the in vivo stability (cytokine phenotype) of these Th17 cells
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is questionable. It has also been shown that Th17 differentiation is modulated by the
activation of the aryl hydrocarbon receptor (AhR) (Veldhoen et al., 2008a).
Interestingly, the culture medium Iscove’s modified Dulbecco’s medium (IMDM), is
rich in aromatic amino acids which give rise to AhR agonists and therefore supports
increased differentiation towards the Th17 phenotype. In contrast, RPMI medium,
which was used here, is thought not to support high Th17 differentiation due to a
lack of AhR agonists (Veldhoen et al., 2008a; Veldhoen et al., 2009). Th17
differentiation in IMDM was trialled during this project, but did not show any
increased differentiation towards the Th17 phenotype in our hands, when compared
to polarisation in RPMI (data not shown). In addition, numerous laboratories
showing strong Th17 polarisation as well as pathogenicity have performed their in
vitro Th17 polarisations in RPMI medium (McGeachy et al., 2007; Jager et al.,
2009), showing that although AhR ligation may indeed be beneficial for Th17
differentiation, it is not essential for their differentiation and pathogenicity.
IL-1 signalling has also been suggested to be important for in vivo Th17
differentiation, especially for regulating the expression o (Chung
et al., 2009). The addition of IL-1 to the Th17 polarisation cytokine mix was trialled
use of only IL-6, IL-23 and TGF- , although it did further downregulate the
expression of T-bet mRNA. IL-1 signalling is also required in EAE, as demonstrated
by the significantly lower disease observed in IL-1R1KO mice compared to
wild-type mice, due to a lack of a Th17 response (Sutton et al., 2006). In addition,
IL-1 and IL- -17 production by CD4+ T
cells (Sutton et al., 2009).
Once the protocol for the most pronounced polarisation of stable Th1 and Th17 cells
had been established, the central hypothesis of this project could be tested. However
this required the establishment of Th17-driven EAE, but Th17 cells could not induce
disease when transferred alone. This was observed for pMOG-reactive Th17 cells
polarised with IL-6, TGF- plus IL-23, as well as for those polarised with just IL-6
and TGF- (O'Connor et al., 2008).
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This inability of the Th17 cells to induce disease correlated directly with their
apparent inability to home to the non-inflamed CNS as opposed to their Th1
counterparts. Once inflammation had been established by the Th1 cells, the Th17
cells could then follow into the CNS, and presumably had a role to play in pathology.
This inability of Th17 cells to home to the site of inflammation has also recently
been demonstrated in a model of RA (Janke et al., 2010). As mentioned earlier,
IL-23 is required for the terminal differentiation of Th17 cells. Numerous early
studies in the role of Th17 cells in autoimmunity used IL-23 conditioned ‘Th17’ cells
(Langrish et al., 2005; Park et al., 2005). However as shown here, polarisation with
IL-23 alone resulted in a very mixed population of IL-17+ and IFN- + cells, resulting
in inconclusive data in which the key pathogenic cell type is unknown. The IL-23R is
not expressed on naïve T cells and its expression is induced in the presence of IL-23
(Langrish et al., 2005). In vivo neutralisation of IL-23R signalling on day 2 and day 4
post-immunisation led to the impairment of in vivo Th17 differentiation (McGeachy
et al., 2009). Neutralisation at day 6 or later had no effect on Th17 differentiation
indicating that IL-23R expression and signalling was required early on in the
differentiation of Th17 cells in vivo (McGeachy et al., 2009). Various different Th17
protocols were trialled in this project including resting the Th17 cells in IL-23 alone,
after their initial differentiation with IL-6 and TGF- . However this did not result in
an enhanced Th17 differentiation in terms of increased IL-17 production and
decreased IFN-
ability to induce disease (data not shown).
The pMOG-reactive Th1 and Th17 cells appeared to have stable cytokine profiles in
vivo. Transferred Th1 cells located in both the spleen and the CNS, continued to
produce IFN-
produce IL-17. Reciprocally, the pMOG reactive Th17 cells continued to produce
IL-17 and did not switch towards an IFN- -producing phenotype.
In marked contrast to this, in the Tg4 TCR transgenic system, transferred Th17 cells
cultured with the same in vitro cytokine cocktail as the pMOG-reactive Th17 cells,
but from a sorted naïve population, have been shown to occasionally be able to
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induce EAE, albeit with a low severity, low incidence and delayed induction
(O'Connor et al., 2008). Interestingly, whenever this observation of disease with
Th17 cells was made, it clearly correlated with instability of these TCR transgenic
Th17 cells, reflected in their switch towards IFN-
IFN- -producing-Th1 phenotype occurred only in the CNS, presumably due to the
stimulation with myelin antigen, whereas this did not occur within the spleen, where
the transferred Th17 cells remained stable (O'Connor et al., 2008). This in vivo
instability was seen when Th17 cells were transferred into both normal B10.PL mice
and lymphopenic RAG2-/- mice (O'Connor et al., 2008). This correlates with in vitro
observations of Th17 cells switching to IFN- -producing phenotype after re-
stimulation with higher concentrations of antigen (O'Connor et al., 2008).
The obvious difference between the pMOG/C57BL/6 and the MBP(Ac1-9)/Tg4
passive transfer models is the nature of the initial antigen challenge i.e. in vivo with
CFA immunisation for the C57BL/6 system, as opposed to in vitro for the Tg4 TCR
transgenic system. The stability of the Th17 cells in the pMOG-passive transfer
model suggests that the pMOG-reactive cells are exposed to an unknown cytokine or
other stimulus in vivo during the initial priming and this confers their later stability.
Th17 cells switching towards a Th1-phenotype have been observed in both EAE and
other models and this adds weight to the numerous recent publications showing Th
subsets are not as stable, or static, as previously thought. In the NOD mouse model
of type 1 diabetes, it was found that Th17 polarised cells were readily able to induce
diabetes in NOD/SCID recipients (Bending et al., 2009). However, these Th17 cells
were found to have converted to an IFN- -producing phenotype within the recipient
mice highlighting the plasticity of this Th subset. Polarising Th17 cells using the
method outlined from Vijay Kuchroo’s lab (Jager et al., 2009) produces cells with a
high number of IL-17+ cells in the population. On transfer of these cells, they were
found to induce severe EAE. However, in our hands these ‘Th17’ cells, that show
negligible numbers of IFN- + cells on input, have a high proportion of IFN- + cells in
the population in the CNS, and reduced levels of IL-17+ cells again indicating a
switch towards a Th1 phenotype (Richard O’Connor, personal communication). This
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leads to uncertainties as to whether the disease observed is indeed due to the IL-17+
Th17 cells, or due to the switch in phenotype towards a Th1 IFN- -secreting
phenotype. Treatment of NOD/SCID mice that had Th17-induced diabetes with an
IL-17 neutralizing antibody had no effect on disease, whereas treatment with a
neutralising IFN- -induced disease, indicating
that at least in that model, IFN- -phenotype, is more important for the
induction of diabetes (Bending et al., 2009).
A simple explanation for the lack of disease observed after Th17 passive transfer
would be the presence of high numbers of Treg within the transferred population.
However, the transferred cells were checked for their level of FoxP3+ cells, and this
was found to be low in both the Th1 and Th17 polarised cells (data shown here;
(O'Connor et al., 2008). Secondly, it has been shown that Th17 cells polarised with
IL-6 and TGF- alone, have higher levels of IL-10 production and these cells do not
have any pathogenic potential (McGeachy et al., 2007), and even have a suppressive
effect if co-transferred with a pathogenic population (McGeachy et al., 2007). The
level of IL-10 in the Th1 and Th17 cultures here was verified by ELISA and cytokine
bead array, and found to be very low in the Th17 cultures, and even slightly higher in
the Th1 cultures (O'Connor et al., 2008). The presence of increased IL-10 could not
therefore explain the lack of pathogenic potential of these Th17 cells.
As shown in the TCR transgenic Tg4 model, Th1 cells induce disease in a dose
dependent manner and can be located in the CNS as early as day 3 post-transfer, well
before any clinical signs of disease. The presence of the donor Th17 cells in the
CNS, only when co-transferred with Th1 donor cells, suggests a model in which it is
the Th1 cells that are able to cross the non-inflamed BBB into the CNS. Once
inflammation is established, BBB ‘permeabilisation’ allows the Th17 cells and other
pro-inflammatory cells to gain access to the CNS. In order to determine whether
Th17 cells can have a role in EAE pathology in this TCR transgenic model, different
numbers of donor T cells were transferred. When the low dose of Th1 cells and high
dose of Th17 cells were transferred together, the disease observed was more severe
than that of the Th1 low dose alone. Importantly, the high dose of Th17 cells, when
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transferred alone, was not able to induce disease indicating that the presence of the
Th1 cells was necessary, to allow the Th17 cells entry into the CNS. The Th17 donor
cells clearly could not enter the CNS across the non-inflamed CNS when transferred
alone. However, when transferred together with the donor Th1 cells, a small but
significant population of Th17 cells was then found within the CNS. This indicates
the sub-optimal number of donor Th1 cells were able to cross the BBB, to establish
sub-optimal CNS inflammation, allowing the Th17 donor cells to gain access to the
CNS and increase the severity of disease.
The mechanism of this disease exacerbation is still unknown with several different
possibilities: 1) The donor Th17 cells could indeed be exacerbating disease directly
themselves, through the production of IL-17 or another pro-inflammatory cytokine,
however, it has been suggested that IL-17 is not required for disease induction (Haak
et al., 2009), which would suggest the disease exacerbating agent might be another
pro-inflammatory cytokine that the Th17 cells can produce; 2) the donor Th17 cells,
once in the CNS, could be facilitating the Th1 cells to exacerbate disease; 3) the
Th17 cells could switch towards a more Th1-phenotype in the CNS and this could be
contribute to the increased severity of disease.
On immunisation to induce EAE, the peptide is presented by APCs in the draining
lymph node to naïve T cells. These naïve T cells are then activated and depending on
the cytokine milieu, they proliferate and differentiate towards a particular phenotype,
Th1 or Th17. Subsequently these cells migrate towards the CNS where they are able
to elicit an inflammatory response. This involves the production of IFN- -17 or
TNF- , depending on their phenotype although the precise role for these cytokines
remains controversial. It is not fully understood what cytokines are first upregulated
within the draining lymph node after immunisation and how these may affect the
drive towards a Th1 or Th17 inflammatory response. Here the mRNA expression
levels of innate cytokines, and those produced directly by the T cells were
investigated after immunisation with pMOG mixed together with CFA, and CFA-
only controls, compared to non-immunised control mice. No difference was found
between mice immunised with pMOG/CFA and CFA-only, indicating that high
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amounts of cytokines were not produced by the T cells in response to pMOG itself.
However, it appears the CFA promoted both the Th1 and Th17 responses. In most
cases cytokines were upregulated in both the draining lymph nodes and the non-
draining lymph nodes, suggesting drainage from the inguinal lymph nodes through to
the axillary and brachial lymph nodes, and a systemic effect of the immunisation
(Harrell, Iritani and Ruddell, 2008). IL-12 and IL-18, both Th1 inducing cytokines,
were upregulated above the non-immunised controls. This was reflected by the up-
regulation of IFN- -bet suggesting the presence of a Th1 response.
There was a strong upregulation of IL-
indicative of a Th17 response. No clear IL-6 signal was detected for some of the
samples, indicating very low expression levels of mRNA. Furthermore, and notably,
no clear signal at all was found for IL-23 (data not shown). There was a trend
towards an upregulation (2- <2) of TGF- and FoxP3 indicating a possible
increase in Foxp3+ Treg after immunisation.
To determine what phenotype naïve T cells adopt after immunisation in the MBP
(Ac1-9) model, naïve Tg4 cells were transferred in host mice and the mice
immunised to induce EAE. Interestingly, by day 6, the donor cells had already
adopted a strong inflammatory response and there were high proportions of IFN- +,
IL-17+ and TNF- + T cells within the donor cell population in the tissues sampled
with no particular skew towards a Th1 or Th17 response. Although this time-point
was pre-clinical, it would be important to look even earlier in the disease course to
determine if the naïve T cells have a particular skewing towards a Th1 or Th17
phenotype when they are first activated. The data presented here would suggest that





Protocols for the polarisation of populations of IFN- + Th1 cells (using IL-12,
IL-18 and IL-2), and IL-17+ Th17 cells (using IL-6, IL-23 and TGF- ), with
negligible numbers of contaminating cells in either population were
established.
The Th1 cells were clearly able to home to the CNS, crossing the non-
inflamed BBB to induce EAE. In contrast the Th17 cells were unable to enter
the non-inflamed CNS, and therefore did not induce disease when transferred
alone.
There was no increased numbers of FoxP3+ Treg, or IL-10 producing Tr1
cells in the Th17 population that would account for their lack of
pathogenicity.
In the pMOG passive transfer model, when Th17 cells did gain access to the
CNS (when co-transferred with Th1 cells), the Th17 cells remained stable
and continued to produce IL-17 in vivo in both the CNS and the spleen.
In contrast, in the TCR transgenic model, when Th17 cells gained access to
the CNS, the Th17 cells appeared to be more plastic and had a high
proportion of IFN- + cells in the population, within the CNS, but
interestingly, not in the spleen. Therefore, in vitro generated Th17 cells are
not stable in their phenotype, and have the ability to switch towards a more
Th1-IFN- -producing phenotype, in comparison to Th17 cells initially primed
in vivo.
After in vivo immunisation, Th1 and Th17-associated innate and T cell-
produced cytokines are upregulated in the draining and non-draining lymph
nodes, indicating the initiation of both Th1 and Th17 responses.
The following two chapters explore the pathogenicity of these two T helper subsets
using ‘Th1’ cells as a pathogenic subset, and ‘Th17’ cells as a non-pathogenic subset
to determine how the pathogenic cells induce disease and why the non-pathogenic
cells do not. Chapter 4 addresses the differential expression of homing molecules on
the pathogenic and non-pathogenic cells, which could define the ‘pioneer’ cells that
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first enter the CNS. Chapter 5 addresses the cytokines produced by the pathogenic
(Th1) cells and the requirement for these cytokines in the clinical expression of EAE.
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IFN- and IL-17 production by in vitro polarised ‘Th1’ and ‘Th17’
pMOG-reactive cells








































Figure 3.1 Optimisation of in vitro polarisation of pMOG-reactive Th1 and
Th17 cells.
C57BL/6 mice were immunised with 100 g pMOG mixed with CFA, ten days later the draining
lymph nodes were harvested and the cells cultured for 72 hours in vitro under the conditions outlined.
A, gated on CD4+ cells, percentage IFN- + and IL-17+ cells in pMOG-reactive cells polarised in the
presence of 10 g/ml pMOG and the indicated polarising cytokines; gated on CD4+ cells, expression
of B, T-bet and C, -reactive Th1 (polarised using IL-12, IL-18 and IL-2) and Th17
(polarised using IL-6, IL-23 and TGF- ) cells showing expression on Th1 (red), Th17 (blue) cells and
the isotype control (grey fill); mRNA expression levels of D, T-bet and E, in vitro
polarised Th1 cells and Th17 cells (polarised with IL-6, IL-23 and TGF- , or with IL-6 and TGF-
only), as compared to Th0 cells (pMOG-reactive cells cultured with pMOG and no exogenous




mRNA expression of T-bet and ROR t on in vitro polarised Tg4 cells







































Figure 3.2 Optimisation of in vitro polarisation of naïve Tg4 T cells to a Th1 and
Th17 phenotype.
Naïve CD4+ CD62Lhi CD25- Tg4 T cells were sorted and polarised in vitro in the presence of
irradiated B10.PL splenocytes, 10 g/ml MBP (Ac1-9) and the indicated polarising cytokines for 72
hours. A, gated on CD4+ cells, percentage IFN- +, IL-17+ and IFN- + IL-17+ cells after 72 hours
polarisation under stated conditions; mRNA expression levels of B, T-bet and C,
and Th17 cells polarised under the stated conditions. ‘Th1’ denotes polarisation with IL-12, IL-18 and
IL-2. ‘Th17’ denotes polarisation with IL-6, IL-23 and TGF- . ‘Th0’ denotes cells cultured in the
presence of MBP (Ac1-9) with no exogenous cytokines. The T-bet control sample was Th17 polarised
- = 1
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Figure 3.3 In vitro polarised pMOG-reactive Th1 cells induce EAE whereas
Th17 cells do not.
A, Experiment scheme; B, Mean clinical EAE scores after transfer of Th1 only ( ), Th17 only (
and Th1 plus Th17 ( . Disease incidence: Th1 (4/5), Th17 (0/5), Th1+Th17 co-transfer (7/7).
Error bars represent mean ± standard error. The proportion of mice with severe EAE is higher in the
Th1 transfer versus the Th17 transfer (* p=0.0476), and in the Th1+Th17 co-transfer versus Th17
transfer (** p=0.0047). There was no significant difference in severity between the Th1 and the
Th1+Th17 transfer groups (p=1.0000). Statistics performed using the Fisher’s exact test comparing
mice with maximum scores of 2 and below, and, 3 and above. (In vivo work performed by Dr Richard
O’Connor due to not having a Home Office license at this stage). Representative of numerous pMOG-
reactive Th1 versus Th17 passive transfer experiments.
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Figure 3.4 Disease induction correlates with the ability of the pMOG-reactive
Th1 cells to home to the CNS, whereas Th17 cells do not do so.
Gated on the CD4+ CD11b- cells, presence of the CD45.1+ Th1 donor cells and the CD90.1+ Th17
donor cells, in the A, spleen and B, CNS in the Th1 only transfer (left panel), Th1+Th17 co-transfer
(middle panel) and Th17 only transfer (right panel) at day 16 post-transfer; Quantitative analysis
showing absolute number of Th1 donor cells (red bar) and Th17 donor cells (clear bar) in the C,
spleen and D, CNS in the Th1-only (Th1) and Th17-only (Th17) transfer, and the co-transfer
(Th1:Th17). There was a significant difference between the number of Th1 and Th17 donor cells in
the co-transfer in the CNS (** p=0.0025). There were significantly more Th17 cells in the CNS in the
co-transfer compared to when transferred alone (** p=0.0061). Statistical analyses performed using
Mann Whitney test (‘*’ represents: *p<0.05; **p<0.01; ***p<0.001). Error bars represent mean ±
standard error. See Appendix 1 for flow cytometry gating strategy for donor T cells. ‘#’ denotes
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Figure 3.5 pMOG reactive Th1 and Th17 cells do not switch phenotype in vivo.
Production of IFN- -17 by donor T cells after an over-night re-stimulation with 20 g/ml
pMOG, A, gated on CD11b- cells presence of CD4+ CD45.1+ Th1 donor cells in the Th1 only transfer
(left panel), and in the Th1+Th17 co-transfer (middle panel), and the presence of the CD4+ CD90.1+
Th17 donor cells in the Th1+Th17 co-transfer (right panel); B, gated on each donor cell population,
production of IFN- -17 by the donor cells in each respective transfer. Underlined population
represents the population being viewed. CNS samples pooled for each group and re-stimulated over-
night. Gating determined on relevant isotype controls.
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Figure 3.6 pMOG-reactive Th1 and Th17 cells remain phenotypically stable and
produce IFN- -17 respectively in vivo.
Gated on the CD4+ donor population, quantitative representation of the percentage of A, IFN- + and
B, IL-17+ cells in the spleen; and the percentage of C, IFN- + and D, IL-17+ cells in the CNS showing
the Th1 donor cells (red bar) and Th17 donor cells (clear bar) after an over-night re-stimulation in
the presence of 20 g/ml pMOG. In the spleen significantly more Th1 cells were IFN- + compared to
Th17 cells (*** p=0.0006), and significantly more Th17 cells were IL-17+ compared to Th1 cells (***
p=0.0006). Statistics performed using Mann Whitney test (‘*’ represents * p<0.05; ** p<0.01;
*** p<0.001). Error bars represent mean ± standard error. See Appendix 2 for flow cytometry gating
strategy for donor cells and cytokine production. For the spleen, n=5 (Th1); 5 (Th17); 7 (Th1+Th17
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Figure 3.7 Tg4 Th1 cells induce disease whereas Tg4 Th17 cells do not
A, Experiment scheme; B, Gated on CD4+ cells, pre-transfer phenotype of Tg4 Th1 (left) and Th17
(right), showing IFN- -17 production, C, EAE scores after transfer of Tg4 Th1 (
( D, total number of viable cells; E, absolute number of CD4+ cells; F, absolute number of
CD45.1+ donor cells in the spleen (top) and CNS (bottom) in the Th1 and Th17 transfers. Disease
incidence: Th1 (4/5) and Th17 (0/5). The proportion of mice with more severe EAE is higher in the
Th1 transfer compared to the Th17 transfer (* p=0.0476). Statistics performed using Fisher’s exact
test comparing mice reaching a maximum EAE score of 1 and below, and, 2 and above. Error bars
represent mean ± standard error. Statistical analyses for D-F performed using Mann Whitney test (‘*’
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Figure 3.8 Tg4 Th1 cells can be located in the CNS as early as day 3
post-transfer.
A, Experiment scheme; B, Pre-transfer phenotype of Tg4 Th1 cells after PMA re-stimulation, gated
on CD4+ cells showing IFN- -17 production; C, EAE scores after transfer of Tg4 Th1 cells
( ); D, Percentage (left) and absolute number (right) of CD45.1+ donor Th1 cells in the CNS at days
3, 6 and 9 post-transfer. Disease incidence: Th1 (3/3) (considering only mice taken through to day 9
post-transfer). Significantly higher percentage and absolute number of donor Th1 cells in the CNS
between day 3 and day 9 post-transfer. Statistics performed using Kruskal Wallis test (KW p=0.0273)
and a Dunn’s multiple comparison post test. Error bars represent mean ± standard error. See appendix
3 for flow cytometry gating strategy for donor T cells in the CNS. Time-course of donor cell entry
































































































In vivo stability of TCR transgenic Tg4 Th1 cells
Figure 3.9 In vitro polarised Tg4 Th1 cells appear stable in vivo.
Intracellular cytokine staining on donor Th1 cells after an over-night re-stimulation with 20 g/ml
MBP (Ac1-9), and four hours incubation with Brefeldin A, Gated on CD11b- cells, presence of CD4+
CD45.1+ donor Th1 cells in the A, spleen and B, CNS; gated on the donor populations, production of
IFN- -17 in the C, spleen and D, CNS. Samples taken at day 9 post-transfer; 3 mice per group;
showing pooled samples of each group. Gating determined on relevant isotype controls. Data
























3 day polarisation in the presence
of 10 g/ml MBP (Ac1-9) and
irradiated B10.PL APCs.































Figure 3.10 Tg4 Th1 cells induce EAE in a dose dependent manner.
A, Experiment scheme; B, Pre-transfer phenotype of in vitro polarised Tg4 Th1 cells, gated on CD4+
cells showing IFN- -17 production; C, EAE scores after transfer of 4x106 ( ), 2x106 ( 6
( 6 ( 6 ( ) Th1 blasts. Disease incidence: 4x106 (1/1), 2x106 (2/3), 1x106 (1/3),
0.5x106 (1/3), 0.2x106 (1/3) Th1 blasts. No significant differences in EAE severity between the
groups. Statistical analyses performed using the Fisher’s exact test. See Appendix 4 for summary of
results of statistical analyses. Error bars represent mean ± standard error. Dose-experiment





Tg4 splenocytes. 3 day polarisation in the presence
of 10 g/ml MBP (Ac1-9)
Th1: IL-12 + IL-18 + IL-2




1x106 Th1 blasts +
4x106 Th17 blasts
Cell transfer i.v.
200 ng Ptx i.p.
























































































































































Figure 3.11 Transfer of sub-optimal numbers of Th1 cells together with high
numbers of Th17 cells.
A, Experiment scheme; B, Pre-transfer phenotype of donor Tg4 Th1 (left) and Th17 (right) cells,
gated on CD4+ cells showing IFN- -17 production (top) and TNF- and IL-17 production
(bottom); C, level of IFN- ) and IL-17 (bottom) production in the Th1 and Th17 culture
supernatant after 72 hours in vitro polarisation, as determined by ELISA; D, gated on CD4+ cells,
FoxP3 expression on Tg4 Th1 and Th17 cells prior to transfer. Error bars represent mean ± standard
error. See Appendix 5 A for representative isotype controls for cytokine staining.
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Figure 3.12 Tg4 Th17 cells are able to exacerbate disease to the same level as the
Th1hi transfer when co-transferred with a sub-optimal number of Th1 cells.
A, EAE scores after transfer of Th1hi (4x106; ), Th1lo (1x106; ), Th1lo and Th17hi (1x106 Th1 +
4x106 Th17; ) and Th17hi (4x106; ) cells, Disease incidence: Th1hi (5/5), Th1lo (5/5), Th1lo and
Th17hi (5/5) and Th17hi (0/5); Location of the donor T cells in the spleen showing B, total number of
viable cells; C, percentage and absolute number of CD4+ cells; D, percentage and absolute number of
CD45.1+ Th1 donor cells; E, percentage and absolute number of donor CD90.1+ Th17 cells for each
transfer type; Th1hi transfer ( lo transfer ( lo Th17hi transfer ( ), Th17hi transfer ( ).
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Underlined cells highlight the population being viewed. Statistical analyses performed using Kruskal-
Wallis test and Dunn’s Multiple comparison post test, or Mann Whitney test. Error bars represent
mean ± standard error. The proportion of mice with severe EAE is significantly higher in the Th1hi
transfer group compared to the Th1lo and Th17hi transfer (*p=0.0476 and *p=0.0079 respectively); as
well as in the co-transfer group compared to the Th17hi group (*p=0.0476). Statistical analysis for
EAE curve performed with the Fisher’s exact test. See Appendix 5 B for details of statistical results.

















































































Figure 3.13 A significant number of Tg4 Th17 cells are able to enter the CNS
when co-transferred with a sub-optimal number of Tg4 Th1 cells.
Ex-vivo analysis of location of donor cells in the CNS, A, total number of viable cells in the CNS; B,
percentage and absolute number of CD4+ cells; C, percentage and absolute number of CD45.1+ Th1
donor cells; D, percentage and absolute number of CD90.1+ Th17 cells in each transfer type, Th1hi
transfer ( lo transfer ( lo Th17hi transfer ( ), Th17hi transfer ( ); Summary of quantitative
analysis of CD45.1+ Th1 and CD90.1+ Th17 donor cell in the E, CNS; and F, spleen showing Th1
donors (red bar) and Th17 donors (blue bar). Underlined cells highlight the population being
viewed. Statistical analyses performed using Kruskal-Wallis test and Dunn’s Multiple Comparison
post test, and Mann Whitney test. Error bars represent mean ± standard error. See Appendix 5 C for





























































































Day 0: 100 g pMOG in CFA s.c.
Day 0 and day 2: 200 ng Ptx i.p.
WT C57BL/6
At the peak of disease (day
13 post-immunisation):
Cytokine production in CNS
samples in response to
over-night re-stimulation
with pMOG.




Figure 3.14 IFN- +, IL-17+ and TNF- + CD4+ T cells are in the CNS of EAE
mice
A, Experiment scheme showing in induction of active EAE with pMOG/CFA immunisation of
C57BL/6 mice; B, CNS samples taken at day 13 post-immunisation, gated on the CD4+ cells showing
IFN- IL-17 and TNF- after an over-night re-stimulation in the presence or absence of 20 g/ml





Days 1, 3, 5, and 7 post-immunization samples
taken from each:
• Draining (inguinal) LNs
• Non-draining (axillary) LNs
Single cell suspension obtained, cells washed in
PBS, resuspended in Qiazol and frozen at -80 °C
for further analysis.
• mRNA expression of IL-12, IL-18, IFN- , IL-23,
IL-6, TGF- , IL-17, FoxP3, T-bet and ROR t
determined by RT-qPCR analysis.
Experiment schemeA
0.0 0.5 1.0 1.5 2.0 2.5
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Figure 3.15 Levels of mRNA expression of IL-12, IL-18, TGF- and TNF-
after CFA immunisation with/without pMOG, as compared to a non-immunised
control
A, Experiment scheme; Changes in relative mRNA levels at days 1, 3, 5 and 7 post-immunisation for
B, IL-12; C, IL-18; D, TGF- ; and E, IL-6 in draining lymph nodes (dln), non-draining lymph nodes
(ndln) and CFA only controls (CFA) as compared to non-immunised naïve cells and to the house
keeping gene, HPRT. Dotted line represents the control 2- = 1, which corresponds to no change in
gene expression. Four pMOG/CFA mice per day, one CFA only control mouse per day, one non-
immunised control per day. Error bars represent the mean ± standard error. Statistical analyses
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Figure 3.16 Level of mRNA expression for IFN- -17, IL-17, T-
FoxP3 and IL-6 after CFA immunisation with/without pMOG, as compared to a
non-immunised control
Changes in relative mRNA levels at days 1, 3, 5 and 7 post-immunization for A, IFN- B, T-bet; C,
IL-17; D, E, FoxP3 and F, TNF- in the draining lymph nodes (dln), the non-draining lymph
nodes (ndln) and CFA only controls (CFA) as compared to the non-immunised naïve cells and to the
house keeping gene, HPRT. Dotted line represents the control 2- = 1, which corresponds to no
change in gene expression. Four pMOG/CFA mice per day, one CFA only control mouse per day, one
non-immunised control per day. Error bars represent the mean ± standard error. ‘n.d.’ indicates ‘not
detected’. Statistical analyses performed using Kruskal-Wallis test and Dunn’s Multiple Comparison
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** (p<0.01) ** (p<0.01)
Figure 3.17 Phenotype of naïve Tg4 cells polarised in vivo after MBP
(Ac1-9)/CFA immunisation.
A, Experiment scheme; B, Mean clinical EAE scores after disease induction (disease incidence
(10/10)); day 6 post-immunisation, C, percentage CD4+ CD11b- cells in CNS, spleen and draining
(inguinal) lymph nodes; D, percentage CD45.1+ donor Tg4 cells in the CNS, spleen and draining
(inguinal) lymph nodes; E, absolute number of CD4+ cells in each tissue; F, absolute number of
CD45.1+ donor cells in each tissue; 5 mice per group, all mice taken were score zero of clinical EAE.
Error bars represent mean ± standard error. Statistics performed using Kruskal-Wallis test and Dunn’s
Multiple Comparison test (*p<0.05; **p<0.01; ***p<0.001). (KW p values: *p=0.0210 (C);
**p=0.0019 (D); **p=0.0068 (E)). See Appendix 6 A for flow cytometry gating strategy for donor T
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Figure 3.18 No indication of a differential skewing towards a Th1 or Th17
phenotype of the previously naïve Tg4 T cells at day 6 post immunisation.
Gated on CD4+ CD45.1+ donor Tg4 cells A, percentage IFN- +, IL-17+ and TNF- + in the CNS (left
panel), draining (inguinal) lymph node (middle panel) and spleen (right panel); B, percentage FoxP3+
cells in the host and donor populations in the Spleen (left panel) and CNS (right panel); C, T-bet and
red), draining lymph node
(blue) and spleen (purple) and isotype control (grey fill), representative of 5 mice. No significant
difference in cytokine production in each tissue, as determined by Kruskal Wallis test. Statistics for
FoxP3 expression performed using Mann Whitney test (‘*’ represents: * p<0.05; ** p<0.01;




4 Migration of encephalitogenic T cells into the
central nervous system for the induction of
EAE
4.1 Introduction
As demonstrated in Chapter 3, Th1 cells are readily able to infiltrate the CNS across
the BBB and induce EAE (O'Connor et al., 2008). This ability of Th1 cells to home
to the CNS has also been demonstrated in MS, in which Th1 cells are readily found
in the CSF and within the CNS lesions of MS patients (Teleshova et al., 2002).
Results in Chapter 3 showed within our passive transfer models, that Th17 cells have
a poor ability to cross the BBB and induce disease. A simple explanation for the
inability of Th17 cells to enter the CNS and induce disease, would be the lack of
expression of one or more of the chemokine receptors, adhesion molecules or
selectins that are involved in the entry of T cells across the BBB.
4.1.1 Aims
This observation allowed the comparison of pathogenic (Th1) cells with non-
pathogenic (Th17) cells in terms of the cell surface phenotype. The aims were a) to
identify molecules that were specifically expressed (or expressed at higher levels) on
Th1 cells, and b) to block the function of these molecules, and assess the impact of
this blockade on pathogenic activity using the passive transfer of Tg4 cells.
The establishment of disease by the accumulating Th1 cells in the CNS presumably
led to increased permeability of the BBB, resulting in the further influx of more Th1
cells and other inflammatory cells, including Th17 cells into the CNS. The
mechanisms involved in entering the non-inflamed CNS compared to the inflamed
CNS, once disease is established, are presumably very different. It is therefore
important to determine what allows these ‘pioneer’ Th1 cells across the normal ‘non-
inflamed’ BBB before inflammation is established.
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The CNS was long considered to be an immune privileged site (Barker and
Billingham, 1977) with the BBB controlling the entry of T lymphocytes into the
brain parenchyma. Wekerle and colleagues hypothesised that under normal
physiological conditions, activated immune cells enter the CNS for the purpose of
immune surveillance (Wekerle et al., 1986; Hickey, Hsu and Kimura, 1991).
However during inflammatory conditions, seen with bacterial or viral infection, there
is a large influx of lymphocytes across the BBB and into the CNS.
T lymphocyte entry to the brain parenchyma is a complex process involving
numerous different molecules, including selectins, chemokine receptors, adhesion
molecules and matrix metalloproteinases (reviewed in (Prendergast and Anderton,
2009)). In general there are thought to be four main steps for leukocyte trans-
endothelial migration across the BBB: 1) an initial low-affinity contact between the
lymphocyte and the endothelium is made resulting in the tethering of the lymphocyte
and this facilitates their rolling along the endothelial cell surface. This initial process
is mediated by selectins on the endothelial surface binding to glycosylated ligands on
the lymphocyte surface (Engelhardt, 2008); 2) chemokines activate their respective
chemokine receptors on the surface of the lymphocytes resulting in induction of G
protein-linked intracellular signals. These signals lead to the activation of integrins
on the lymphocyte surface, which then alter their conformation from the low affinity
to the high affinity state; 3) integrins are then able to interact with their respective
ligands on the surface of the endothelium, providing firm adhesion or complete arrest
of the lymphocyte on the endothelium surface; 4) the lymphocyte extravasates across
the endothelial layer into the perivascular space. To enter the brain parenchyma or
spinal cord, the lymphocyte navigates through the tight junctions of the BBB or the
blood-spinal cord barrier respectively. Due to the numerous different molecules
involved in these processes and the various barriers in place, immune cell entry is
kept to a minimum under normal physiological conditions.
Naïve T cells have a CD44lo CD62Lhi phenotype. On activation, they downregulate
molecules required for lymph node entry (e.g. CD62L and CCR7) (von Andrian and
Mempel, 2003; Klinger et al., 2009) and upregulate molecules required for
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lymphocyte migration to non-lymphoid tissues or the site of inflammation. Also on
activation, CD4+ T cells differentiate into particular effector sub-types, namely Th1,
Th2, Th17 or Treg cells depending on the cytokine milieu in the surrounding
environment. Each Th subset expresses a distinct pattern of adhesion molecule and
chemokine receptor expression allowing them to have differing abilities to enter the
CNS or other non-lymphoid tissues according to their homing molecule expression
profile.
In general, human Th1 cells are thought to express CCR5 and CXCR3 whereas
human Th2 cells express CCR3 and CCR4 (Bonecchi et al., 1998). This view
correlated with MS being viewed as a Th1-mediated disease due to a large influx of
CCR5+ CXCR3+ T cells in MS lesions, as well as increased expression of MIP-1
and IP-10, their respective ligands (Balashov et al., 1999). Human Th17 cells have
been found to have a CCR2+ CCR5- phenotype (Sato, Aranami and Yamamura,
2007) and to express CCR6 (Annunziato et al., 2008). The expression of different
chemokine receptors on the surface of T cell subsets, suggests a role in differential
migration of the cells to specific tissues and sites of inflammation.
Chemokine receptors or adhesion molecules involved in the entry of T cells into the
CNS are attractive targets for therapeutics for CNS autoimmune disease. Preventing
the entry of the inflammatory T cells into the CNS would prevent the induction of
CNS inflammation, subsequent demyelination and lesion formation. The feasibility
of targeting migration molecules for therapeutics has been demonstrated by the
development of Natalizumab (Tysabri®) a monoclonal antibody against integrin
4 1 for the treatment of RRMS. It was initially found that EAE was both
suppressed and reversed after the administration of a monoclonal antibody to alpha 4
integrin (Kent et al., 1995) in the guinea pig. This then novel therapeutic was
translated into the clinic. Natalizumab is used for the treatment of both MS and
Crohn’s disase and it is found to decrease relapses and prevent the formation of new
lesions within the CNS of RRMS patients. The efficacy of Natalizumab shows the
potential for targeting other migratory molecules for the inhibition of inflammatory T
cell entry into the CNS for the treatment of MS. However, 4-integrins are expressed
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on all leukocytes and therefore Natalizumab is a fairly non-specific treatment with
the development of PML as its major risk. Identification of a homing molecule
specifically expressed on encephalitogenic T cells would provide greater specificity
for therapeutics and fewer side effects or risks.
4.1.2 Approach
First, phenotypic differences between pathogenic Th1 and non-pathogenic Th17 cells
were determined. Once particular molecules of interest were identified, their function
was blocked in vivo. The Tg4 passive transfer model was used to investigate the
effect of blocking the homing molecules on EAE pathogenicity. To do this Tg4
splenocytes were taken and polarised towards a Th1 phenotype in the presence of
polarising cytokines IL-12, IL-18 and IL-2 and in the presence of 10 g/ml MBP
(Ac1-9) for three days. Cells were then washed and transferred into host mice by
intravenous injection with/without either pre-treatment of the cells, or in vivo
administration of blocking molecules, dependent on the molecule being investigated.
4.2 Results
4.2.1 Th1 and Th17 cells have comparable levels of expression
of 4 1-integrin
As blocking 4 1-integrin has been shown to have high efficacy in treating both
EAE and MS, it was first verified whether in vitro polarised Th1 cells expressed
higher levels of 4 1-integrin which could explain their ability to home to the CNS
in comparison to Th17 cells. However, Tg4 Th1 cells did not have a higher
expression level of 4 1-integrin than Th17 cells (Figure 4.1 A and B). In fact,
neither population appeared to express 4 1-integrin above the isotype control.
However, due to the absence of a positive control for the 4 1-integrin staining, it
cannot be concluded from this data that neither population express 4 1-integrin.
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4.2.2 Expression of chemokine receptors on Th1 and Th17
cells
The expression of a panel of chemokine receptors was verified on the in vitro
polarised Th1 and Th17 cells. Expression of CCR2, CCR3 and CCR4 was absent on
the Th1 and Th17 cells (Figure 4.2 A-C). Both Th1 and Th17 cells expressed
CXCR3 to the same level (Figure 4.2 F). CCR5 was expressed to a higher level on
the Th1 cells in comparison to the Th17 cells (Figure 4.2 D; n=3) although no
statistical analyses were performed here.
4.2.3 Th1 cells express Th17-associated CCR6 at the protein
level
By flow cytometry analysis both populations expressed the Th17-associated
molecule CCR6 to the same extent (Figure 4.2 E). This observed expression of
CCR6 on Th1 cells was surprising. In a second experiment, CCR6 expression was
determined by flow cytometry analysis with the use of in vitro polarised Th2 cells as
a negative control for CCR6 expression. CD4+ Th2 cells did not express CCR6,
whereas both CD4+ Th1 and CD4+ Th17 cells did (Figure 4.3 A, B). CCR6 mRNA
expression was assessed on Tg4 Th1 and Th17 cells. Using Th0 cells as the control
(2- = 1), Th1 cells had a 2- of 1.6 whereas CCR6 was highly upregulated on
Th17 cells with 2- of 14.7 as compared to the control, showing a nearly 15-fold
upregulation (Figure 4.3 C). Th1 cells therefore appeared to express CCR6 at the
protein level but have low mRNA CCR6 expression, perhaps indicating instability in
the CCR6 mRNA in these cells, as discussed later.
4.2.4 Th1 cells express higher levels of CD62L and PSGL-1
Investigating other homing molecules, Th1 cells had higher expression levels of
CD62L (Figure 4.4 B) and PSGL-1 (Figure 4.4 C) compared to Th17 cells.
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In summary, the expression of CCR5, CD62L and PSGL-1 were observed to be
upregulated on Th1 cells compared to Th17 cells and these were followed up in more
detail through the use of blocking studies. CCR6 was expressed on both the Th1 and
Th17 cells at the protein level. In the same way, 4 1-integrin expression was
comparable on Th1 and Th17 cells. These two molecules were not followed up in
detail as they did not exhibit differential expression on the two in vitro polarised
populations, and the aim was to identify phenotypic differences that would account
for the ability of the pathogenic Th1 cells to enter the CNS and not the Th17 cells.
4.2.5 Blocking CCR5 signalling using Tak779 has no effect on
EAE induction by Tg4 Th1 passive transfer
As shown in Figure 4.2 in vitro polarised Th1 cells had a higher expression of CCR5
compared to Th17 cells. The next question to answer was whether CCR5 was
necessary for the entry of Th1 cells into the CNS to induce disease. This was done
using Tak779, a low molecular weight non-peptide inhibitor that binds CCR5,
CXCR3 and CCR2, thereby inhibiting the signalling through these molecules (Baba
et al., 1999; Gao et al., 2003). It is thought to bind CCR5-expressing cells and
prevent the binding of its ligand CCL5 (RANTES).
Tg4 Th1 blasts were transferred into hosts. The following day, and every second day
thereafter, each host mouse was treated with 50 g Tak779 (equivalent to
approximately 2 mg/kg), or PBS, by intravenous injection (Figure 4.5 A). The
transferred cells had a Th1 phenotype (Figure 4.5 B and C) and had a CD4+ CCR5+
population as compared to the isotype control (Figure 4.5 D).
There was no significant difference in the disease induction, severity or incidence
between the Tak779 and PBS treated groups (Figure 4.6). A pre-clinical sample of
mice from both groups was taken at day 7 post-transfer. There was no significant
difference in the total number of cells in the spleen or CNS at this time point (Figure
4.7 A). There was also no significant difference in the number of CD4+ cells or
CD45.1+ Th1 donor cells in the spleen or CNS (Figure 4.7 B and C) indicating the
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treatment of the mice with Tak779 had had no effect on the entry of the donor Th1
cells into the CNS.
4.2.6 CD62L is not required for the induction of EAE or the
entry of Tg4 Th1 cells into the CNS
CD62L is known to be required for the entry of naïve T cells into the lymphoid
organs but it is not clear if it is required for the entry of Th1 cells into the CNS due to
conflicting data in the literature. To determine if it was required for the induction of
EAE here, Tg4 Th1 cells were transferred into host mice together with either an
infusion of either PBS or the anti-CD62L monoclonal antibody, Mel-14. Every two
days post-transfer, the mice received a further dose of Mel-14 or PBS (Figure 4.8 A).
The pre-transfer analysis of the donor cells showed their Th1 phenotype with high
IFN- + and TNF- + cells and negligible numbers of IL-17+ cells (Figure 4.8 B) and
upregulated expression of T-bet (Figure 4.8 C). Importantly the Th1 cells were
CD62Lhi (Figure 4.8 D) and when treated with Mel-14 in vitro the cells were shown
to have lower levels of CD62L expression, confirming the binding of the antibody
(Figure 4.8 D).
Administration of the Mel-14 had no effect on the induction of EAE by the Tg4 Th1
cells (Figure 4.9). At a pre-clinical time-point, four mice were sacrificed from each
group to determine the effect of the administration of Mel-14 on the location of the
donor Tg4 Th1 cells within the host mice. There was no difference in the total
number of cells or CD4+ cells found in the lymph nodes after in vivo treatment with
Mel-14 (Figure 4.10 A). However, there were significantly lower numbers of Th1
donor cells within the lymph node after treatment with Mel-14 (Figure 4.10 A). In
contrast, the administration of Mel-14 had no effect on the entry of donor Tg4 Th1




4.2.7 Both Th1 and Th17 polarised cells express the enzyme
C2GnT-I to comparable levels
PSGL-1 is a 240 kD homodimer that binds E-, P- and L-selectin when glycosylated.
The two key glycosyltransferases and sialyl transferases required for the expression
of functional PSGL-1 are core 2 -1.6-N-acetyl glucosaminyltransferase (C2GnT-I)
and -(1,3)-fucosyltransferase-VII (FucT-VII). Mice that lack either enzyme have
been shown to have impaired binding of PSGL-1 to P-selectin and this results in
reduced rolling of the lymphocytes in venules in vivo (Smithson et al., 2001;
Sperandio et al., 2001).
The mRNA expression of C2GnT-I was determined on Th1, Th17 and Th0 cells. To
first confirm the phenotype of the cells, T-
on the cells by RT-qPCR. Both Th0 and Th1 cells were found to have upregulated
expression levels of T-bet compared to Th17 cells (Figure 4.11 A) whereas Th17
cells h
cells) (Figure 4.11 B). Th1 cells were found to have 2.5 fold higher expression of
C2GnT-I than Th0 cells and Th17 cells had roughly similar levels at 2.2 fold higher
than the control cells (Figure 4.11 C). Therefore the Th1 and Th17 cells appear to
have comparable expression levels of C2GnT-I, indicating that both cell populations
can express functional PSGL-1.
4.2.8 Pre-treatment of Tg4 Th1 cells with anti-PSGL-1 antibody
results a delay in EAE induction
The 4RA10 monoclonal antibody against PSGL-1 was used to investigate whether
blocking the function of PSGL-1 on Tg4 Th1 cells prior to their transfer would have
an effect on their ability to induce EAE by passive transfer. After polarisation the
cells were washed and treated with 10 g/ml anti-PSGL-1 (or PBS) for 1 hour on ice
(Figure 4.12 A) and subsequently transferred into host mice. On the day of transfer,
the cells showed a Th1 phenotype with high proportions of IFN- + cells and
negligible IL-17+ cells (Figure 4.12 B). In addition, the majority of the CD4+ cells in
the Tg4 Th1 population transferred were PSGL-1+ (Figure 4.12 B).
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Pre-treatment of donor cells with anti-PSGL-1 led to a significant delay in the
induction of EAE (Figure 4.13). However, once disease had developed, the incidence
and severity were comparable to the PBS-treated control group. A Mann Whitney
test was used here in order to determine if there was a significant difference between
the mean day of disease induction between the two groups. A Fisher’s Exact test
would not have been appropriate here as there was no observed difference in disease
severity.
There was no significant difference in the total number of cells in the spleen, or in
the number of CD4+ cells or CD45.1+ donor cells in the spleen at day 4 post-transfer
(Figure 4.14 A-C, left). In the CNS, there was a trend towards fewer total numbers of
cells in the anti-PSGL-1 pre-treated group (Figure 4.14 A, right). The observed delay
in disease induction correlated with fewer CD4+ T cells and CD45.1+ Th1 donor cells
in the CNS (Figure 4.14 B-C, right) at this pre-clinical time-point of disease. The
trend of fewer donor Th1 cells in the CNS of the anti-PSGL-1 treated cells was
consistent over 3 further experiments; however it did not reach significance.
Blocking the function of PSGL-1 on Th1 cells prior to adoptive transfer therefore
appeared to result in a delay in the induction of disease. These cells appeared to have
an impaired ability to cross the BBB and enter the CNS as shown by the reduced
number of donor cells in the CNS at an early pre-clinical time point.
4.2.9 In vivo blockade of PSGL-1 resulted in the abrogation of
disease
As there was a promising trend towards fewer donor cells entering the CNS when
they were pre-treated with anti-PSGL-1, it was next determined whether in vivo
blockade of PSGL-1 would have a more profound affect on the induction of EAE. To
do this, Th1 cells were pre-treated as above with 10 g/ml anti-PSGL-1 for 1 hour
prior to transfer. In addition, the host mice were treated with 25 g anti-PSGL-1 in
PBS, or PBS alone, on days 1, 3, 5, 7, 9, 11 post cell transfer (Figure 4.15 A-C).
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The additional in vivo blockade of PSGL-1 completely abrogated the induction of
EAE for the duration of treatment (Figure 4.16). The two PBS treated mice
developed EAE, however the 3 mice treated with anti-PSGL-1 did not. On day 13
post-transfer (two days after the final antibody dose), one of the anti-PSGL-1 treated
mice began to develop a mild course of disease (Figure 4.16).
To determine if this inhibition of disease was due to the inability of the donor Tg4
Th1 cells to enter the CNS, this experiment was repeated. Anti-PSGL-1, or control
IgG1 antibody, was administered on days 0 (together with transferred cells), 2, 4 and
6 post-transfer (Figure 4.17 A). Importantly, the difference between this experiment
and the one shown in Figure 4.15 is that these cells were not pre-treated with the
blocking antibody prior to transfer.
Due to 2 mice dying on day 6 post-transfer a few minutes after the treatment with the
anti-PSGL-1 (suggestive of an anaphylactic reaction) it was decided to end the
experiment on day 7 post-transfer to determine if there was differential migration of
the donor Tg4 Th1 cells between the two groups. In the spleen (Figure 4.17 B-D,
left) and inguinal lymph nodes (data not shown) there was no significant difference
in the total cell number between the two groups, or in the number of CD4+ cells.
There were significantly fewer CD45.1+ Th1 donor cells in the spleen compared to
the IgG1 control group (Figure 4.17 D, left). In the CNS there were significantly
lower total cell numbers in the anti-PSGL-1 treated mice compared to the IgG1
treated mice (Figure 4.17 B, right). However, this difference in total cell number did
not correlate with a difference in the number of total CD4+ cells in the CNS (Figure
4.17 C, right), or with the number of CD45.1+ donor Th1 cells (Figure 4.17 D right)
between the two treatment groups. As PSGL-1 is also expressed on other cells, the
effect of anti-PSGL-1 treatment on the presence of CD11b+ cells was determined in
the spleen and CNS. In the spleen the treatment with anti-PSGL-1 led to a significant
reduction in CD11b+ cells both as frequency and absolute number (Figure 4.18 A,
B). However, anti-PSGL-1 had no effect on the number of CD11b+ cells in the CNS
(Figure 4.18 C, D). In summary, the treatment with anti-PSGL-1 led to fewer total
lymphocytes in the CNS, but the number of Th1 donor cells was comparable to
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control treated mice. Anti-PSGL-1 also surprisingly and very effectively reduced the
number of CD11b+ cells in the spleen.
4.2.10 Increasing the expression of PSGL-1 and CCR5 on Th17
cells does not confer pathogenic activity
As PSGL-1 expression was found to be lower on Th17 cells compared to Th1 cells, it
was determined whether increasing the expression of PSGL-1 on the Th17 cells, by
the addition of IL-12 to the polarising cytokine mix, would have an effect on PSGL-1
expression, and thereby the ability of Th17 cells to induce EAE. To do this, Tg4
splenocytes were polarised towards a Th1 or a Th17 phenotype, or towards a
‘Th17+IL-12’ phenotype (using IL-6, IL-23, TGF- and IL-12 for this last condition)
(Figure 4.19 A). After 3 days of polarisation the Th1 and Th17 polarised cells
exhibited the anticipated Th1 and Th17 phenotypes (53% IFN- + and 23% IL-17+
cells, respectively) (Figure 4.19 B). In addition to this the ‘Th17+IL-12’ cells had a
similar cytokine profile to the Th17 cells (22% IL-17+ (Figure 4.19 B)). The
‘Th17+IL-12’ cells only had a slight increase in IFN- + cells (from 0.5% to 1.8%)
above the Th17 population (Figure 4.19 B). The Th17 cells expressed PSGL-1 to a
lower level than the Th1 cells with a clear high and low PSGL-1+ population (Figure
4.19 C). Interestingly the ‘Th17+IL-12’ cells expressed PSGL-1 to the same level as
the Th1 cells (Figure 4.19 C). A slight increase in CCR5 expression on the Th17
cells in the presence of IL-12 was also observed (Figure 4.19 D).
Despite the increased expression of PSGL-1 on the ‘Th17+IL-12’ group of cells, this
did not confer pathogenicity (Figure 4.20 A). The mice were sampled at day 20 post-
transfer, as the Th1-transferred group were beginning to recover from disease. At this
time-point, there was a significantly increased total number of cells observed in the
CNS of Th1-transferred group (Figure 4.20 B) compared to both Th17 groups.
Significantly more Th1 donor cells were found in the CNS compared to the very low
numbers of both groups of Th17 donor cells (Figure 4.20 C). In summary, despite the
increase in PSGL-1 expression on the ‘Th17+IL-12’ cells this did not allow them




T cell subsets differentially express selectins, adhesion molecules and chemokine
receptors thereby suggesting a differential ability to enter both non-inflamed and
inflamed sites.
As shown in Chapter 3, in vitro polarised Th1 cells were able to infiltrate into the
non-inflamed CNS whereas in vitro polarised Th17 cells were only able to
accumulate in the CNS once inflammation was already established. Development of
a therapy that specifically blocks the initial migration of Th1 cells into the CNS
should prevent the initiation of inflammation within the CNS. The use of an inhibitor
that specifically targets the pro-inflammatory T cell subset causing the inflammation
would be an attractive therapy as it would result in minimising side effects.
In vitro polarised Th1 cells had a higher expression of CD62L compared to in vitro
polarised Th17 cells. CD62L (or L-selectin) is known to be expressed on naïve T
cells and not on memory T cells, although these can then re-express CD62L to aid
their homing to particular sites highlighting that CD62L follows a cyclical pattern of
expression (Klinger et al., 2009). A carbohydrate binding protein, CD62L is required
for the entry of naïve T cells into the peripheral lymph nodes via adhesion to the high
endothelial venules of the peripheral lymph nodes (Geoffroy and Rosen, 1989;
Bradley, Watson and Swain, 1994). This process allows for immune surveillance to
occur and for the accumulation of antigen specific lymphocytes at the site of antigen
exposure. Conflicting reports using different EAE models make it unclear as to
whether CD62L is important for the induction or the effector phase of EAE. It has
been shown that in vivo treatment with HRL3, another monoclonal antibody against
CD62L, led to inhibition of active EAE in Lewis rats, and had a mild inhibitory
effect on adoptive transfer (Archelos et al., 1998). Fewer inflammatory infiltrates
were found in the CNS as well as a depletion of T cells both in the lymph nodes and
the spleen (Archelos et al., 1998). Interestingly it has also been suggested that
CD62L is required for the actual damage to occur to the myelin within the CNS. This
was shown by CD62L deficient MBP-TCR transgenic mice being resistant to disease
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despite a large infiltration of T cells being observed in the CNS. The resistance to
disease was due to an absence of myelin damage (Grewal et al., 2001) within the
CNS. In contrast Li and colleagues have suggested CD62L is required for the
induction phase of EAE by showing that CD62L-deficient mice were resistant to
MOG-induced EAE due to lack of priming of the T cells in the periphery (Li et al.,
2006).
Contrary to this, with the use of another transgenic model, it was found that passive
transfer of MBP (Ac1-11) specific T cells into (PL x SJL)F1 mice and subsequent
treatment with Mel-14 had no effect on EAE induction compared to the PBS controls
(Brocke et al., 1999). Supporting the case for CD62L not being required for EAE, it
has recently been observed that CD62L-deficient SJL and C57BL/6 mice are both
fully susceptible to PLP-induced and MOG-induced EAE respectively (Uboldi et al.,
2008).
Here, the treatment of the host mice with Mel-14 led to a significant decrease in the
number of Tg4 Th1 donor cells found in the inguinal lymph nodes, correlating well
with the requirement of CD62L for entry of T cells into peripheral lymph nodes, and
confirming that the antibody was indeed having an effect in vivo. However, CD62L
expression seemed not to be required for the entry of Tg4 Th1 donor cells into the
CNS as these were still readily able to migrate to the CNS after Mel-14 treatment.
The discrepancies in contradictory results regarding the role of CD62L in EAE
induction could be reflective of the different genetic backgrounds of the various
polyclonal/transgenic mice used in the models.
Higher levels of soluble CD62L have been found in the serum of MS patients
compared to healthy controls (Mossner et al., 1996; Duran et al., 1999). The level of
soluble CD62L in the serum correlated with the size of enhancing lesions in the
CNS, as well as with the levels of soluble CD62L in the CSF (Mossner et al., 1996)
(the level of soluble CD62L being reflective of the amount of CD62L shed to enter a
site of inflammation) suggesting CD62L may indeed have a role in MS pathogenesis.
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Previously, when MS and EAE were still considered to be Th1 mediated
autoimmune diseases, it was shown that human Th1 clones express CCR5 and
CXCR3 (Bonecchi et al., 1998; Sallusto et al., 1998). CCR5+ and CXCR3+ T cells
have been found to be increased in numbers in the blood and CSF of MS patients
(Teleshova et al 2002) (Balashov et al., 1999; Teleshova et al., 2002). In addition, in
the progressive form of MS, increased numbers of CCR5+ and CXCR3+ T cells were
found in peripheral blood compared to healthy controls. The ligands of CCR5 and
CXCR3 were also found associated with microglia/macrophages and astrocytes in
MS lesions (Balashov et al., 1999).
The in vitro polarised Th1 cells used here expressed CCR5 to a higher level than
their Th17 counterparts. CCR5 expression is upregulated in the presence of IL-12
(Bagaeva, Williams and Segal, 2003), included in the Th1-polarising cocktail used
here. Surprisingly, although CXCR3 was raised on Th1 cells here, this was not a
specific feature of the Th1 cells as it was also expressed on Th17 cells to the same
level. For this reason, the blockade of CXCR3 expression was not actively pursued
here. It is interesting to note that the in vitro polarised Th1 and Th17 cells appeared
to express the same protein level of CXCR3 and CCR6, two chemokine receptors
normally associated with Th1 or Th17 cells respectively.
Tak779 is a small, non-peptide antagonist of CCR5, CXCR3 and, to a lesser extent,
CCR2 (Baba et al., 1999; Gao et al., 2003). Tak779 antagonises the binding of the
CCR5 ligand, RANTES to CCR5+ cells and thereby blocks CCR5-mediated Ca2+
signalling (Baba et al., 1999; Gao et al., 2003). The lack of efficacy of Tak779 seen
here suggests that CCR5 expression on the Tg4 Th1 cells was not required for the
entry of the donor Th1 cells into the CNS to induce disease. This is consistent with
some previous studies. For example, C57BL/6 mice deficient in CCR5 or one of its
ligands, MIP-1 , are both still susceptible to MOG-induced EAE (Tran, Kuziel and
Owens, 2000).
However, efficacy of the dose of Tak779 used here in the Tg4 passive transfer
system, or its stability in vivo was not demonstrated. The dose used, 50 g
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(equivalent to 2 mg/kg), was chosen as this dose was shown to have an effect in a
model of adjuvant arthritis in Lewis rats (Okamoto and Kamatani, 2006). Here, due
to using the intravenous route of injection, the frequency of administration was
reduced to every two days, rather than everyday. The lack of effect observed here
could be due to the low efficacy of Tak779 and a short half-life of the antagonist in
vivo. Unfortunately, due to the absence of a positive control showing the efficacy of
Tak779, it cannot be definitively concluded from this data that Tak779 had no effect
on entry of the donor cells into the CNS. In addition, the use of a ‘scrambled peptide’
control of Tak779 would have been a more appropriate negative control as opposed
to PBS.
The in vitro pre-treatment of Th1 cells with an antibody against CCR5 prior to
transfer also had no affect on EAE induction (Richard O’Connor, personal
communication). In contrast, in experimental autoimmune uveitis (EAU) pre-treating
donor T cells with an antibody against CCR5 led to a reduction of their infiltration
into the retina (Crane et al., 2006). However, these cannot be directly compared as in
EAU, donor cells can enter the retina within hours of transfer, whereas it takes days
in EAE, by which time the antibody could have worn off the donor T cells in vivo.
Recently MOG-induced active EAE in C57BL/6 mice was reported to be reduced
both in severity and incidence by the treatment of Tak779 everyday by subcutaneous
injection (Ni et al., 2009). In correlation with data shown here, Ni and colleagues
also showed that Tak779 had no effect on the transfer of EAE by passive transfer of
MOG-specific encephalitogenic T cells highlighting differences between the active
and passive induction of EAE.
Surprisingly, in vitro polarised Th1 cells exhibited surface CCR6 expression, a
chemokine receptor normally associated with Th17 cells. CCR6 has been shown to
be upregulated in the spinal cord during EAE (Liston et al., 2009) and is thought to
be important in Th17 mediated disease (Reboldi et al., 2009). It is considered
essential for the entry of encephalitogenic T cells into the CNS via the choroid
plexus in particular (Reboldi et al., 2009). However, CCR6 surface expression was
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also observed on Th1 cells here. In contrast, when the mRNA expression of CCR6
was determined, Th1 cells were found to have very low levels, and CCR6 was
clearly highly upregulated on the Th17 cells. Explanations for this could be that the
Th1 cells exhibit instability of the CCR6 mRNA, and/or the protein half-life is
extended in the Th1 cells, and/or the translation of the CCR6 protein is more efficient
in the Th1 cells, as the flow cytometry analysis clearly showed strong positive
staining of CCR6. Despite this, surface expression of CCR6 on both the Th1 and
Th17 cells does not explain how, as shown in this thesis, the Th1 cells are able to
enter the CNS and induce disease and not the Th17 cells.
PSGL-1 is required for the initial tethering of the lymphocyte to the endothelial wall.
Increased expression of PSGL-1 has been found on cells from human CSF compared
to the peripheral blood, and expression of P-selectin was also found to be increased,
specifically in the vasculature of the choroid plexus, suggesting a role for this
PSGL-1/P-selectin interaction in migration of T cells into the CNS (Kivisakk et al.,
2003). Here, PSGL-1 was expressed to a higher level on in vitro polarised Th1 cells
than Th17 cells.
In general, PSGL-1 is expressed on the surface of most circulating myeloid cells,
dendritic cells and T lymphocytes (as well as other lymphoid cells) (Laszik et al.,
1996). Despite the surface expression of PSGL-1 on a broad spectrum of cells, its
surface expression does not necessarily correlate to its functional ability. It has been
shown that Th1 and Th2 cells express PSGL-1 to the same extent, however only Th1
cells are able to bind to P-selectin via PSGL-1; whereas Th2 cells cannot (Borges et
al., 1997). Functional PSGL-1 expression on Th1 cells is required for their entry into
the inflamed skin via binding to P-selectin (Austrup et al., 1997; Borges et al., 1997;
Tietz et al., 1998). Similarly, it has been shown that PSGL-1 is required for Th1 cells
to cross the blood-retina barrier in EAU (Xu et al., 2004). Again, this was not a
function of Th2 cells, and pre-treatment of cells with an anti-PSGL-1 antibody
inhibited rolling and infiltration of Th1 cells specifically into the eye (Xu et al.,
2004). The mechanism, by which PSGL-1 functions to aid T cell arrest and migration
across the endothelial wall, is thought to be mediated through enhancing of LFA-1
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dependent cell binding to ICAM-1. This increased binding leads to integrin
activation and Th1 cell arrest on the surface of the vascular endothelium and
subsequent migration into the target tissue (Atarashi et al., 2005). Here, it was
investigated whether, in the same way as it is required for entry into the skin, and the
eye in EAU, PSGL-1 is required on in vitro polarised Th1 cells to enter the CNS and
induce EAE.
Pre-treatment with anti-PSGL-1 antibody (4RA10) led to a delay in disease onset
compared to the PBS treated controls. Previous work with this blocking antibody had
shown that using the antibody in the same way (pre-treating cells prior to transfer)
led to the induction of milder EAE (Deshpande, King and Segal, 2006). Although a
lower severity of EAE was not seen here, the delay in onset correlates with this
observation. A trend towards fewer donor Th1 cells being able to infiltrate across the
BBB and into the CNS at a pre-clinical time point, suggests PSGL-1 is required at a
very early stage as pathogenic T cells populate the CNS. However, the kinetics of the
effects of the blocking antibody could mean that the effects of the antibody wear off
in vivo after a few days, leading to the donor Tg4 Th1 cells being able to later enter
the CNS and induce a normal level of disease.
To overcome this potential difficulty, the in vivo administration of the blocking
antibody was used to determine if this would abrogate EAE induction completely.
Initial results were promising and showed that pre-treating the donor Tg4 Th1 cells
with the blocking antibody prior to transfer, followed by in vivo administration of
25 g of 4RA10 by intravenous injection every two days from day 1 post-transfer,
led to the inhibition of disease induction for the duration of treatment. The last dose
of antibody was given on day 11 post-transfer, and one out of the three host mice
developed a mild level (maximum score of 2) of EAE on day 13 post-transfer, two
days after the last administration of blocking antibody. This was a strong indication
of the need of functional PSGL-1 expression on Tg4 Th1 cells for the infiltration into
the CNS and subsequent induction of inflammation and EAE.
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On repeat, the host mice were culled on day 7 post-transfer due to apparent
anaphylaxis of some of the mice after antibody treatment. Despite fewer total cells
being present in the CNS after in vivo treatment with the blocking antibody, this
lower number of cells did not correlate to fewer donor Th1 cells entering the CNS. In
the same way, there was no significant difference in the percentage or number of
CD11b+ cells in the CNS at this time-point, indicating the anti-PSGL-1 treatment had
no effect on the number of donor Th1 or CD11b+ cells in the CNS. In contrast,
significantly lower frequencies and absolute numbers of CD11b+ cells were found in
the spleen suggesting the treatment reduced the number of CD11b+ cells in the
spleen. This unexpected result correlates with the expression of PSGL-1 on
monocytes and macrophages (An et al., 2008) suggesting PSGL-1 may be required
for the migration of macrophages to the spleen. Importantly, the key difference
between the experiment presented previously and this was the presence/absence of
the in vitro blocking step, prior to transfer of the cells. Therefore, the initial blocking
of PSGL-1 function prior to transfer may confer the important window of time
necessary to inhibit the induction of EAE via the inhibition of migration of donor
Tg4 Th1 cells into the CNS. The use of PBS as the control for the initial in vivo
experiment is a limitation on the results. The repeat experiment using the IgG1
isotype control where no difference was observed in terms of migration, could indeed
reflect the true result. A repeat of this experiment, again with the appropriate IgG1
isotype control, would give a definitive conclusion to these sets of experiments.
The literature available on the role of PSGL-1 in EAE induction is contradictory.
PSGL-1-deficient C57BL/6 mice were susceptible to the induction of MOG-induced
active EAE (Engelhardt et al., 2005; Osmers, Bullard and Barnum, 2005). In the
same respect, SJL mice did not have an increased expression of E- or P-selectin
during active PLP-induced EAE, suggesting that these molecules are not required for
entry of T cells into the CNS (Engelhardt et al., 1997). SJL mice were also
susceptible to PLP-induced active EAE when treated with 4RA10 anti-PSGL-1
antibody (Engelhardt et al., 2005).
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In contrast, blocking PSGL-1 by pre-treating donor cells with 4RA10 led to the
development of milder EAE after transfer to B10.PL hosts (Deshpande, King and
Segal, 2006). This is consistent with the delayed course of EAE shown here,
correlating with fewer donor cells entering the CNS. The anomalies seen between the
different models could reflect the different genetic backgrounds of the mouse strains
used here i.e. differences between the polyclonal C57BL/6 and SJL mice, compared
to the transgenic system using transgenic T cells for passive transfer into B10.PL (or
B10.PLxC57BL/6) host mice.
Data here would suggest that pre-treatment of Tg4 Th1 T cells with an anti-PSGL-1
antibody does indeed impair the entry of the donor cells into the CNS across the
BBB. Pre-treating the donor Tg4 Th1 cells and subsequently blocking PSGL-1 in
vivo, led to the inhibition of EAE for the duration of treatment, suggesting PSGL-1
signalling is required for the induction of EAE. However, increasing the surface
expression of PSGL-1 on in vitro polarised Th17 cells did not confer their
pathogenicity in vivo. This of course could be due to the increased expression of
PSGL-1 seen on the ‘Th17+IL-12’ cells not being functional. The expression of the
two enzymes C2GnT-I and FucT-VII on the ‘Th17+IL-12’ cells needs to be




In vitro polarised Th1 cells express higher levels of CCR5, CD62L and
PSGL-1 compared to Th17 cells.
Of these, only blockade of PSGL-1 could affect the clinical course of EAE by
passive transfer of Tg4 Th1 cells, leading to a delay in EAE induction. This
correlated with their impaired entry to the CNS at a pre-clinical time-point.
Pre-treatment of Tg4 Th1 cells with an anti-PSGL-1 blocking antibody, and
subsequent in vivo blockade of PSGL-1, completely abrogated EAE for the
duration of treatment.
Increasing the surface expression of PSGL-1 (and CCR5) on Th17 cells
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Figure 4.1 In vitro polarised Tg4 Th1 cells do not express higher levels of 4 1-
integrin (VLA-4) than Tg4 Th17 cells
A, Experimental scheme; B, Gated on CD4+ cells, 4 1-integrin expression on (left) Tg4 Th1 (red)
and (middle) Th17 (blue) cells versus the isotype control (grey fill) and (right) overlay.















































































































































































































































































Th1 Th17 Isotype Control
Figure 4.2 Expression of chemokine receptors on Tg4 Th1 and Th17 in vitro
polarised cells.
Gated on CD4+ cells, expression of A, CCR2, B, CCR3, C, CCR4, D, CCR5, E, CCR6 and F, CXCR3
on in vitro polarised (left) Tg4 Th1 (red), (middle) Th17 (blue) cells versus the appropriate isotype
















































































































































Figure 4.3 In vitro polarised Th1 and Th17 cells both express chemokine
receptor CCR6 as determined by flow cytometry and RT-qPCR .
A, Gated on live lymphocytes, CCR6 expression on CD4+ cells in Th1 (left), Th2 (middle) and Th17
(right) in vitro polarised cells (anti-CD3 stimulated C57BL/6 splenocytes). B, Gated on live
lymphocytes, isotype control IgG2a versus CD4; Th2 cells were polarised by Dominika Nowakowska.
C, mRNA expression level of CCR6 as compared to Th0 control cells (cells stimulated in the absence
of exogenous cytokines). 2– = 1 for the control sample. Expression above this level indicates
upregulation. RT-qPCR representative of 2 separate experiments. Flow representative of two








































































3 day polarisation in the presence of
10 g/ml MBP (Ac1-9)
Th1: IL-12 + IL-18 + IL-2






Th1 Th17 Isotype Control
Figure 4.4 Tg4 Th1 in vitro polarised cells express higher levels of CD62L and
PSGL-1 compared to Th17 cells.
A, Experimental scheme; B, Gated on CD4+ cells, CD62L expression on Tg4 Th1 (red) and Th17
(blue) cells; C, Gated on CD4+ cells, PSGL-1 expression on Tg4 Th1 (red), Th17 (blue) and IgG1
isotype control (grey fill). See Appendix 7 for flow cytometry gating strategy for CD62L,







IL-12 + IL-18 + IL-2
10 g/ml MBP (Ac1-9)
3 days
Wash cells. Transfer 4x106
cells i.v.
200 ng Ptx i.p.
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CCR5 Arm Ham IgG
T-bet
T-bet expression D CCR5 expression
Red: Th1 cells
Grey fill: Isotype control
Figure 4.5 Effect of in vivo treatment with CCR5 inhibitor Tak779 on EAE
induction and development.
A, Experiment scheme; Pre-transfer phenotype of Tg4 Th1 cells showing B, IFN- - and IL-17
production, gated on the CD4+ cells; C, T-bet expression gated on CD4+ cells showing T-bet (red)
and IgG1 isotype control (grey fill); D, CCR5 expression gated on CD4+ cells and the isotype control.
Representative of two experiments.
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Figure 4.6 Treatment with Tak779 has no effect on EAE induction by adoptive
transfer of Tg4 Th1 cells.
Mean EAE scores versus days post transfer of mice treated with PBS ( g Tak779 ( ) i.v. on
days 1, 3, 5, 7, 9, 11 post-transfer. Disease incidence: PBS (4/4), Tak779 (3/4). Results are
representative of two experiments. No significant difference in EAE severity between PBS and
Tak779 treated groups, as determined by Fisher’s exact test (p=1.0000). Error bars represent mean ±












































Figure 4.7 Location of Tg4 Th1 CD45.1 donor cells in the periphery and CNS
after in vivo treatment with Tak779.
A, Total number of viable cells, B, total number CD4+ cells and C, total number of Tg4 Th1 CD45.1+
donor cells entering the spleen (left) and CNS (right) at day 7 post-transfer for PBS treated (
Tak779 treated ( ) mice. Statistics performed with Mann Whitney Test. See Appendix 8 for
representative flow cytometry gating strategy for presence of donor T cells. n=4 for both groups.






IL-12 + IL-18 + IL-2
10 g/ml MBP (Ac1-9)
3 days
Wash cells. Transfer 4x106 cells i.v.
in PBS alone, or with
Mel-14 (Mel-14 added to
cells pre-transfer).
200 ng Ptx i.p.
B10.PL host
Experimental SchemeA





























































































Figure 4.8 Pre-transfer phenotype of Tg4 Th1 cells prior to treatment with
Mel-14 in vivo.
A, Experiment scheme; Phenotype of Tg4 Th1 polarised cells after PMA stimulation, gated on CD4+
cells showing B, IFN- -17 and TNF- production; C, T-bet expression on Tg4 Th1 cells (red)
versus IgG1 isotype control (grey fill) gated on CD4+ cells; D, CD62L expression on PBS treated Tg4
Th1 cells (red) versus Mel-14 treated Tg4 Th1 cells (blue) and IgG2a isotype control (grey fill).











Figure 4.9 Treatment with Mel-14 has no effect on EAE induction or
development.
Mean EAE score versus days post cell transfer for Mel-14 treated ( ) versus PBS treated mice (
Mice treated on days 0, 2, 4, 6, 8, 10 post-transfer with 100 g Mel-14 or PBS i.v. Disease incidence:
PBS (3/3); Mel-14 (3/3). Results representative of two experiments. No significant difference in EAE
severity between the PBS treated and Mel-14 treated groups, as determined by Fisher’s exact test
(p=1.0000). Error bars represent mean ± standard error.
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Figure 4.10 Treatment of mice with Mel-14 has no effect on the migration of
Tg4 Th1 donor cells in to the CNS.
Total number of viable cells, total CD4+ cells and absolute number of CD45.1+ Tg4 Th1 donor cells
entering the A, inguinal lymph nodes, B, spleen and C, CNS at day 5 post-transfer (pre-clinical) for
PBS treated ( and Mel-14 treated ( ). Results are representative of two experiments. n=4 for both






















Figure 4.11 Expression of C2GnT-I on in vitro polarised Th1 and Th17 cells.
In vitro polarised Tg4 Th0, Th1 and Th17 cells showing mRNA expression of A, T-bet, B,
C, C2GnT-I, as determined by RT-qPCR. HPRT used as the control house-keeping gene. T-bet
the control sample; C2GnT-I expression calculated using Th0 as the control sample. Error bars
represent standard deviation in replicate samples. Dotted line denote 2– = 1 of control sample.
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Figure 4.12 Tg4 Th1 cells treated with anti-PSGL-1 prior to transfer induce a
delayed course of disease.
A, Experiment scheme; B, Pre-transfer phenotype of Tg4 Th1 polarised cells showing IFN- -17
and TNF- production, gated on CD4+ T cells, and PSGL-1 surface expression gated on live
lymphocytes. Staining representative of numerous Tg4 Th1 passive transfer experiments with pre-
transfer phenotyping of Tg1 Th1 cells, another example of which is shown in Figure 4.15.
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Figure 4.13 Pre-treatment of Tg4 Th1 cells with anti-PSGL-1 resulted in a delay
in disease induction.
In vitro polarised Tg4 Th1 cells were pre-treated with 10 g/ml anti-PSGL-1 or PBS for one hour
prior to transfer. Mean clinical EAE scores versus days post-transfer. Disease incidence: PBS (4/4),
anti-PSGL-1 (5/5). There is a significant delay in the induction of disease in the anti-PSGL-1 pre-
treated group compared to the PBS pre-treated group, as determined by Mann Whitney test
(* p=0.0317). Error bars represent mean ± standard error. Representative of two experiments, see












































Figure 4.14 Anti-PSGL-1 pre-treatment resulted in a trend towards fewer Tg4
Th1 donor cells entering the CNS at a pre-clinical stage.
A, Total number of viable cells; B, Total number of CD4+ T cells; C, Total number of CD45.1+ donor
Th1 cells in spleen (left) and CNS (right) taken at day 4 post-transfer, PBS ( -PSGL-1 ( )
in vitro treated Th1 cells; Statistics performed using a Mann Whitney test. n=3 for both groups. Pre-
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Figure 4.15 Effect of in vivo treatment of anti-PSGL-1 on Tg4 Th1 passive
transfer EAE.
A, Experiment scheme; B, pre-transfer phenotype of Tg4 Th1 cells showing IFN- - and IL-17
production, gated on CD4+ cells, and PSGL-1 expression gated on live lymphocytes; C, T-bet
expression on Tg4 Th1 cells, gated on CD4+ cells showing T-bet (red) versus IgG1 isotype control
(grey fill). Staining is representative of numerous Tg4 Th1 passive transfer experiments with pre-
transfer phenotyping, another example of which is shown in Figure 4.12.
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Figure 4.16 Effect of in vivo treatment of anti-PSGL-1 on Tg4 Th1 passive
transfer EAE.
Mean EAE scores versus days post-transfer of PBS ( -PSGL-1 ( ) treated mice. Host mice
treated with anti-PSGL-1 or PBS i.v. on days 1, 3, 5, 7, 9, 11 post-transfer. Disease incidence: PBS
(2/2), anti-PSGL-1 (1/3). Error bars represent mean ± standard error. No significant difference in EAE
severity between PBS or anti-PSGL-1 in vivo treated groups, as determined by Fisher’s exact test
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Figure 4.17 Effect of in vivo treatments with anti-PSGL-1 on entry of donor Tg4
Th1 cells into the periphery and CNS.
A, Experiment scheme; B, total number of viable cells; C, total number of CD4+ T cells, and D,
absolute number of CD45.1+ Tg4 Th1 donor cells in the spleen (left) and CNS (right) at day 7 post-
transfer after treatment with anti-PSGL-1 ( ) or IgG1 isotype control (
Mann Whitney Test (*p<0.05; **p<0.01; ***p<0.001). n=7 (IgG1 treated); n=6 (anti-PSGL-1
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Figure 4.18 Effect of anti-PSGL-1 on the migration of CD11b+ cells into the
spleen and CNS during EAE.
A, Percentage and B, absolute number of CD11b+ cells in the spleen; C, percentage and D, absolute
numbers of CD11b+ cells in the CNS. Samples taken at day 7 post-transfer after in vivo treatment on
days 0, 2, 4 and 6 post-transfer with anti-PSGL-1 ( ) or IgG1 isotype control (
with Mann Whitney Test (*p<0.05; **p<0.01; ***p<0.001). n=7 (IgG1 treated); n=6 (anti-PSGL-1
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Figure 4.19 IL-12 increases the expression of PSGL-1 on Th17 cells in vitro.
A, Experiment scheme; B, Pre-transfer phenotype of Th1 and Th17 cells polarised in the
presence/absence of IL-12, gated on CD4+ cells showing IFN- nd IL-17 production; Gated on CD4+
cells C, PSGL-1 expression and D, CCR5 expression, on Th1 (black), Th17 (blue) and Th17+IL-12


























Th1 Th17 + IL-12Th17
Figure 4.20 Increased PSGL-1 expression on Th17 cells does not confer
pathogenicity.
A, Mean EAE scores versus days post transfer of mice with Th1 ( , Th17 ( and Th17 + IL12 ( )
cells. B, Total number of lymphocytes in the CNS at day 20 post-transfer; C, Total number CD45.1+
donor cells in the CNS at day 20 post-transfer. Disease incidence: Th1 (3/3), Th17 (0/3) and Th17+IL-
12 (0/3). Results representative of 2 experiments. Statistics performed using Kruskal Wallis test (KW
p value: *p=0.0273 (B) and *p=0.0390 (C)) and Dunn’s Multiple comparison post test (*p<0.05;




5 The requirements of IFN- -17 and TNF- in
EAE
5.1 Introduction
As shown in Chapter 3, Th1 cells were able to infiltrate the CNS and induce EAE
whereas Th17 cells could not (O'Connor et al., 2008). One clear difference between
the pathogenic Th1 cells and the non-pathogenic Th17 cells is their production of
their signature cytokines, IFN- -17 respectively. IFN-
have a pivotal role in promoting a pro-inflammatory response by the activation of
macrophages, upregulation of adhesion molecules and the upregulation of MHC
molecules (Steeg et al., 1982; Basham and Merigan, 1983; Dore-Duffy et al., 1996).
However, despite its obvious role in promoting a pro-inflammatory environment, the
involvement of IFN- rd and it appears to have
a protective effect (Ferber et al., 1996; Willenborg et al., 1996). Mice with a
disrupted IFN- -induced EAE (Ferber et al., 1996).
Similarly, mice lacking the ligand binding chain of the IFN-
MOG-induced EAE (Willenborg et al., 1996). In addition to this, the transfer of
MOG-specific IFN- -deficient cells, into IFN- -deficient hosts results in severe
EAE with no recovery. In contrast, if the cells are transferred into IFN- -competent
hosts, these mice develop severe EAE as well, but recover from disease (Willenborg
et al., 1996). Treatments with anti-IFN-
development (Billiau et al., 1988; Lublin et al., 1993). Reciprocally, the
administration of IFN- to EAE mice resulted in the suppression, or amelioration of
disease (Billiau et al., 1988; Voorthuis et al., 1990). This evidence all suggested
IFN-
Despite the possible beneficial roles of IFN-
mediated disease due to the inhibition of disease after anti-IL-12 treatments
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(Leonard, Waldburger and Goldman, 1995; Bright et al., 1998a; Bright et al., 1998b)
and the clear encephalitogenic potential of Th1 cells (Ando et al., 1989). In addition
to this, IL-12-deficient mice exhibited resistance to EAE induction (Segal, Dwyer
and Shevach, 1998). However, since the discovery of IL-23, a cytokine that shares its
p40 chain with IL-12 (Oppmann et al., 2000), and the discovery that IL-23 had a
dominant role to play in EAE pathology (Cua et al., 2003; Chen et al., 2006a), this
view-point shifted towards Th17 cells being the key pathogenic lineage (Langrish et
al., 2005; Park et al., 2005). Studies into the role of IL-17 in autoimmune
inflammation are extensive, some showing evidence for its pro-inflammatory effects
(Komiyama et al., 2006) and others showing evidence for IL-17 not being the key
pro-inflammatory cytokine (Haak et al., 2009).
Overall, studies have therefore suggested that, although both Th1 and Th17 cells
appear able to induce disease, neither of the signature cytokines is required for the
induction of EAE (Willenborg et al., 1996; Haak et al., 2009). Therefore, perhaps
another pro-inflammatory cytokine, for example TNF- , which is produced by both
Th1 and Th17 cells, is required for the induction of disease and this was investigated
here.
‘Atypical’ or ‘non-classical’ EAE has been described recently in different models of
EAE, including BALB/c IFN- -deficient mice, as well as spontaneous atypical EAE
in TCR transgenic RAG-/- IFN- -deficient mice (Muller, Pender and Greer, 2000;
Abromson-Leeman et al., 2004; Wensky et al., 2005). Notably, it is often associated
with an absence of IFN-
deficit, starting with tail paralysis and leading to forelimb paralysis which may or
may not resolve. This appears to be caused by inflammation especially within the
spinal cord, and little involvement of the brainstem and cerebellum (Muller, Pender
and Greer, 2000; Abromson-Leeman et al., 2004). Atypical EAE is characterised by
inflammation within the cerebellum and/or brainstem, with very limited spinal cord
involvement and therefore presents as axial rotatory movement and disturbance in





The aims of this final chapter were to investigate the requirements of a) IFN-
signature cytokine of pathogenic Th1 cells, b) TNF- , as a pro-inflammatory
cytokine produced by both pathogenic Th1 cells and non-pathogenic Th17 cells, and
c) IL-17 as the signature cytokine of non-pathogenic Th17 cells, in EAE induction.
5.1.2 Approach
Both the C57BL/6/MOG and the Tg4/MBP(Ac1-9) models were used to investigate
the requirements of IFN- -induced active EAE was induced
in WT C57BL/6 and IFN-
others in IFN- KO mice. The pathogenic ability of MOG-responsive WT and
IFN-
pMOG/CFA immunisation and the subsequent polarisation of Th1 cells in vitro. The
C57BL/6 IFN- ed with Tg4 CD45.1 mice, to generate Tg4
IFN- -
using naïve T cells activated for the first time in vitro in the presence of MBP
(Ac1-9). Polarised Th1 cells from Tg4 or Tg4 IFN- mice were then transferred
into B10.PLxC57BL/6 host mice. The role of TNF- was investigated by antibody
blockade using the Tg4 Th1 passive transfer model as described above.
IL-17FKO (H-2b) mice were obtained and crossed with IFN- -2b to generate
IL-17FKO/IFN- e
transfer. Delays in the generation of these double knockout mice prevented the




5.2.1 IFN- p a
more severe chronic form of disease compared to WT
mice
Initial experiments to verify the reported protective role of IFN- (Ferber et al., 1996;
Willenborg et al., 1996) used actively induced disease in IFN- O versus wild-type
C57BL/6 mice (Figure 5.1 A). The IFN-
susceptibility to the induction of EAE (Figure 5.1 B). This initial experiment was
repeated and spleen, lymph node and CNS samples taken from both groups at days 6,
13 and 21 post-immunisation, see Figure 5.2 A for the EAE scores. At day 6, there
was no significant difference in the total number of viable cells or number of CD4+ T
cells in the spleen or inguinal lymph nodes between the WT and IFN-
(Figure 5.2 B, C). There was an increased percentage of CD4+ T cells in the spleen of
the IFN- +
T cells due to these mice having slightly lower total cells in the spleen (Figure 5.2
B). Similarly, there was no evidence for a greater infiltrate in the CNS of the IFN-
Figure 5.2 D).
At day 13 post-immunisation (the peak of disease in WT mice) there were no
significant differences between the WT and IFN- Figure 5.3A). In
the inguinal lymph nodes, there were significantly higher proportions and absolute
numbers of CD4+ T cells in the IFN- Figure 5.3 B). In the CNS there was
a significantly higher percentage of CD4+ T cells in the IFN-
the WT. However, this did not translate to higher absolute numbers of CD4+ T cells
in the CNS of the IFN- Figure 5.3 C).
At day 21 post-immunisation, (corresponding to the recovery phase in the WT mice),
significantly fewer total cell numbers were observed in the spleen of the IFN-
mice compared to the WT mice, and this also correlated with significantly fewer
CD4+ T cells in the spleen (Figure 5.4 A). The same trend was seen in the inguinal
lymph nodes and CNS as was observed at day 13 post-immunisation (Figure 5.4 B,
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C) with no differences in absolute number of CD4+ T cells within the CNS between
the WT and IFN- + cells being significantly
higher in the IFN-
5.2.2 Comparable numbers of FoxP3+ Treg in the CNS of WT
and IFN-
The resolution of classical EAE correlates with an accumulation of Treg in the CNS
leading to the suppression of inflammation (McGeachy, Stephens and Anderton,
2005; O'Connor, Malpass and Anderton, 2007). Therefore, the prolonged disease
observed in the IFN- + Treg-mediated
suppression in the CNS as has been suggested (Wang et al., 2006). However, there
were no significant differences in proportions of, or absolute numbers of, FoxP3+
Treg in the CNS (Figure 5.5 A-C) or spleen and inguinal lymph nodes (data not
shown) at days 6, 13, or 21 post-immunisation between the WT and IFN-
5.2.3 Significantly increased numbers of IL-17+ T cells in the
CNS of IFN- KO mice compared to WT mice, in response
to pMOG stimulation
Another explanation for the extended disease course observed in the IFN-
could be increased levels of pro-inflammatory cytokines within the target organ,
compared to the WT mice. The level of IL-17 was investigated and, at day 13 post-
immunisation, elevated numbers of IL-17+ T cells were found in the CNS of
IFN- -stimulation (~11 % of the CD4+ population
in the IFN- Figure 5.6 A, lower
panel).
Importantly, the FoxP3+ Treg in the CNS of the IFN-
significantly increased frequency of IL-17+ cells after re-stimulation with pMOG
(Figure 5.6 A), compared to WT FoxP3+ Treg. Quantitatively, there was a
significantly higher percentage of pMOG-specific IL-17+ cells in both the FoxP3-
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and FoxP3+ populations in the CNS of the IFN-
counterparts (Figure 5.6 B). Secondly, the percentage of IL-17+ cells within the
FoxP3+ and FoxP3- CD4+ compartments was comparable in the IFN-
(Figure 5.6 B). 10% of the IFN- -17+. It has been shown
that in the FoxP3+ Treg in the CNS (of WT mice) ~25% are pMOG-responsive (Korn
et al., 2007; O'Connor, Malpass and Anderton, 2007). This would suggest that ~40%
pMOG-responsive Treg are producing IL-17 here. This observed increase in IL-17
was specific to the CNS and was not observed in the spleen or lymph nodes (data not
shown). These results indicated that the prolonged disease observed in the IFN-
mice is associated with the increased numbers of IL-17+ cells in the target organ.
5.2.4 pMOG-reactive IFN-
inducing EAE
The next step was to determine the requirement for IFN-
encephalitogenic T cells in the passive transfer models used in this thesis. Firstly the
phenotype of IFN- -deficient ‘Th1’ cells was investigated (Figure 5.7 A).
pMOG-reactive IFN- cells produced higher percentages of IL-17 compared
to the WT Th1 cells (Figure 5.7 B) as well as higher levels of TNF- (Figure 5.7 C).
The IFN- -bet although a clear T-bet- population was
apparent whereas T-bet expression in WT Th1 cells was more uniform, as
determined by flow cytometry analysis (Figure 5.7 D).
The pMOG passive transfer model was used to determine if the IFN- -deficient Th1
cells could induce disease (Figure 5.8 A). At the time of transfer the WT Th1 cells
had 1% IFN- + cells. Interestingly, in this experiment the IFN-
~14% IL-17+ cells (as compared to 0.5% IL-17+ WT Th1 cells) (Figure 5.8 B). WT
Th17 cells had ~6% IL-17+ and again, in the absence of IFN- -
cells had a higher percentage of IL-17+ cells (~19%) (Figure 5.8 B) as well as higher
MFI values of the IL-17+ population, indicating higher levels of IL-17 production.
The level of IFN- -17 production was also verified by ELISA using
supernatants from the 3 day in vitro culture of Th1 polarised cells. The WT Th1 cells
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produced greater than 100 ng/ml IFN- maximum limit of detection of the
ELISA) (Figure 5.8 C, left). IL-17 was detectable in the supernatants from WT Th1
cells, but more was produced by the IFN- Figure 5.8 C, right).
Both WT and IFN- able to induce EAE. Despite the high IL-17
production in both Th17 populations, these were once again unable to induce disease
(Figure 5.9 A). At day 12 post-transfer donor cells were evident in the spleens of
each group, but only Th1 donor cells were enriched within the CNS (Figure 5.9 B).
The WT Th1 donor cells had highly upregulated IFN-
whereas the IFN- -17 production in the CNS
(Figure 5.9 C). This was after PMA re-stimulation, and is therefore representative of
non-specific cytokine production and not pMOG-specific production showing that
the cells were capable of producing these cytokines on activation. The high number
of IL-17+ cells in the CNS of the IFN- s could have an
influence on the disease severity. However, an increased disease severity by the
IFN- -deficient cells was not evident from this experiment.
All mice showed signs of classical, rather than atypical, EAE.
5.2.5 TCR transgenic Tg4 IFN- KO Th1 cells also express
T-bet to the same level as the Tg4 WT Th1 cells
The phenotype of Tg4 IFN- h1 cells was determined by flow cytometry and
RT-qPCR analysis (Figure 5.10 A). As expected, the WT Th1 cells (denoted here as
IFN- +/+) had the highest frequency of IFN- + cells, with the IFN-
cells (IFN- +/-) having less and the IFN- - -/-) none (Figure 5.10
B, top). There were consistently slightly increased numbers of IL-17+ cells in the
IFN- -/- cells compared to the wild-type Th1 cells (Figure 5.10 B, top) although
interestingly not to the levels observed in the C57BL/6/pMOG system. The




The IFN- -/- Th1 cells expressed T-bet (68.6% T-bet+), albeit to a slightly decreased
level compared to the IFN- +/+ (82% T-bet+) and IFN- +/- (76.6% T-bet+) populations
(Figure 5.10 C, D). This mimicked the T-bet expression observed on the
pMOG-reactive IFN- Figure 5.7 D). T-be
mRNA expression was also determined on these cell populations, using RT-qPCR.
T-bet was found to be upregulated to the same level in the three Th1 populations as
compared to the Th17 control as well as being upregulated on a Th0 population
(Figure 5.10 E). Th1 IFN- +/+
expression (Figure 5.10 -
fold on the Th1 IFN- +/- cells and upregulated four fold on the Th1 IFN- -/- cells
compared to a Th0 control, but this was still much lower than the highly upregulated
expression levels on IFN- +/+ Th17 polarised Tg4 cells (Figure 5.10 E).
5.2.6 Tg4 IFN-
EAE
The pathogenic potential of the Tg4 IFN- Figure 5.11
A). The IFN- a slightly higher percentage of IL-17+ cells
compared to the WT Th1 cells (Figure 5.11 B, top) and comparable frequencies of
TNF- + cells (Figure 5.11 B, bottom). Both populations were T-bet+ (Figure 5.11 C).
Both WT and IFN- Figure 5.11 D).
Interestingly, however, the IFN-
EAE (Figure 5.11 E) whereas the WT Th1 cells did not. Of the ten mice that received
IFN-
EAE, whereas all the mice with WT Th1 cells developed classical disease. Mice that
developed classical disease did not show signs of atypical disease and vice versa.
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5.2.7 Donor cell infiltration and inflammation occur
specifically in the brain during atypical EAE but not the
spinal cord
Atypical EAE is characterised by inflammation within the brain-stem and cerebellum
and no involvement of the spinal cord (Wensky et al., 2005). To determine whether
this was the same in our Tg4 passive transfer model, spleen, brain and spinal cord
samples were taken at day 11 post-transfer. There was no significant difference in the
total number of viable cells, the proportion and total number of CD4+ T cells, or the
proportion and total number of donor cells in the spleen (Figure 5.12 A) or brain of
mice with classical versus atypical EAE (Figure 5.12 B). However, there were
significantly fewer total cells in the spinal cord of mice with atypical EAE. This
correlated with significantly fewer total CD4+ T cells and fewer donor CD45.1+ cells
despite no difference in the proportion of donor CD45.1+ cells between the two
groups (Figure 5.12 C). In summary, during classical EAE donor cell infiltration and
inflammation appeared to be observed in both the spinal cord and the brain (Figure
5.13 A). In contrast during atypical EAE, the donor T cells were located in the brain
specifically and not the spinal cord (Figure 5.13 A).
5.2.8 Increased frequencies of IL-17+ cells in the donor cells in
the brains of mice with atypical EAE
The cytokine production by the donor T cells at day 11 post-transfer was investigated
after an over-night re-stimulation with MBP (Ac1-9). Of the twelve mice sampled at
this time-point, seven had exhibited classical disease and five atypical. The
remaining mice (all classical EAE) were left to run the course of the disease. Of the
seven mice exhibiting classical disease, five had received WT Th1 cells and two had
received IFN-
In response to peptide stimulation there were approximately 8% IFN- + donor cells
in the spleen, with higher frequencies apparent in the spinal cord and brain (~20%) in
the mice with classical EAE (Figure 5.13 B). The mice that exhibited atypical EAE
had negligible proportions of IFN- + cells due to the donor cells, all being IFN-
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(Figure 5.13 B). Comparable percentages of donor T cells were TNF- + in the spleen
and brain of mice with classical EAE induced by WT or IFN-
atypical EAE (Figure 5.13 B). Significantly lower percentages of donor cells were
TNF- + in the spinal cord of mice with atypical EAE compared to those with
classical disease. However, this was most likely due to technical issues, given the
very low cell numbers in these samples. The percentage of IL-17+ cells in the spleen
was low in both classical and atypical disease. In the spinal cord, percentages of
IL-17+ cells were comparable between classical (induced by WT or IFN-
versus atypical EAE. In the brain, the IFN- -17
regardless of inducing classical or atypical disease, and the WT Th1 cells did not
(Figure 5.13 B), however this was not statistically significant. The increased
percentages of IL-17 cells in the brain in atypical EAE mice suggests perhaps the
increased IL-17 production in the brain had led to the development of atypical EAE,
however the two mice that developed classical EAE also had higher levels of IL-17
production in the brain which would argue against this idea.
5.2.9 Requirements of IL-17 for the induction of atypical EAE
The observation of increased IL-17+ cells specifically in the brain of mice with
atypical EAE, and not in the spleen, led to the assessment of whether this IL-17
production by the donor T cells was required for the induction of atypical disease.
The experiment was repeated with the addition of the Miltenyi IL-17 secretion and
detection assay which was used to deplete the IL-17+ cells from a portion of Tg4
IFN- - -
IL-17- cells were transferred separately into host mice (Figure 5.14 A). Pre-transfer
analysis of the phenotype of the polarised cells showed they had a Th1 phenotype in
terms of cytokine production and T-bet expression (Figure 5.14 B-D). The depletion
step removed the majority of IL-17+ cells from the Tg4 IFN- ation,
reducing the IL-17+ fraction from ~2% to 0.46%, generating a Tg4 ‘IFN- -17-
Th1’ population for transfer (Figure 5.14 E, F).
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Tg4 Th1 cells induced classical EAE, and not atypical EAE (Figure 5.15 A). As seen
in previous experiments, Tg4 IFN-
atypical forms of EAE (50% exhibited classical disease and 50% atypical disease).
Interestingly, the Tg4 IFN- -17- population also induced either classical
or atypical EAE (37.5% exhibited classical disease and 62.5% atypical disease)
(Figure 5.15 A).
At day 13 post-transfer 20 mice were sampled. Of these, 13 had classical EAE (8
induced with transfer of WT Th1 cells; 2 with transfer of Tg4 IFN-
with transfer of Tg4 IFN- -17- Th1 cells); and 7 had atypical EAE (3 induced
with transfer of Tg4 IFN- - -17-
cells). The accumulation of the donor T cells during classical and atypical EAE was
also similar to previous experiments. Comparable numbers of total viable cells and
donor cells were found between the two groups in the spleen (Figure 5.15 B, C, left).
A significantly higher number of total viable cells and donor T cells were found in
the brain of the mice with atypical disease (Figure 5.15 B, C, middle). This had not
reached significance in previous experiments. A significantly lower number of viable
cells and donor T cells were observed in the spinal cord of mice with atypical EAE
compared to those with classical (Figure 5.15 B, C, right).
The cytokine production by the Tg4 IFN- t had been
depleted of the IL-17+ cells was tested to determine whether these cells could now
produce IL-17 in response to MBP (Ac1-9) stimulation. Interestingly, both Tg4
IFN-
IL-17+ cells or not, had raised frequencies of IL-17+ cells in the brain in response to
stimulation (Figure 5.16 A). The frequency of IL-17+ cells in the Tg4 IFN-
populations was comparable and did not account for why some induced classical and
not atypical disease. There was a trend towards lower frequencies of IL-17+ cells in
the Tg4 IFN-
significant. Frequencies of IL-17+ cells were negligible in the spleens of these mice




Comparable percentages of TNF- + donor cells appeared in the spleen of mice
receiving the different donor cell populations after stimulation with MBP (Ac1-9)
stimulation (Figure 5.16 B). However, in the brain, the Tg4 Th1 donor cells had
lower frequencies of TNF- + cells compared to the Tg4 IFN- ls
although this was not significant (Figure 5.16 B). The Tg4 IFN-
had induced classical EAE and not atypical EAE did not show significantly different
cytokine production that could account for their induction of classical EAE. There
was no significant difference in the percentage of IFN- + cells between the spleen
and brain in the Tg4 Th1 transfers (Figure 5.16 C). The very low number of Tg4
IFN- cells observed in the spinal cord made the comparison of cytokine
staining between them and the WT cells in this tissue very unclear, so this has not
been shown. Importantly, this cytokine production has clearly shown that despite
depleting IL-17+ cells prior to transfer, the Tg4 IFN-
produce IL-17 in vivo and/or on re-stimulation. This could either be an outgrowth of
the 0.46% of IL-17+ cells that were still present in the pre-transfer population, or
could be previously IL-17- cells becoming IL-17+. However, it has not been possible
to determine which population they came from in these experiments.
5.2.10 The presence of IL-18 in the polarising Th1-cocktail
results in higher IFN- TNF- production by these
cells, and increased severity and incidence of disease
As shown here, IFN-
that IL-17 is not required for the induction of disease (Haak et al., 2009). However,
both Th1 cells (O'Connor et al., 2008) and Th17 cells (Jager et al., 2009) appear able
to induce EAE. Perhaps TNF- , which is produced by both Th1 and Th17 cells, is
required for disease induction by these cell populations. IL-18 was found to induce
higher proportions of IFN- + and TNF- + cells in Th1 populations and it was
investigated as to whether this had an effect on their ability to induce EAE (Figure
5.17 A). The ‘IL-12-alone’ polarised Th1 cells had 14% IFN- + cells and 40%
TNF- + cells (Figure 5.17 B, left). The addition of IL-18 increased the proportion of
IFN- + cells two-fold to 31%, and increased the proportion of TNF- + cells to 57%
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(Figure 5.17 B, right). Both populations induced classical EAE. However, the ‘IL-12
+ IL-18’ polarised cells induced an apparent higher severity of disease although this
was not statistically significant (Figure 5.17 D) compared to the ‘IL-12-alone’ cells.
The increased production of IFN- - by the ‘IL-12 + IL-18’ may have
contributed to the enhanced disease severity. As it has been shown earlier that IFN-
is not required for disease induction by Th1 cells, the observed increased severity of
disease may be due to the increased proportion of TNF- + cells, although this is not
clear as other changes imposed by exposure to IL-18 were not determined.
5.2.11 Neutralising TNF- during Tg4 Th1-driven EAE results in
decreased severity of disease
To determine whether TNF- had a role in EAE severity, a Tg4 Th1 passive transfer
was done, and the host mice treated with a neutralising antibody against TNF-
(Figure 5.18 A). The donor Tg4 Th1 cells had a Th1 phenotype (Figure 5.18 B-C). A
single treatment of a neutralising antibody against TNF- (on the day of Tg4 Th1 cell
transfer), resulted in a trend towards reduced disease severity as compared to the
PBS-treated controls (although this was not statistically significant) (Figure 5.18 D)
suggesting TNF- has a key role in inducing severe EAE.
5.3 Discussion
The precise requirements for T cell derived factors to drive EAE remain
controversial. It has clearly been shown here that Th1 cells are capable of infiltrating
into the CNS and inducing EAE (O'Connor et al., 2008). This observation runs
counter to the knowledge that IFN-
required for the induction of disease. This led to the decision to revisit the
requirement for IFN- -9) passive
transfer models. The endeavour was to use the traceable models developed here to
shed new light on the reasons for exacerbated disease in the absence of IFN-
Previously, it has been shown that disruption of IFN-
targeting either IFN- -
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EAE (Ferber et al., 1996; Willenborg et al., 1996; Willenborg et al., 1999). Here,
pMOG-induced EAE was compared between WT C57BL/6 and IFN-
the same background. A more severe and chronic form of EAE was observed in the
IFN-
absolute numbers of inflammatory CD4+ T cells in the CNS at a pre-clinical time-
point, the peak of disease, or at the point where the WT mice were recovering. There
was a significant increase in the number of IL-17+ cells in the CNS of IFN-
which could contribute to the more severe disease observed, and is suggestive of
upregulated IL-17 response in the absence of IFN-
reported. Another simple explanation for the more severe disease observed in the
IFN- + Treg in the CNS as has been
observed previously (Wang et al., 2006). IFN-
the conversion of CD4+ CD25- cells to CD4+ CD25+ Treg, and reduced frequency
and function of Treg was observed in IFN- (Wang et al., 2006). This was
thought to contribute to the enhanced disease severity observed in these mice
compared to the WT mice. However, no evidence for such an explanation was
obtained in this study as FoxP3+ Treg frequencies were comparable between WT and
IFN-
Surprisingly, despite not finding differences in the frequency or number of FoxP3+
Treg in the CNS, a significant proportion of the Foxp3+ cells in the CNS of the
IFN- ce were IL-17+, whereas this was not observed either in the spleen of the
same mice (data not shown), or in the CNS or spleen of the WT mice. This effect
was also not observed in the case of IFN- - (data not shown). This suggests
that the FoxP3+ Treg in this setting are able to switch from a regulatory phenotype to
a pro-inflammatory phenotype, which could have a large impact on the current
interest in using Treg for cell therapy in autoimmune disease. The observation of the
apparent Treg plasticity in the IFN-
that IFN- -17 production in vitro (R. O’Connor,
personal communication). This is supported by a recent observation in human T
regulatory cells (Beriou et al., 2009). In this case a population of human FoxP3+ Treg
began producing IL-17 if stimulated in the presence of pro-inflammatory cytokines.
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The Foxp3+ IL-17+ cells obtained could exhibit both suppressive and pro-
inflammatory effects depending on the cytokine environment (Beriou et al., 2009).
Treg are becoming an attractive route of therapy for autoimmune disease. However,
care should therefore be taken in determining whether Treg have a fixed phenotype
or whether they can switch from a regulatory to an inflammatory role in particular
settings as has been shown (Yang et al., 2008c; Komatsu et al., 2009), as this would
clearly have a negative impact on their use for therapeutics. In the same way, it has
been recently shown that other CD4+ T cell subsets e.g. Th17 and Th2 cells, exhibit
plastic phenotypes (Bending et al., 2009; Hegazy et al., 2010).
The phenotype of IFN-
investigated. Both pMOG-reactive IFN- -
had increased capacity for IL-17 production compared to WT cells, an attribute
which has not been directly reported before. The Tg4 IFN-
the differentiation of Th17 cells including IL-2 through the activation of STAT5
(Laurence et al., 2007) and nuclear receptor peroxisome proliferators-activated
receptor- (Klotz et al., 2009). The neutralisation of IL-4 and IFN-
Th17 differentiation is thought to increase the proportion of IL-17+ cells produced by
inhibiting the Th2 and Th1 pathways respectively, suggesting that IFN-
IL-17 production (Harrington et al., 2005; Park et al., 2005) and this is routinely used
in in vitro Th17 differentiation by some groups. Here the absence of IFN-
be sufficient to allow IL-
conditions, suggesting that IFN- -17 production in
cells that would otherwise be producing IFN-
pMOG-reactive IFN- -bet, the key transcription factor of
the Th1 lineage (Szabo et al., 2000), albeit to a slightly decreased level compared to
the WT cells. This is perhaps not surprising as T-bet expression can be upregulated
through IL-12, which is present in the polarising cytokine mix. The same was
observed in the Tg4 IFN- , which expressed T-bet (albeit at slightly
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lower levels) as did the WT Th1 cells both at the protein and mRNA level. T-bet is
known to be the master regulator of Th1 differentiation, as it was first reported to be
specifically expressed on Th1 cells. Ectopic expression of T-bet in Th2 cells resulted
in suppression of the Th2 cytokine responses, and up-regulation of IFN- (Szabo et
al., 2000; Lovett-Racke et al., 2004). It has been suggested that T-bet expression is
dependent on IFN- (Afkarian et al., 2002), however, data
presented here shows that T-bet can still be induced in IFN-
towards a Th1 phenotype. Although IFN-
regulation of T-bet expression, T-bet is clearly not absent from IFN-
STAT-1KO mice (data presented here; (Lighvani et al., 2001)) indicating that there
are other IFN- -independent regulators of T-bet expression, perhaps directly through
IL-12 signalling (Schultz et al., 2009).
It has previously been shown that TCR transgenic RAG-/- mice lacking IFN-
susceptible to spontaneous atypical EAE (Wensky et al., 2005). Classical and
atypical EAE present very distinct signs of disease; classical EAE being
characterised by spinal cord inflammation leading to increasing paralysis, from the
tail forwards, and atypical EAE being characterised by inflammation specifically
within the brain-stem and cerebellum leading to ataxic movements and loss of
balance of the mice (Muller, Pender and Greer, 2000; Muller, Pender and Greer,
2005). To support the study of this, the involvement of brain-stem inflammation has
also been observed in MS patients (Shibasaki, McDonald and Kuroiwa, 1981).
Although classical EAE recapitulates some of the signs of MS, there are certain
aspects that are not represented by the study of classical EAE. For example, MS
patients display symptoms such as vestibular (balance) problems and vertigo (Sasaki
et al., 1994; Williams, Roland and Yellin, 1997; Frohman et al., 2000), and the study
of atypical EAE could allow for these other aspects of MS to be investigated.
Here, only classical EAE was induced by the transfer of WT Tg4 Th1 cells.
However, the transfer of Tg4 IFN-
classical or atypical forms of EAE. Tracking the donor T cells revealed their
accumulation in both the spinal cord and the brain during classical EAE, but only in
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the brain during atypical EAE, supporting previous reports that have shown
inflammation during atypical EAE is specifically within the brain-stem and
cerebellum (Wensky et al., 2005). It has been shown that co-transfer of WT Th1 cells
together with the IFN-
spinal cord and the development of classical EAE (Lees et al., 2008) suggesting a
protective effect of IFN- lly within the brain.
The IL-17 production by the Tg4 IFN-
significantly higher levels of IL-17+ cells in the donor cell population during
atypical, but not classical, EAE suggested that in the absence of IFN- -17 could
drive pathology in the brain. Tg4 IFN- -17+ cells prior to
transfer could still induce either classical or atypical EAE, to the same extent as the
unsorted Tg4 IFN- cells
were recovered from the brain, these now contained measurable IL-17+ cells.
Therefore these results are not conclusive as to whether IL-17 is required for the
induction of atypical EAE. The experiment needs to be refined in a cleaner system
ideally through the transfer of IFN- -deficient-IL-17F-deficient cells together with
the use of a neutralising antibody against IL-17A, to inhibit any IL-17 signalling.
The transfer of cells in the absence of both IFN- -17 signalling has been
achieved recently through the transfer of pMOG-reactive IFN-
IL-17R -deficient mice (Kroenke, Chensue and Segal, 2010). This resulted in a shift
from atypical EAE if the cells were transferred into WT hosts, to classical EAE,
when transferred into IL-17R -deficient mice, suggesting that IL-17 is required (at
least in a polyclonal setting) for the initiation of brainstem infiltrates and the
induction of atypical EAE as opposed to classical EAE. This study also found that
classical EAE, which could occur in the absence of both IFN- -17, was
dependent on GM-CSF as treatment with anti-GM-CSF led to the complete
abrogation of disease (Kroenke, Chensue and Segal, 2010).
To support the idea that IL-17 may be required for the initiation of atypical disease, it
has been shown, again in a polyclonal MOG system, that the induction of EAE in
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transgenic mice in which IL-6 production is restricted specifically to the cerebellum,
resulted in the induction of the atypical form of EAE, in contrast to the wild-type
mice that developed classical EAE (Quintana et al., 2009). Inflammation was
specifically located in the cerebellum of these mice, with no evidence of spinal cord
involvement, suggesting site-specific IL-6 production re-directed the inflammatory
response to the cerebellum only, away from the spinal cord where inflammation
would normally occur (Quintana et al., 2009). This would suggest that IL-6
production specifically in the cerebellum would result in local inflammation, or in an
increase in IL-17 signalling in that area, leading to the induction of atypical EAE.
This adds weight to the suggestion that IL-17 signalling, or IL-17 itself, is required
for the induction of atypical EAE within the polyclonal system. Interestingly, results
here showed that transfer of polyclonal pMOG-responsive IFN-
which had high percentages of IL-17+ cells resulted in the development of classical
EAE, not atypical EAE, whereas in the TCR transgenic model atypical EAE was
induced. Furthermore in the Tg4 transfer model only ~50% developed atypical EAE,
the rest showing classical EAE. It would be interesting to definitively determine if
IL-17 signalling is also required for the induction of atypical EAE in the TCR
transgenic system with the Tg4 IFN- uld be an important
next step to investigate.
The literature surrounding the roles of IL-17 in the induction of inflammation is
extensive, and somewhat contradictory. It has largely been accepted that IL-17 is
required for the induction of EAE. Early evidence after the discovery of the Th17
lineage showed that IL-17A-deficient mice displayed a delayed onset and reduced
severity of EAE, and the passive transfer of IL-17-deficient CD4+ T cells led to the
inefficient induction of EAE (Komiyama et al., 2006). It has also been shown that
IL-17A has a more important role to play in the initiation of EAE, as opposed to
IL-17F (Yang et al., 2008b). However, other recent evidence has shown that the
over-expression of IL-17A did not exacerbate EAE severity, and secondly, the
deficiency of either IL-17A, or its closely related family member, IL-17F, had a no
significant impact on the severity of disease (Haak et al., 2009). Both IL-17A and
IL-17F deficient mice are still fully susceptible to EAE induction, and blocking the
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signalling of both to remove any compensatory effects also had no significant effects
(Haak et al., 2009). This suggests that neither cytokine is required for the induction
of disease, despite Th17 cells being able to induce EAE inflammation in numerous
different settings (Langrish et al., 2005; Park et al., 2005). However, these early
works that highlighted the pro-inflammatory role of ‘Th17’ cells used IL-23-induced
‘Th17’ cells which have since been shown to be unstable and not fully differentiated
Th17 cells as IL-23 is only required for the stability of already differentiated Th17
cells (Stritesky, Yeh and Kaplan, 2008).
Other cytokines associated with Th17 cells have been shown not to have an
important role in autoimmune inflammation. For example, IL-22 is produced by
Th17 cells in an IL-23 dependent manner, and is co-expressed by the IL-17+ cells.
However, IL-22-deficient mice were observed to be fully susceptible to EAE
(Kreymborg et al., 2007). IL-21 is another cytokine produced by Th17 cells however
it has been found to be more important for the promotion of the Th17 lineage rather
than for inducing pro-inflammatory responses. IL-21 is now known to be an
autocrine regulator that promotes the production of IL-17 by Th17 cells and induces
the expression o (Nurieva et al., 2007; Wei et al., 2007).
Interestingly though, the requirements of IL-21 in induction of EAE are
controversial, with reports that IL-21-deficient mice are protected from disease
induction, due to the impaired Th17 response (Nurieva et al., 2007). Contrasting with
other studies reporting IL-21-deficient mice or IL-21R-deficient mice to have
enhanced disease possibly due to a defect in the Treg mediated suppression of
disease (Coquet et al., 2008; Liu et al., 2008a; Piao et al., 2008).
TNF- has been shown to have a role in the development of EAE and is efficiently
produced by both Th1 and Th17 cells. In MS, TNF- has been reported to be
upregulated in the acute lesions and chronic active lesions of MS patients, indicating
that it has a role to play in the pathogenesis of MS (Selmaj et al., 1991). Treating
host mice with a neutralizing antibody that blocks both LT and TNF- resulted in a
reduced severity of disease by passive transfer (Ruddle et al., 1990). Similarly, using
a SJL/J passive transfer model, it was demonstrated that treating mice with an
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anti-TNF- antibody resulted in the abrogation of disease (Selmaj, Raine and Cross,
1991). This correlates with results presented here which showed that, in the Tg4
passive transfer model, treatment of host mice with TN3-19.12, a monoclonal
antibody against TNF (neutralises both TNF- and TNF- (LT )) (Sheehan, Ruddle
and Schreiber, 1989), gave rise to a lower severity of disease.
The role of lymphotoxin- , which is produced by both Th1 and Th17 cells, has not
been investigated in this project. LT has been found to be upregulated in the lesions
of MS patients in the same way as TNF- suggesting that it may have a role in
disease pathogenesis (Selmaj et al., 1991). Neutralizing both LT and TNF- as
mentioned above led to a reduced severity of EAE by passive transfer (Ruddle et al.,
1990). Neutralizing LT led to the inhibition of EAE as well as collagen-induced
arthritis (CIA) (Chiang et al., 2009). This inhibition of disease was due to depletion
of IFN- -, IL-17- and TNF- -producing cells.
However, in contrast to these apparent roles for TNF- and LT in autoimmune
disease, it has also been reported that neither is required for EAE pathogenesis,
through the generation of 129xC57BL/6 and SJL/J mice that are deficient for both
TNF- and LT . Both double-knockout strains developed EAE after immunisation
with mouse spinal cord homogenate, the SJL/J strain to a more severe extent (Frei et
al., 1997). However, it could be that the entire knock-out of both genes could result
in many more downstream processes being affected, resulting in differing results
compared to the in vivo blocking through the use of a neutralizing antibody. To
support this thought, another study involved the generation of another
TNF- -deficient mouse strain and these were found to be highly susceptible to
MOG-induced EAE, once again suggesting that TNF is not required for EAE
induction (Liu et al., 1998). Similarly, treatment with TNF, to either TNF-deficient
mice, or wild-type mice, led to the development of less severe EAE, suggesting that
it may indeed be beneficial and may be acting as an anti-inflammatory cytokine in
this setting (Liu et al., 1998).
Anti-TNF therapy is widely used for the treatment of autoimmune diseases. After
discovery that treatment with a monoclonal antibody against TNF had a beneficial
CHAPTER 5 ESULTS
184
effect on CIA, this therapy was successfully translated to RA. Since then Etanercept,
a TNF-receptor fusion protein and infliximab, an anti-TNF- antibody, are known to
be effective treatments for both RA and Crohn’s disease (Moreland et al., 1997;
Targan et al., 1997; Feldmann and Maini, 2010). Similarly, as mentioned above and
in data presented here, anti-TNF treatments appear to decrease the severity of disease
in EAE. Unfortunately, trials using anti-TNF therapies in MS patients resulted in
worsening of disease (van Oosten et al., 1996; 1999) and it has even been shown, in
rare cases, to cause development of MS-symptoms in patients treated for RA (Sicotte
and Voskuhl, 2001). It is interesting that anti-TNF may be able to both inhibit
inflammation in the joint in RA but increase de-myelination in the CNS. However,
divergent roles of the TNF receptors in EAE have been identified which could shed
light on the unexpected effects of anti-TNF therapy in MS patients. In the absence of
TNFRI signalling, mice were resistant to MOG-induced EAE, however
TNFRII-deficient mice exhibited exacerbated EAE suggesting TNFRII is required
for the regulation of the immune response (or the integrity of CNS function) whereas
TNFRI is involved in the initiation of inflammation (Suvannavejh et al., 2000).
Notably both infiximab and etanercept block TNFRII signalling, possibly accounting
for their exacerbating effects in MS (Franklin, 1999; Agnholt and Kaltoft, 2001;
Ebert, 2009).
It is likely that all three cytokines investigated here produced by the encephalitogenic
Th1 and Th17 cells have an interactive role to play with each other, and simply
taking one out of the picture at a time, through the use of knock-out mice or
neutralising antibodies does not allow for the full investigation of their pathogenic
requirements. It would be interesting to determine whether CD4+ T cells unable to
elicit IFN- -17 and TNF- signalling are still able to induce disease. In addition,
it could be that too much importance is being laid on the cytokine production by the
CD4+ encephalitogenic T cells. Perhaps it is other factors that confer their
pathogenicity. It has been suggested that T-bet is a key regulator of pathogenicity in
EAE (Bettelli et al., 2004; Lovett-Racke et al., 2004; Nath et al., 2006; Gocke et al.,
2007; Yang et al., 2009). T-bet expression inducing pathogenicity would support the
data shown here which indicates that T-bet+ Th1-polarised cells, in the presence or
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absence of IFN- -bet- Th17 cells cannot. It has
been shown that ‘Th17’ cells require T-bet expression for encephalitogenicity (Yang
et al., 2009). In addition, TGF- has been shown to suppress whereas IL-23 promotes
Th17 differentiation and pathogenicity (Ghoreschi et al., 2010) and IL-23 has been
shown to promote T-bet expression here (Chapter 3). The study of the down-stream
products of Th1 and Th17 have not led to conclusive targets for therapy. Perhaps, the
focus should shift more towards the study of the upstream pathways that lead to the
production of encephalitogenic Th1 and Th17 cells, and determine what is key to




The prolonged active EAE observed in the IFN-
decrease in the proportion or number of FoxP3+ Treg accumulating in the
CNS of these mice.
In the absence of IFN- -17+ cells were observed
in the CNS, in the FoxP3- and FoxP3+ populations.
IFN- in vitro express T-bet, and
also produce IL-17 and these cells can transfer EAE. In contrast, Th17 cells
which produce IL-17, but do not express T-bet, cannot transfer EAE.
IFN- in vivo priming, induce
only classical EAE (in both pMOG active EAE and pMOG passive EAE).
In contrast, IFN- in
vitro, (in the Tg4 model), induce both classical and atypical EAE (with a
50:50 ratio).
Classical EAE is characterised by inflammation in the spinal cord. In
contrast, atypical EAE is characterised by donor cell migration and
inflammation localised to the brain and not the spinal cord.
Atypical EAE occurs in the absence of IFN- -17
signalling.
TNF- has a role in disease pathogenesis as observed by the decrease in EAE
severity in the absence of TNF- signalling.
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Day 0: 100 g pMOG in CFA s.c.













B Mean clinical scores
Experiment scheme
** p=0.0010
Figure 5.1 IFN- -induced active EAE
compared to wild-type C57BL/6 mice.
A, Experiment scheme; B, Mean scores of active EAE induced in wild-type mice ( versus IFN-
mice ( ). Disease incidence: WT (7/10), IFN- KO (10/11). The proportion of mice with severe EAE
is significantly higher in the IFN-


























Total # viable cells % CD4+ cells # CD4+ cells


































Figure 5.2 CD4+ T cell infiltration into the periphery and CNS during active
EAE in WT versus IFN- -immunisation.
A, Mean EAE scores after EAE induced in WT versus IFN- Day 6 post immunisation.
Total number viable cells, percentage and absolute numbers of CD4+ T cells in the B, Spleen; C,
inguinal lymph nodes; and D, CNS between WT ( - ) mice. Disease incidence: WT
(9/12), IFN- (‘*’ represents:
* p<0.05; ** p<0.01; *** p<0.001). Error bars represent mean ± standard error. EAE severity not
significantly different between WT and IFN- KO mice (p=0.1131 as determined by Fisher’s exact



















































Figure 5.3 Day 13 post-immunisation (peak of disease): no significant difference
in number of CD4+ T cells in the CNS between WT and IFN-
Total number viable cells, percentage and absolute number of CD4+ T cells in the A, spleen; B,
inguinal (draining) lymph nodes; and C, CNS between WT ( - ) mice. Statistical


















































Figure 5.4 Day 21 post-immunisation: no significant difference in number of
CD4+ T cells in the CNS between WT and IFN-
Total number viable cells, percentage and absolute number of CD4+ T cells in the A, spleen; B,
inguinal (draining) lymph nodes; and C, CNS between WT ( - ) mice. Statistical










































Figure 5.5 No significant difference in the percentage or absolute number of
FoxP3+ Treg in the CNS between WT and IFN-
Ex-vivo analysis of FoxP3 expression on CD4+ cells in CNS, showing percentage and absolute
number of FoxP3+ Treg in the CNS at A, day 6; B, day 13 and C, day 21 post-immunisation, between
WT ( - ) mice. Statistical analyses performed with Mann Whitney Test (‘*’
represents: * p<0.05; ** p<0.01; *** p<0.001). See Appendix 10 B for representative flow cytometry
gating strategy. For day 6, n=3 for both groups; for day 13, n=4 for both groups; for day 21 n=5 (WT)












































































































Figure 5.6 Increased production of IL-17 by FoxP3+ Treg in response to
pMOG-stimulation in the CNS.
A, gated on CD4+ cells from the CNS of WT (left) and IFN- ght) mice at day 13 post-
immunisation (peak of disease in WT mice). Showing IL-17 production by FoxP3- and FoxP3+ cells
after an overnight re-stimulation +/- 20 g/ml pMOG; B, Quantitative representation of IL-17
production, in the presence (black bar) and absence (clear bar) of pMOG stimulation, by the FoxP3+
and FoxP3- cells as a proportion of their respective populations. Statistical analyses performed with
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WT Th1 IFN- KO Th1
WT Th1 IFN- KO Th1 Overlay
IFN-
TNF-
66% T-bet+ 47% T-bet+
Figure 5.7 Phenotype of in vitro polarised pMOG-reactive IFN-
A, Experiment scheme; gated on CD4+ cells, B, IFN- -17 production and C, TNF- and IL-17
production by WT Th1 (left) and IFN- -stimulation; D,
gated on CD4+ cells, T-bet expression on WT (red, left) and IFN- red, middle) Th1 cells versus
the IgG1 isotype control (grey fill), and overlay of T-bet expression on WT Th1 (red), IFN-
(blue) and isotype control (grey fill). n=1 for both cell populations. Increased IL-17 production
observed in IFN- cells representative of two experiments. The same trend but at much higher
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WT Th17 IFN- KO Th17
Th17: IL-6 + IL-23 + TGF-
Th17: IL-6 + IL-23 + TGF-
Figure 5.8 Pre-transfer phenotype of pMOG-reactive WT and IFN-
cells.
A, Experiment scheme; B, Phenotype of pMOG-reactive WT and IFN- and WT and
IFN- after PMA/ionomycin stimulation, gated on CD4+ cells, showing IFN-
IL-17 production; C, IFN- -17 production by WT and IFN-
ELISA using supernatants obtained after 3 days of in vitro polarisation of cells. Higher mean































































Cytokine production by donor cells in CNS
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Figure 5.9 pMOG-reactive IFN-
despite not producing IFN-
A, Mean EAE scores after transfer of WT Th1 ( ), IFN- ) and IFN-
Th17 ( ) cells, neither Th17 population was able to induce disease; B, Percentage donor cell
infiltration into the spleen (left) and CNS (right) at day 12 post-transfer; C, gated on the donor CD4+
cells, in the CNS at the peak of disease IL-17 and IFN- the donor WT Th1 cells (left)
and the donor IFN- -stimulation with PMA/ionomycin (pooled CNS
samples from each group). Disease incidence: WT Th1 (5/5), WT Th17 (0/5), IFN-
IFN-
compared to WT Th17 (p=0.0079) and IFN-
mice with severe EAE between WT Th1 and IFN- See Appendix 11 for summary
of p values. Statistics performed using Fisher’s exact test. No difference in percentage of donor cells
in the spleen (p=0.3916) or CNS (p=0.3916) between the groups, as determined by Kruskal-Wallis




































Th1 IFN- +/+ Th1 IFN- -/-Th1 IFN- +/-
B Phenotype of in vitro polarised cells
All polarised towards Th1 phenotye:






























































































































































































Figure 5.10 Phenotype of TCR transgenic Tg4 Th1 IFN- +/+, IFN- +/- and
IFN- -/- cells.
A, Experiment scheme; B, gated on CD4+ cells, IFN- -17 and TNF- production by Tg4 Th1
IFN- +/+ (left), IFN- +/- (middle) and IFN- -/- (right) cells; C, gated on CD4+ cells, T-bet expression on
Tg4 Th1 IFN- +/+, IFN- +/- and IFN- -/- cells (red) versus IgG1 isotype control (grey fill); D, overlay
of T-bet expression on Th1 IFN- +/+ (red), Th1 IFN- +/- (blue) and Th1 IFN- -/- (purple) cells
highlighting percentage of T-bet+ cells in gate; E, RT-qPCR for T-
expression on Th1 polarised IFN- +/+, IFN- +/- and IFN- -/- cells, and Th0 and Th17 cells using Th17
cells as the control for T-
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Figure 5.11 TCR transgenic Tg4 IFN-
atypical EAE.
A, Experiment scheme; Pre-transfer phenotype of Tg4 WT and IFN- 4+
cells showing B, IFN- -17 and TNF- production after PMA/ionomycin re-stimulation; and C,
T-bet expression on Tg4 WT Th1 (red), Tg4 IFN- blue) and the isotype control (grey fill);
D, Mean EAE scores after transfer of Tg4 WT Th1 ( FN- ) cells for both
classical (left) and atypical (right) EAE. Error bars represent mean ± standard error. Disease
incidence: WT Th1 cells: 10/10 classical EAE, 0/10 atypical EAE; IFN-
EAE, 5/10 atypical EAE. The classical disease course (D) represents only mice that developed
classical disease, and the atypical disease course (E) represents the mice that developed atypical
disease in each transfter group. The proportion of mice showing severe classical EAE is significantly
higher in the IFN-
significantly higher in the IFN- the WT Th1 transfers. EAE statistical






















































































Figure 5.12 Donor cell infiltration into the brain, spinal cord and spleen during
classical and atypical EAE.
Total number viable cells, percentage and absolute numbers of CD4+ T cells and CD45.1+ donor cells
in the A, spleen, B, brain; and C, spinal cord at day 11 post-transfer in classical ( )
EAE. Statistical analyses performed using the Mann Whitney test (‘*’ represents: * p<0.05;
** p<0.01; *** p<0.001). See Appendix 12 for representative flow cytometry gating strategy. For
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Figure 5.13 Donor cells infiltrate into the brain specifically and not the spinal
cord during atypical EAE.
A, donor cell infiltration during classical (blue) and atypical (red) EAE in the spleen, spinal cord and
brain taken at day 11 post-transfer; B, IFN- -17 and TNF- production by donor T cells in the
spleen, spinal cord and brain during classical (blue) and atypical (red) EAE. Statistical analyses
performed using Kruskal-Wallis test (KW p values: Spinal cord IFN- -
**p=0.0088; spinal cord TNF- **p=0.0090) and Dunn’s multiple comparison post test (‘*’
represents: * p<0.05; ** p<0.01; *** p<0.001). See Appendix 12 B for representative flow cytometry
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Surface IL-17 staining using Miltenyi antibody
Tg4 Th1
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Isotype control
Figure 5.14 Requirements of IL-17 for the induction of atypical EAE.
A, Experiment scheme; Pre-transfer phenotype of transferred gated on CD4+ cells showing B, WT
Th1 cells (IFN- - production) and C, IFN- - and IL-17 production);
and D, T-bet expression on WT Th1 (red), IFN- blue) and IgG1 isotype control (grey fill);
and surface staining of IL-17 using ‘Miltenyi IL-17 detection and secretion kit’ after 3 hours of re-
stimulation with MBP (Ac1-9) showing percentage of IL-17+ cells E, prior to; and F, after IL-17
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Figure 5.15 Tg4 IFN- -17- Th1 cells are still capable of inducing atypical
EAE.
A, Mean EAE scores after transfer of Tg4 Th1 ( ), Tg4 IFN- - -17-
Th1 ( ) cells in terms of classical (left) and atypical (right) EAE; Day 13 post-transfer, B, total
number of viable cells in the spleen (left), brain (middle) and spinal cord (right); C, number of
CD45.1+ donor cell numbers in the spleen (left), brain (middle) and spinal cord (right). Disease
incidence: WT Th1 (7/8): 7/8 classical EAE, 0/8 atypical EAE; IFN-
4/8 atypical EAE; IFN- -17-(8/8) 3/8 classical EAE, 5/8 atypical EAE. No significant
differences in EAE severity as determined by Fisher’s exact test. See Appendix 13 A and B for
summary of p values. Error bars represent mean ± standard error. Statistical analyses performed using
Mann Whitney test (‘*’ represents: * p <0.05; ** p <0.01; *** p <0.0001). For harvest, n=13 for
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Figure 5.16 Increased production of IL-17 in the brain by Th1 IFN-
Th1 IFN- -17- cells at day 13 post-transfer compared to those in the
spleen.
Gated on CD4+ CD45.1+ donor cells, percentage of A, IL-17+; B, TNF- + and C, IFN- + cells in the
brain and the spleen at day 13 post-transfer after an over-night re-stimulation in the presence of 20
g/ml MBP (Ac1-9) and four hours of incubation with Brefeldin A. A and B highlight cytokine
production by the WT Th1 cells (black bar), IFN- blue bars), and IFN-
IL-17- cells (red bars). In the IFN-
to classical disease, and closed bars represent donor cells that gave rise to atypical EAE. There were
significantly higher percentages of IL-17+ cells in the brain of EAE mice with IFN-
IFN- -17- cells transferred, compared to the spleen with WT Th1 cells transferred
(* p<0.05). No significant difference in proportion of TNF- + cells or IFN- + cells in the brain and
spleen. Statistics performed using the Kruskal-Wallis test (KW p value: ***p=0.0003 for A) and
Dunn Multiple comparison post test (A, B) and the Mann Whitney test (C). For harvest, n=13 for
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Figure 5.17 Tg4 Th1 polarisation in the presence of IL-18 results in increased
IFN- - production and increased disease incidence and severity.
A, Experiment scheme; B, Pre-transfer phenotype of Tg4 Th1 cells polarised with IL-12 alone (left),
and IL-12 and IL-18 (right), gated on CD4+ cells, showing IFN- -17 production (left) and
TNF- and IL-17 production (right); C, gated on CD4+ cells, T-bet expression on IL-12 (red), IL-12
and IL-18 (blue) Th1 polarised cells and IgG1 isotype control (grey fill); D, EAE scores after transfer
of Tg4 cells polarised in the presence of IL-12 alone ( -12 and IL-18 ( ). Disease incidence:
IL-12 alone (3/4) or IL-12 and IL-18 (4/4). Error bars represent mean ± standard error. The proportion
of mice with severe EAE is not significantly higher, as determined by the Fisher’s exact test
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Figure 5.18 Neutralising TNF- results in decreased severity of EAE by Tg4
Th1 passive transfer.
A, Experiment scheme; Pre-transfer phenotype of donor Tg4 Th1 cells, gated on CD4+ cells, showing
B, IFN- - and IL-17 production; and C, T-bet expression (red) versus IgG1 isotype control
(grey fill); D, Mean EAE scores after passive transfer of Tg4 Th1 cells and one pre-treatment with
anti-TNF- ( ) or PBS ( -TNF- (4/4). No significant difference
in disease severity (as determined by Fisher’s exact test, p=1.0000). Anti-TNF- treatment




This thesis has investigated the pathogenic abilities of myelin-reactive Th1 and Th17
cells in EAE. The results can be summarised as follows:
Myelin reactive Th1 cells were capable of migrating to the CNS and induce
EAE, whereas myelin reactive Th17 cells did not. Only when inflammation
was already established could the Th17 cells gain access to the CNS and have
an effect on EAE severity.
In vitro polarised Th1 cells expressed higher levels of PSGL-1 than Th17
cells. However, the mRNA expression level of C2GnT-I was comparable on
both Th1 and Th17 cells, therefore surface PSGL-1 expression on either cell
population was functional. The effect of blocking PSGL-1 in vitro prior to
transfer led to Th1 cells having a decreased ability to migrate in to the CNS,
as determined at a pre-clinical time point. Blocking PSGL-1 in vivo resulted
in the complete abrogation of disease for the length of treatment indicating an
important requirement for PSGL-1 in disease induction.
IFN- -type
C57BL/6 mice. This was not due to a decrease in Treg accumulation in the
CNS.
Significantly elevated proportions of CD4+ IL-17+ cells were observed in the
CNS of IFN- AE, in the FoxP3- and FoxP3+ cell
populations.
In vivo primed pMOG-reactive Th1 cells deficient in IFN-
EAE. Importantly these cells expressed T-bet under in vitro Th1 conditions
despite the absence of IFN-
Interestingly in vitro primed TCR transgenic Tg4 IFN-
expressing T-bet, induced atypical as well as classical EAE. The increased
ability of these IFN- -deficient Th1 cells to produce IL-17 may be important
for their ability to induce atypical disease.
TNF- plays a role in EAE pathogenesis as decreased disease severity was
observed in its absence.
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6.1 Th1 versus Th17 in EAE induction: What is required
for pathogenesis?
Data presented here clearly show that Th1 cells are able to induce disease both in the
presence and absence of IFN- -signalling. In our model, as well as in a study of CIA
(Janke et al., 2010), Th17 cells are unable to induce inflammation when transferred
alone. However, other groups have shown Th17 cells to be pathogenic although the
stability of the Th17 cells in these studies is still in question (Bending et al., 2009;
Jager et al., 2009; Ghoreschi et al., 2010). These Th17 populations all exhibited a
phenotype switch from IL-17-producing on input, to IFN- -producing when sampled
ex vivo and re-stimulated. Therefore, it is not clear which cell phenotype, ‘Th1’ or
‘Th17’ induced the disease. In addition, IL-17 has been shown to not be required for
the induction of EAE (Haak et al., 2009). Data presented here clearly show that when
Th17 cells are polarised in vitro from in vivo primed pMOG-reactive cells, these
cells remain stable in vivo and importantly do not induce disease (O'Connor et al.,
2008). In contrast, when the Th17 cells are polarised from naïve in vitro primed TCR
transgenic Tg4 cells, these Th17 cells can induce disease, albeit mild and slightly
delayed. However, these Th17 cells exhibited phenotypic plasticity and switched
towards an IFN- -producing phenotype when recovered from the CNS at the peak of
disease (O'Connor et al., 2008). In summary, stable in vivo primed Th17 cells cannot
induce disease whereas phenotypically unstable Th17 appear able to induce disease,
bringing the question as to which cell type is encephalitogenic.
What is it that makes Th1 cells, and not Th17 cells, pathogenic if it is not the
signature cytokines that the cells produce? One of the key differences between the
cell populations is their expression of T-bet the master regulator of Th1 cells. T-bet
remains one of the key factors that is consistently reported to be required for EAE
induction in numerous different studies (Lovett-Racke et al., 2004; Nath et al., 2006;
Gocke et al., 2007; Abromson-Leeman, Bronson and Dorf, 2009; Yang et al., 2009).
Disrupting T-bet signalling, either through the use of T-bet deficient mice (Nath et
al., 2006) or siRNA against T-bet (Lovett-Racke et al., 2004) resulted in resistance to
EAE induction. In addition, T-bet expression on Th1 or Th17 cells has been shown
to be required for their encephalitogenicity (Abromson-Leeman, Bronson and Dorf,
2009; Yang et al., 2009). Data presented here would correlate with the requirement
GENERAL DISCUSSION
207
for T-bet expression on encephalitogenic T cells. Th1 cells, both wild-type and
IFN- -bet, and these cells induce EAE whereas Th17 cells, which are
T-bet-, do not induce disease. STAT1, another Th1-promoting transcription factor is,
however, dispensable for EAE induction as STAT1KO mice display enhanced EAE
(Bettelli et al., 2004). The loss of STAT4 results in the abrogation of disease
induction, with the isoform STAT4 having more of an influence compared to the
STAT4 isoform (Chitnis et al., 2001; Mo et al., 2008). Therefore, two transcription
factors vital for the generation of a Th1 response, T-bet and STAT4, remain key
factors that are consistently required for induction of disease. Perhaps more emphasis
should be put on the role of these two molecules in their requirements for Th1/Th17
mediated pathology.
The EAE experiments presented in this thesis always used Ptx for the induction of
disease. In our passive transfer models of EAE, Ptx is required for disease induction
otherwise the disease induced is of low severity and low incidence. Other groups,
have reported that the use of Ptx can inhibit the induction of disease by Th17 cells
(Jager et al., 2009). In those studies, Ptx was thought to inhibit the migration of
encephalitogenic T cells across the BBB by affecting the chemokine receptor
expression on the T cells. However, as Th1 cells were still able to induce disease in
the presence of Ptx in our model, this would argue that the Ptx is not affecting the
chemokine receptor expression on the Th17 cells to inhibit their migration to the
CNS. It has been suggested that Ptx specifically affects the chemokine receptor
signalling on Th17 cells, and not Th1 cells (Jager et al., 2009). However, it is
debatable whether Ptx would specifically target particular chemokine receptors,
especially as it was found that Ptx had no effect on CCR6 expression on Th17 cells
in vitro (Jager et al., 2009). EAE induction by Th17 cells with the addition of Ptx has
been shown to be feasible (McGeachy et al., 2007), supporting the view that Ptx does
not specifically affect the migration of Th17 cells to the CNS.
TNF- was shown to play a role in disease pathogenesis in EAE (Ruddle et al., 1990;
Selmaj, Raine and Cross, 1991), and as shown in Chapter 5, although there are also
contradictory data suggesting TNF- is an anti-inflammatory cytokine in EAE (Frei
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et al., 1997; Liu et al., 1998). When translated to human autoimmune disease,
anti-TNF- therapy was found to be an effective treatment for RA and Crohn’s
disease (Moreland et al., 1997; Targan et al., 1997), but it led to the exacerbation of
disease in MS patients (van Oosten et al., 1996; Lenercept-MS-Study, 1999). The
differential roles of TNF receptors TNFRI and TNFRII (Suvannavejh et al., 2000)
may account for the exacerbation of disease in MS as anti-TNF therapeutics,
infliximab and etanercept, block the TNFRII signalling (Franklin, 1999; Agnholt and
Kaltoft, 2001) which is thought to have a role in the regulation of inflammation in
the CNS, rather than its initiation.
Currently there is a drive towards focusing on Th17 cells and their role in inducing
CNS autoimmune disease, despite clear evidence that Th1 cells also induce CNS
inflammation. Although neither IFN- -17 is required for disease pathogenesis
(Ferber et al., 1996; Wensky et al., 2005; Haak et al., 2009), T-bet and STAT4
however remain key in the pathogenesis of CNS autoimmune disease and perhaps
research should focus more on other functions of Th1 and Th17 cells that could
induce disease rather than on their end signature products.
6.2 Migration of encephalitogenic T cells into the CNS
One of the treatments for MS is Natalizumab, a monoclonal antibody against 4-
integrin. 4 1 is fairly widely expressed on all leukocytes, therefore Natalizumab
blocks all leukocyte entry in to the CNS. A major concern over the use of
Natalizumab as a treatment, comes from the development of PML, a serious
demyelinating disease of the CNS (Kleinschmidt-DeMasters and Tyler, 2005;
Langer-Gould et al., 2005). This seems to reflect reduced surveillance allowing
reactivation of latent JC virus (Engelhardt and Kappos, 2008). The risk of developing
PML increases after 2 years of treatment with Natalizumab, so this is now avoided if
possible and it is chiefly prescribed to MS patients that are non-responders to IFN-
or glatiramer acetate, and only to new MS patients if they present with unusually
high disease activity. The non-specificity of the treatment, blocking all leukocytes
from entering the CNS and other tissues was part of the rationale for investigating
what molecules influenced the migration of pathogenic Th1 cells into the CNS.
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Identification of a more specific therapeutic target that only blocks the entry of the
inflammatory encephalitogenic T cells in to the CNS, might allow for normal
immune surveillance.
As described in Chapter 4, blockade of PSGL-1 could affect the entry of the pioneer
encephalitogenic T cells into the CNS. However, the expression of PSGL-1, like
4 1, is fairly ubiquitous, and therefore blocking PSGL-1 in vivo would affect
various different cell types, as seen by it affecting the proportion and number of
CD11b+ cells in the spleen. Therefore, the likelihood of PSGL-1-blockade being a
feasible therapy for MS seems low. It is nonetheless important to determine the role
that PSGL-1 has in the entry of pathogenic T cells into the CNS. It has been shown
that T-bet is required for the trafficking of Th1 cells to inflammatory sites and has a
role in controlling PSGL-1-mediated migration (Lord et al., 2005). It would be
interesting to determine whether T-bet-deficient Th1 cells have an impaired ability to
migrate to the CNS to induce EAE in our TCR transgenic passive transfer model.
6.3 Classical versus atypical EAE
Interestingly, TCR transgenic IFN-
and atypical EAE, whereas Tg4 Th1 cells induced only classical EAE. It is not fully
understood where encephalitogenic T cells initially enter the CNS, except possibly
through the choroid plexus through CCR6/CCL20 signalling (Reboldi et al., 2009).
A possible model for the initiation of classical versus atypical EAE is suggested here
on Figure 6.1. For the induction of classical disease, Tg4 Th1 cells enter the CNS at
the brain-stem and then migrate towards the spinal cord where inflammation is
established. In contrast, in atypical disease, the donor IFN-
towards the cerebellum and brain-stem and induce local inflammation in this area.
The lack of IFN- -
upregulated levels of IL-17 produced by these cells, appeared to localise these donor
cells to the brain area, and prevent them from migrating towards the spinal cord, as
highlighted in Figure 6.1. This localisation of encephalitogenic T cells to the brain-































Figure 6.1 Model of migration of TCR transgenic Th1 cells into the CNS to
induce classical versus atypical EAE
A, Induction of classical EAE by transfer of WT Th1 cells. The cells enter the CNS via the brain-stem
and then migrate down towards the base of the spinal cord, mediated by chemokine gradients. Cells
then induce inflammation localised in the spinal cord. B, Induction of atypical EAE by transfer of
IFN- -stem as well, and migrate to the
cerebellum as well. Due to the absence of IFN- -signalling in the donor cells, increased IL-17
signalling or perhaps the absence of particular chemokine gradients, the cells remain in the brain-stem
and cerebellum and induce localised inflammation in that area.
6.4 Future Work
6.4.1 Role of Th17 cells in EAE exacerbation
It would be interesting to determine what role the Th17 cells have in exacerbating
disease once they have gained access to the CNS (via the production of IL-17 or
another effector function). If the Th1 cells co-transferred with Th17 cells are
specifically deleted from the host mice, would the mice recover, or would those Th17
cells that have reached the CNS be able to sustain EAE by themselves? A system that
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allows deletion of Th1 or Th17 cells at different time-points would reveal the
requirements of each cell type at different stages of disease.
6.4.2 Requirements of IL-17 in induction of atypical EAE
It is important to determine whether IL-17 signalling is required for atypical EAE
induction. The use of a blocking antibody against IL-17A would determine whether
IFN-
IL-17-signalling. IL-17FKO mice could also be used to look at the role of pathogenic
IFN- -17F and IFN- -production.
Unfortunately this could not be investigated within the timescale of this PhD project.
6.4.3 Is the increased severity of disease observed in IFN-
mice attributed to the upregulated IL-17 production?
Increased percentages of IL-17+ cells were observed in the FoxP3- and FoxP3+ cells
in the CNS of IFN-
blocking this IL-17 production would result in decreased severity or duration of
disease.
6.5 Closing Statement
In summary, this thesis provides data that counter the new dogma that views EAE as
a Th17-mediated disease. Th1 cells were able to home to the CNS and induce EAE,
whereas Th17 cells did not. PSGL-1 was found to have a role in the entry of the
pioneer Th1 cells across the non-inflamed BBB. The project has highlighted that
neither 'Th1' nor 'Th17' appears to be an unambiguous descriptor of the T cells that
drive pathology. Rather, EAE is a CD4+ T cell-mediated disease with no essential
requirement for either IFN- -17. In contrast, TNF- , which can be produced by
both Th1 and Th17 cells, does appear to have a role to play in EAE pathogenesis.
This thesis has also shown that classical and atypical EAE correlated with
inflammation in distinct areas of the CNS (the spinal cord and brain, respectively),
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Appendix 1 Flow cytometry gating strategy for location of donor T cells from
Figure 3.4. CD45.1+ Th1 donor cells and CD90.1+ Th17 donor cells in the A, spleen and B, CNS,
highlighting the gating strategy. Representative of all gating.
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Isotype controlSpleen gatingA
B
Appendix 2 Flow cytometry gating strategy for donor cell location and cytokine
production for Figure 3.6. CD45.1+ Th1 donor cells and CD90.1+ Th17 donor cells cytokine
production for IFN- -17 in the A, spleen and B, CNS. Representative of gating for all samples.
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Appendix 3 Flow cytometry gating strategy for location of donor Th1 cells in the
CNS for Figure 3.8. Gating of CD4+ CD45.1+ Th1 donor cells in the CNS at day 3, 6, and 9 post-
transfer.
Parameters: # Th1 cells Significance p value
4x106 2x106 ns p=1.0000
4x106 1x106 ns p=1.0000
4x106 0.5x106 ns p=0.2500
4x106 0.2x106 ns p=0.2500
2x106 1x106 ns p=1.0000
2x106 0.5x106 ns p=0.4000
2x106 0.2x106 ns p=0.4000
1x106 0.5x106 ns p=1.0000
1x106 0.2x106 ns p=1.0000
0.5x106 0.2x106 ns Not possible
Appendix 4 Fisher’s exact test for significant differences in EAE severity for
Figure 3.10 A. As determined by comparing number of mice with EAE maximum score of 2 and

































































































Appendix 5 A Isotype control on Th1 and Th17 polarised cells for Figure 3.11 B.
IgG1 FITC was the isotype for IFN- -17, and IgG1 PE for TNF- . All flow
cytometry cytokine analysis was gated on isotype controls to ensure no non-specific staining.
Representative of all isotype control analyses and gating.
Parameters Significance p value
Th1 hi Th1 lo * p=0.0476
Th1 hi Th1 lo + Th17 hi ns p=1.0000
Th1 hi Th17 hi ** p=0.0079
Th1 lo Th1 lo + Th17 hi ns p=0.2063
Th1 lo Th17 hi ns p=1.0000
Th1 lo + Th1 hi Th17 hi * p=0.0476
Appendix 5B Fisher’s exact test for significant differences in EAE severity for
Fig. 3.12 A. As determined by comparing number of mice with EAE maximum score 2 and below,
to EAE mice with a score of 3 and above.
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Appendix 5 C. Flow cytometry gating strategy for the location of donor Th1 and
Th17 cells for Figure 3.12. Gating strategy to determine location of CD45.1+ Th1 donor cells




































































































FSC CD11b CD45.1 TNF- IFN-
CNS sample, +20 g/ml MBP (Ac1-9)
Appendix 6. Flow cytometry gating strategy for location of donor cells and
cytokine production for Figure 3.18 A. Gating of CNS sample, highlighting production of
IFN- -17 and TNF- in response to MBP (Ac1-9) re-stimulation. Representative of gating for































































































Appendix 7. Flow cytometry gating on Th1 and Th17 cells for phenotypic
analysis highlighting CD62L expression for Figure 4.4. Gating strategy for in vitro
polarised Th1 cells (top) and Th17 cells (bottom) showing CD62L expression on Th1 (red) versus















































































































Appendix 8. Flow cytometry gating for location of donor Th1 cells for Figure
4.7. Gating strategy for presence of CD45.1+ Th1 donor cells in the A, spleen, and B, CNS.












Appendix 9. Observed delay in EAE induction observed after pre-treatment of
Tg4 Th1 cells with anti-PSGL-1 as compared to the PBS control. This experiment
was sampled at days 4, 7 and 10 post-transfer and therefore the disease course ends at day 10 post-
















































































































Appendix 10. Flow cytometry gating strategy for determination of CD4+ T cell
frequency in spleen and CNS, and FoxP3 expression, for Figure 5.2. A, gating
strategy for presence of CD4+ T cells in WT with EAE, in spleen (top) and CNS (bottom),
representative of gating for IFN- B, gating on CD4+ T cells in the WT CNS, FoxP3
expression and the relevant isotype control. Gating always done on isotype controls, and applied to
samples. Representative of FoxP3 gating strategy on IFN-
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Parameters (A versus B) Significance p value
WT Th1 IFN- ns p=0.4444
WT Th1 WT Th17 ** p=0.0079
WT Th1 IFN- ** p=0.0079
IFN- WT Th17 ns p=0.1667
IFN- IFN- ns p=0.1667
Appendix 11. Fisher’s exact test for significance for EAE scores for Fig. 5.9 A.
As determined for disease severity (number of mice with score 3 and below versus number of mice




















































































































































FSC-A FSC-A CD11b CD45.1
IgG1 PE IsoTNF- PEIgG1 FITC isoIFN- FITC
Gated on the CD4+ CD45.1+ donor cells; Cytokine production:
A
B
Appendix 12. Flow cytometry gating for presence of donor Th1 cells in the brain
for Figure 5.12. A, gating for presence of CD45.1+ Th1 donor cells in the brain. Gating strategy is
representative of that in the spinal cord and spleen for both Tg4 Th1 transfer and Tg4 IFN-
transfer groups. B, cytokine production by CD45.1+ donor T cells in terms of IL-17, IFN- -
production showing the relevant isotype controls. Gating always determined on isotype controls and
subsequently applied to samples; representative of cytokine gating and cytokine production in the
spinal cord and spleen.
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Parameters (A versus B) Significance p value
WT Th1 IFN- ns 1.0000
WT Th1 IFN- -17- ns 1.0000
IFN- IFN- -17- ns 1.0000
Appendix 13 A. Fisher’s exact test for significance for Classical EAE scores for
Fig. 5.15 A. As determined for disease severity (number of mice with score 3 and below versus
number of mice with score 4 and above for each group).
Parameters (A versus B) Significance p value
WT Th1 IFN- ns 1.0000
WT Th1 IFN- -17- ns 0.0769
IFN- IFN- -17- ns 0.2821
Appendix 13 B. Fisher’s exact test for significance for Atypical EAE scores for
Fig. 5.15 A. As determined for disease severity (number of mice with score 3 and below versus




Publications relevant to this thesis are now presented, with permission from the
respective publishers.
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